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Glossary 
AADC Aromatic amino acid decarboxylase 
A/C Adenine/cy to sine 
ACE Angiotensin-converting enzyme 
ACR Albumin-to creatinine ratio 
AER Albumin excretion rate 
AGT Angiotensinogen 
ANCOVA Analysis of covariance analysis 
Angiotensin II Ang II 
Angiotensin III Ang III 
Angiotensin IV Ang IV 
APM Affected pedigree member (method) 
ASP Affected sib pair (method) 
ATiR Angiotensin II type 1 receptor 
BAT Brown adipose tissue 
BD Body density 
BMI Body mass index 
BP Blood pressure 
bp Base pairs (nucleotide) 
cAMP Cyclic adenosine monophosphate 
C.I. Confidence interval 
CVD Cardiovascular disease 
DA Dopamine 
DBH Dopamine beta-hydroxylase 
DBP Diastolic blood pressure 
DOPA Dihydroxyphenylalamine 
DRD2 Dopamine D2 receptor 
EDTA Ethylene diamine tetraacetic acid 
% fat Percentage body fat 
FFA Free fatty acid 
FPG Fasting plasma glucose 
GPCR G protein-coupled receptor 
HDL- High density lipoprotein- (cholesterol) 
HT Hypertension/hypertensives 
IBD Identity by descent 
IBS Identical by state 
I/D Insertion/ deletion 
IGT Impaired glucose tolerance 
LDL- Low density lipoprotein- (cholesterol) 
MAP Mean arterial pressure 
MCV Mean cell volume 
mRNAs Messenger ribonucluic acids 
NGT Normal glucose tolerance 
NIDDM Non-insulin-dependent diabetes mellitus 
NT Normotension/normotensives 
PGR Polymerase chain reaction 
PNMT Phenylethamolanine-N-methyl transferase 
QTL Quantitative traits linkage analysis 
RAS Renin angiotensin system 
RFLP Restriction fragment length polymorphism 
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RMR Resting metabolic rate 
SBP Systolic blood pressure 
SDS Sodium dodecyl sulphate 
SFT Skin-fold thickness 
SMC Smooth muscle cells 
SNS Sympathetic nervous system 
TE Tris-EDTA 
TH Tyrosine hydroxylase 
UCP Uncoupling protein 
WHR Waist-to-hip ratio 
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Genetic and biochemical parameters associated with hypertension — 
a sibling study 
It has been reported that certain genes are linked to hypertension in other ethnic 
groups, but data in Chinese are lacking. We identified the polymorphisms of four 
genes, which have been reported as having a relationship to hypertension or obesity 
in Caucasians, in our siblings with a family history of hypertension in Hong Kong 
Chinese. 
In this study, we recruited patients from the hypertension clinic in the Prince of 
Wales Hospital. All the patients with their siblings were living in the Hong Kong 
SAR. There were 96 sibships and the total number of subjects was 281, including 
133 hypertensive, from which there were 58 concordant sib pairs and 224 discordant 
sib pairs. All the sibships had hypertensive family history, which mean that at least 
one of their parents was hypertensive. All the hypertensive patients were asked to 
stop medication for at least 2-4 weeks, if it was considered safe to do so, before 
attending for measurement of blood pressure and biochemical parameters. All the 
siblings were typed for the polymorphisms of four genes. Subjects were defined as 
hypertensive if systolic blood pressure was greater than 140 mm Hg and/or diastolic 
blood pressure was greater than 90 mm Hg. 
The main findings were as follows: 
1. The insertion/deletion polymorphism in the ACE gene: the I allele frequency was 
62% in the hypertensive sibs compared to 65% in mormotensive sibs. No 
significant relationships were found between this polymorphism and blood 
pressure in linkage analysis in discordant or concordant sib-pairs. There was a 
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trend for higher frequency of the DD genotype and D allele with increased 
albuminuria in hypertensive siblings. It indicated that the ACE gene and 
albuminuria interact with each other, and blood pressure together. 
2. The angiotensin II type 1 receptor gene A1166C polymorphism: In our sibling 
study, there was no subject homozygous for the C allele genotype. In the linkage 
analysis, we only found significant linkage between this polymorphism and 
obesity/central obesity in hypertension-normotension sib pairs by affected 
pedigree member (APM) method. No significant evidence of linkage was found 
between this polymorphism and hypertension. 
3. The dopamine Di receptor gene TaqI polymorphism: We conclude that the 
DRD2 TaqI polymorphism gene is associated with central obesity-related 
hypertension in hypertensive families of Hong Kong Chinese. The A1 allele of 
this gene polymorphism was related to higher WHR but not related to higher 
blood pressure in the hypertensive families of Hong Kong Chinese. 
4. The uncoupling protein 1 (UCPl) gene A-3826G polymorphism: There was an 
evidence of linkage between this gene and systolic blood pressure in the siblings 
of families with a history of hypertension in Hong Kong Chinese. 
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1 Introduction 
1.1 Overview of the study 
Hypertension is an important public health challenge in the world, because of its high 
prevalence and the concomitant increase in the risk of cardiovascular and renal 
disease. In Hong Kong, a recent cross-sectional study showed the prevalence of 
definite hypertension in men ranged from 0.9% (95% CI, 0.0-2.8) at age 25-34 to 
26.5% (95% CI, 18.9-34.2) at age 65-74 years. In women, the corresponding 
prevalences were 0.6% (95% CI, 0.0-2.2) and 35.7% (95% CI, 27.9-43.6), 
respectively (Janus 1997). Hypertension was defined as having a systolic blood 
pressure (SBP)> 140mm Hg and/or diastolic blood pressure (DBP) > 90mm Hg 
(section 3.2.1). Moreover, hypertension is one of the most important modifiable risk 
factors for coronary heart disease, stroke, congestive heart failure, end-stage renal 
disease, and peripheral vascular disease. In Hong Kong coronary heart disease is 
currently the second commonest cause of death after cancer. 
Currently available data suggest a continuous increase in obesity prevalence, which 
is now seen on a worldwide basis as it is also being observed in developing 
countries. This has prompted some authors to predict an "obesity epidemic" with an 
increased prevalence of hypertension, stroke, coronary artery disease and type 2 
diabetes mellitus, for all of which obesity is a major risk factor. Obesity is now 
common in the adult population of Hong Kong and is associated with a high degree 
of morbidity. In Hong Kong, over one third of adults are overweight by standards 
recently introduced for Asian subjects (body mass index, BMI >23kgW). (section, 
1.3) 
It is generally accepted that blood pressure is a continuously distributed variable and 
that essential or primary hypertension, is not a distinct, single-gene disorder. Blood 
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pressure, like many other quantitative characteristics, is a multifactorial trait that is 
determined by the interaction of multiple genetic and environmental factors. 
This study was performed to determine if any differences existed between 
hypertensive and normotensive siblings with regards to anthropometry, biochemistry 
and genetics. 
The genetic components which were studied were the common polymorphisms of 
four genes: the insertion/deletion polymorphism in the angiotensin-converting 
enzyme (ACE) gene (section 1.4.4), the A1166— C variant in the type 1 angiotensin 
receptor (ATi) gene (section 1.4.5), the Taq I polymorphism in the dopamine D2 
receptor (DRD2) gene (section 1.4.6) and the A to G polymorphism in uncoupling 
protein 1 (UCPl) gene (section 1.3.4.2). 
In this study, we recruited patients from the hypertension clinic in the Prince of 
Wales Hospital. All the patients with their siblings were living in the Hong Kong 
SAR (section 3.1). There were 96 sibships and a total number of 313 subjects, 
including 142 hypertensives, from which there was 84 discordant sib pairs. All the 
hypertensive patients were asked to stop medication for at least 2-4 weeks, if it was 
considered safe to do so, before attending for measurement of blood pressure and 
biochemical parameters (section 3.1). 
The renin-angiotensin system (RAS) plays a key role in the regulation of blood 
pressure as well as in the maintenance of fluid and electrolyte balance (section 1.4.1). 
ACE converts the inactive decapeptide angiotensin I to the active octapeptide 
angiotensin II by releasing the C-terminal histidyl-leucine dipeptide. The ACE gene 
is located on the q23 region of chromosome 17. It has been reported that the I/D 
polymorphism of ACE gene is associated with changes in blood pressure (section 
1.4.4). 
2 
The ATi receptor is sensitive to guano sine triphosphate (GTP), indicating that it has 
heterogeneous states of affinity owing to its association with G-proteins. Several 
studies suggest that the ATi receptor might be involved in hypertension (section 
1.4.5.1). The type 1 angiotensin receptor (ATi) gene is located on chromosome 3 in 
humans and is encoded on exon 3. Some association and linkage studies found that a 
common genetic variation at the ATi gene locus influences the risk for primary 
hypertension. In the previous population study in Hong Kong, no significant 
association (p>0.05) was found between the A1166— C variant and blood pressure. 
In this study sib pair linkage analysis was used to analyse the sibship data in 
concordant and discordant pairs and no linkage was present between this ATj gene 
polymorphism and hypertension (p>0.05) (section 1.4.5.2). In the APM analysis, 
data showed that this gene locus was significantly linked to obesity and central 
obesity (p = 0.01847, 0.0312) (section, 4.4.2.3). 
Dopamine (DA) is an endogenous neurotransmitter catecholamine that also serves as 
the biochemical precursor of norepinephrine and epinephrine. Dopamine modulates a 
variety of physiological functions including behaviour, movement, nerve conduction, 
hormone synthesis and release, ion transport, vascular tone, and blood pressure. The 
dopamine 2 receptor is located both pre- and postsynaptically. Stimulation of the 
presynaptic dopamine 2 receptor inhibits catecholamine release from sympathetic 
neurons. The dopamine 2 receptor gene has been localized to the llq21 to llq23 
region of the human genome and a Taq I polymorphism is locatcd 10 kb away from 
the DRD2 gene. Many studies have shown thai polymorphisms of the DRD2 gene 
were associated with changes in height and weight (section 1.4.6). 
The UCP has been established as the major, perhaps even the sole, component of 
brown adipose tissue (BAT) mitochondria that confers upon them their unique 
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thermogenic property, that is of becoming physiologically and reversibly uncoupled 
(section 1.3.4.1). The human UCP gene has been cloned and mapped to the long arm 
of chromosome 4 (q31). An A to G polymorphism in the 5'-flanking region of the 
uncoupling protein 1 (UCPl) gene has been identified in Caucasian subjects (section 
1.3.4.3). There are studies which showed that this gene is not a major gene 
determining obesity and suggested an absence of linkage with obesity (section 
1.3.4.4). 
This study therefore will attempt to identify those common biochemical and 
anthropometric markers associated with blood pressure in these Chinese hypertensive 
families. An attempt will also be made to investigate the association of obesity-
related hypertension. Following the identification of factors associated with 
hypertension, the involvement of the genetic parameters described above in 
modulating these parameters will then be assessed. Overall we hope to find a trend 
that these gene polymorphisms are linked to hypertension or obesity-related 
hypertension in our Chinese hypertensive families. 
1.2 Overview of Hypertension 
Blood pressure measurement is the basic way to make the diagnosis of hypertension 
and should be performed in a standardised manner. The patient should be seated 
comfortably with the arm supported and positioned at the level of the heart. 
Measurements taken with the arm dependent by the side average 8 mm Hg higher 
than those taken with the arm supported in a horizontal position at heart level 
(Mariotti et al 1987). If arm circumference exceeds 33 cm, a large cuff must be 
used. Place the stethoscope diaphragm over the brachial artery. The column of 
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mercury must be vertical. Inflate the cuff occlude the pulse. Measure systolic (first 
sound) and diastolic (disappearance) to the nearest 2 mm Hg. 
Blood pressure variations have been demonstrated, and considerable differences in 
readings can be seen at different times of the day (Zachariah et al 1988). (Figure 1, 
page 5) 
We measured blood pressure according to the guidelines in Table 1 (page 6), adapted 
from those recommended by the American Heart Association (Perloff et al. 1993), 
the British Hypertension Society (Petrie et al. 1986), and the American Society of 
Hypertension (1992), to help prevent most measurement errors. 
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Figure 1 Computer printout of blood pressures obtained by ambulatory blood 
pressure monitoring over 24 h beginning at 9 A.M. in a 50-year-old man with 
hypertension receiving no therapy. The patient slept from midnight until 6 A.M. 
solid circles, heart rate in beats per minute (Zachariah, Sheps and Smith 1988). 
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Table 1 Guidelines for Measurement of Blood Pressure 
Patient Conditions 
Posture 
• Initially, particularly in patients >65 years, with diabetes, or receiving antihypertensive therapy, check for 
postural changes by taking readings after 5 min supine, then immediately upon and 2 min after standing 
• For routine follow-up, the patient should sit quietly for 5 min with the arm bared and supported at the level 
of the heart and the back resting against the chair 
Circumstances 
• No caffeine or smoking within 30 min preceding the reading 
• No exogenous adrenergic stimulants (e. g., phenylephrine in nasal decongestants) 
• A quite, warm setting 
Equipment 
Cuff size 
• The bladder should encircle at least 80% of the circumference and cover two-thirds of the length of the 
arm; if it does not, place the bladder over the brachial artery 
• A too small bladder may cause falsely high readings 
Manometer 
• Either a mercury, recently calibrated aneroid or validated electronic device 
Stethoscope 
• The bell of the stethoscope should be used; to avoid interference, the cuff may be placed with the tubing at 
the top 
Infants 
• Use ultrasound (e. g., the Doppler method) 
Technique 
Number of readings 
• On each occasion, take at least two readings, separated by as much time as is practical; if readings vary by 
>5 mm Hg, take additional readings until two are close 
• For diagnosis, obtain three sets of readings at least 1 week apart 
• Initially, take pressure in both arms; if the pressures differ, use the arm with the higher pressure 
• If the arm pressure is elevated, take the pressure in one leg, particularly in patients <30 years old 
Performance 
• Inflate the bladder quickly to a pressure 20 mm Hg above the systolic pressure, recognized by 
disappearance of the radial pulse, to avoid an auscultatory gap 
• Deflate the bladder 3 mm Hg/s 
• Record the Korotkoff phase I (appearance) and phase V (disappearance), except in children, for whom use 
of phase IV (muffling) may be preferable 
• If the Korotkoff sounds are weak, have the patient raise the arm and open and close the hand 5-10 times; 
then inflate the bladder quickly 
Recordings 
• Note the pressure, patient position, the arm, and cuff size (e. g., 140/90, seated, right arm, large adult cuff) 
Epidemiologists, statisticians, and clinicians have grappled with the problem of 
defining hypertension for many years. Some studies provide simplifying and 
practical concepts. For the broad range of blood pressure found in large populations, 
the risk of future cardiovascular disease (stroke of coronary heart disease) begins to 
increase when average diastolic pressures exceed 80 mm Hg (Taylor 1977; 
MacMahon et al. 1990), and for the middle-aged and older patient, systolic pressures 
exceed 130 to 135 mm Hg (Lichtenstein et al. 1985; Glynn et al. 1995). In the 
Hypertension Optimal Treatment (HOT) Study, the most important finding was the 
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blood pressure level achieved by patients that provided the maximum protection 
against major cardiovascular events: this was 138.5/82.6 mm Hg. Reducing systolic 
blood pressure to 138.5 mm Hg lowered the risk of major cardiovascular events by 
22%, and reducing diastolic blood pressure to 82.6 mm Hg lowered this risk by 30%. 
Additional decreases in systolic or diastolic blood pressure did not produce 
additional reductions in the risk. The estimated risk of myocardial infarction or 
stroke was lowest at a systolic blood pressure of 142.2 mm Hg. However, a definite 
diastolic value for the lowest risk of myocardial infarction or stroke could not be 
identified. The lowest risk of cardiovascular mortality was estimated to be at an 
achieved blood pressure of 138.8/86.8 mm Hg. 
Pickering in 1955 (Pickering 1955) qualitatively differentiated hypertension into 
essential hypertension and secondary hypertension. Essential hypertension was 
characterized by high blood pressure and hypertensive cardiovascular hypertrophy of 
the heart and arteries. Secondary hypertension was defined as hypertension occurring 
as the prominent phenomenon of a disease. Renovascular hypertension, primary 
aldosteronism hypertension, pheochromocytoma hypertension, and others are 
considered as secondary hypertension. Aoki proposed in 1985 (Aoki 1985), an 
etiological classification of hypertension, the following three-way classification: (1) 
genetic (essential) hypertension, (2) environment (accessory gene) hypertension, and 
(3) disease (non-gene) hypertension. Gene hypertension, inherited through the major 
hypertension genes, may correspond to essential hypertension. Environment 
hypertension is characterized by the development of hypertension due to an 
interaction of environmental factors on accessory hypertension genes. Salt-sensitive 
hypertension, obesity-sensitive hypertension, alcohol hypertension, and other types 
of environment hypertension are considered. Disease hypertension, defined as high 
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blood pressure resulting from a disease, corresponds to Pickering's secondary 
hypertension. 
Hypertension is a common multifactorial vascular disorder of largely unknown 
cause. Recognition that hypertension is in part genetically determined has motivated 
studies to identify mutations that confer susceptibility. Some of the candidate genes 
have been found to contribute to high blood pressure. In addition to justification 
based on functional relevance, candidate genes can command greater attention if they 
fall within chromosomal regions that are linked with blood pressure in chromosomal 
or genome-wide mapping studies. The list of candidates that might be derived from 
pathophysiological evidence or positional mapping is potentially enormous. To date, 
a handful of candidate genes have captured the attention of genetic researchers. Some 
of the candidates that have been linked to or associated with high blood pressure are 
shown in Table 2 (page 9). 
Lifestyle related factors such as obesity, drinking habits, sodium and potassium 
intake and physical inactivity are well established determinants of high blood 
pressure. An increase in blood pressure is virtually always found in populations that 
have migrated from rural to urban living. This can be exemplified by the 
observations in a Pacific island population that migrated from the Tokelau Island to 
New Zealand to take up living in an urban and industrialized society (Beaglehole et 
al. 1977). Similar observations have been made in China on the Yi people who 
moved from a very primitive rural life to a somewhat more culturated lifestyle (He et 
al. 1991), as well as in several studies from Africa (Scotch 1963; Sever et al. 1980; 
M'Buyamba-Kabangu et al. 1987). The differences in blood pressure between 
migrants and those who remain in their original habitat are not due to selective 
migration (Poulter et al. 1988). Migration from a rural to an urban setting usually 
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means that a number of factors of importance for blood pressure undergo change. 
These include dietary habits, usually leading to a higher intake of calories, salt, 
animal protein, simple carbohydrates, saturated fat, and processed foods (Poulter et 
al. 1994). Often there is an increase in the amount of alcohol consumed in addition to 
a number of sociocultural factors changing. Essential hypertension is associated with 
an increased prevalence of insulin resistance and other metabolic abnormalities. 
Insulin resistance, hyperinsulinemia, and hyperglycemia have been implicated as 
contributing factors in the pathogenesis of hypertension (Falkner et al. 1990; Sowers 
et al 1993; Afonso et al. 1997). The Renin-angiotensin system also plays a critical 
role in the pathogenesis of hypertension (Laragh 1995). 
Table 2 Genes implicated in High Blood Pressure 
6-Phosphogluconate dehydrogenase (Wilson et al. 1991) 
ACE (Fomage et al 1998; O'Donnell et al. 1998) 
Angiotensinogen (Jeunemaitre et al. 1992) 
Glucocorticoid receptor (Watt et al. 1992) 
Insulin receptor (Ying et al. 1991) 
Complement C3F (Schaadt et al. 1981) 
P 2 - A d r e n e r g i c receptor (Kotanko et al 1997; Timmermann et al. 1998) 
Lipoprotein lipase (Wu et al. 1996) 
Type lA dopamine receptor (Krushkal et al. 1998) 
a IB-Adrenergic receptor (Krushkal et al. 1998) 
a-Adducin (Casari et al. 1995) 
Endothelial nitric oxide synthase (Miyamoto et al 1998) 
Pancreatic phospholipase (Frossard et al. 1995) 
a2-Adrenergic receptor (Lockette et al. 1995) 
SA gene (Iwai et al. 1994) 
Angiotensin II type 1 receptor (Bonnardeaux et al. 1994) 
G-protein P3 subunit (Siffert et al. 1998) 
Prostacyclin synthase (Nakayama et al 1997) 
Growth hormone (Julier et al. 1997) 
1.3 Overview of Obesity-Related Hypertension 
Over the past few decades there has been a steady increase in the prevalence of 
obesity, with between 20% and 40% of adults in developed countries being 
overweight [body mass index (BMI) > 25 kgW] (Kuczmarski et al. 1994). Between 
1980 and 1995, the prevalence of obesity in the United Kingdom (UK) nearly 
doubled, increasing from 8% to 15% (Wilding 1997). In Europe, more than half of 
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adults 35 to 65 years of age are overweight or obese (Seidell et al 1997), and in the 
United States (US), reports suggest that approximately one-third of persons 20 years 
of age and older fall into this category (Kuczmarski et al. 1994). Surveys in the UK 
and the US show steady increases in the prevalence of obesity with age in both men 
and women (Millar et al. 1987). The prevalence of obesity also varies with race and 
socioeconomic status. For example, poor African Americans and Mexican 
Americans are at increased risk for developing obesity (Bjomtorp 1997). The 
increased prevalence of obesity has been attributed to genetic factors, sedentary 
lifestyles and the ready availability of palatable, high-fat foods (Wilding 1997). The 
problem of obesity is also increasing rapidly in urbanized areas of developing 
countries. Obesity substantially increases morbidity and mortality risk, and especially 
predisposes to hypertension, type II diabetes, cardiovascular and cerebrovascular 
disease. 
Obesity and obesity related-hypertension are major and growing, international health 
problems, described by the World Health Organization (WHO) in its "Global Burden 
of Disease" report (Manton 1988). The nationwide Community Hypertension 
Evaluation Clinic (CHEC) screening, which included one million Americans, 
showed that the prevalence of hypertension was 0.5 to 3 times higher in those who 
reported being overweight compared with those who classified themselves as normal 
or low weight (Stamler et al 1978). Data derived from the NHANES III study, 
which comprised more than 30,000 people, showed that systolic and diastolic blood 
pressure increased with increased BMI (Ernst et al. 1997). Results from the 
Framingham study show that there is increased prevalence of obesity in subjects who 
have had established hypertension (Kannel et al 1967). Thus, the relationship 
between obesity and hypertension may operate in both directions, where 
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hypertensive subjects have more of a tendency toward obesity and obese subjects are 
more prone to hypertension. Indirect evidence also shows that obesity may antedate 
hypertension. The Coronary Artery Risk Development in Young Adults (CARDIA) 
study (Burke et al 1994) has shown that young normotensive people with a positive 
family history of hypertension have significantly elevated body weight compared 
with those with negative family history. 
The association of obesity with blood pressure is present since childhood. The 
Bogalusa Heart Study showed that blood pressure was proportional to body mass and 
height in about 3,500 children 5 to 14 years of age (Voors et al 1977). 
Racial influences also play an important role in the linkage between obesity and 
hypertension. In black populations, there is less impact of BMI on blood pressure. In 
the NHANES III report, the increased prevalence of high blood pressure in 
overweight compared to normal weight individuals was highest in white women 
(75%), followed by white men (60%), followed by black men (40%), and lowest in 
black women (20%). The reason may be related to the high incidence of 
hypertension in nonobese blacks and suggests in addition that genetic factors are 
implicated in obesity-related hypertension (Ernst et al. 1997). In Pima Indians, in 
contrast, obesity is not associated with hypertension (Sead et al. 1991). In Hispanics 
of Mexican-American descent, however, BP is related to obesity but the impact is 
less than in the Caucasian population (Haffiner et al. 1992). 
1.3.1 Body fat distribution 
One of the major confounding variables in metabolic studies of obese patients is 
body fat distribution. Several reports have indicated that hypertensive patients have a 
more centralized and/or abdominal fat pattern than normotensive control subjects of 
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similar weight (Blair et al 1984; Weinsier et al 1985; Gillum 1987; Selby et al. 
1989). Another series of investigations, carried out at the same time, indicated that 
insulin resistance and type II diabetes mellitus were also associated with the upper 
body fat pattern. Studies from the laboratories of Kissebah and coworkers (Kissebah 
et al. 1982) and Bjorntorp and associates (Krotkiewski et al 1983) demonstrated that 
insulin resistance and hyperinsulinaemia were more common in subjects with the 
upper body fat distribution phenotype. In addition, insulin levels began to emerge as 
an independent risk factor for hypertension (Modan et al 1985; Ferrannini et al 
1987). The relationship between insulin and hypertension, although strongest in the 
obese, was present in the nonobese as well. Insulin and hypertension, therefore, 
appear to be linked and related to upper body fat distribution. 
1.3.2 Insulin resistance and Hyperinsulinaemia 
Insulin resistance and hyperinsulinaemia can be implicated in the aetiology of 
glucose intolerance, dyslipidaemia and obesity (Zimmet et al 1994). The evidence 
for hyperinsulinaemia playing a role in hypertension is not consistently supported by 
epidemiological data (Zimmet 1995). Insulin resistance and hyperinsulinaemia are 
more severe and more closely associated with hypertension in obese patients than in 
nonobese patients (Christlieb et al. 1985; Modan et al. 1985; Manicardi et al. 1986; 
Rournier et al. 1986; Rose et al. 1987; Tappy et al. 1991). Moderately obese 
hypertensives were demonstrated to have higher glucose and insulin levels during a 
glucose tolerance test as compared with normotensive obese individuals (Manicardi 
et al. 1986). In a large Israeli population-based cohort with a high prevalence of 
hypertension and obesity (Modan et al. 1985), hypertension was correlated with 
elevated insulin levels. Taken together, these and other studies (Foumier et al 1986; 
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Tappy et al. 1991) provide convincing evidence that hypertension in the obese is 
associated with hyperinsulinaemia. 
1.3.3 Sympathetic nervous system activity 
The association of insulin resistance with hypertension could result from a primary 
increase in sympathetic nervous system activity (Julius 1993). Increase in such 
activity induced by antagonize insulin-mediated uptake of glucose in the forearm of 
humans (Lembo et al. 1994). Although a primary increase in sympathetic activity 
might cause both hypertension and insulin resistance, studies in animals indicate that 
insulin resistance induced by a high-fat diet occurs before the onset of hypertension 
(Hall et al. 1993), an observation consistent with the primacy of insulin-mediated 
stimulation of the sympathetic nervous system. Several lines of evidence suggest that 
sympathetic stimulation plays a major role in causing obesity-induced hypertension 
(Landsberg 1989; Hall et al. 1996; Hall et al 1998): (1) high caloric intake increases 
norepinephrine turnover in peripheral tissues and raises resting plasma 
norepinephrine concentrations; (2) high caloric intake amplifies the rise in plasma 
norepinephrine that occurs with stimuli such as upright posture and isometric hand 
grip; (3) compared to lean subjects, obese hypertensive subjects have increased 
sympathetic activity, measured directly with microneurographic methods (Grassi et 
al 1995; Jones et al. 1997); and (4) pharmacologic blockade of adrenergic activity 
markedly blunts the rise in blood pressure associated with obesity (Hall et al 1993). 
Many studies had confirmed the sympathetic nervous system control of brown 
adipose tissue in relation to thermal balance. Electrical stimulation of specific areas 
of the hypothalamus showed that brown adipose tissue was usually activated when 
the ventromedial region was stimulated (Perkins et al. 1981; Minokoshi et al. 1986; 
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Freeman et al 1987; Holt et al 1987; Iwai et al 1987; Holt et al 1988), was 
sometimes activated when the paraventricular nucleus was stimulated (Freeman et al. 
1987; Holt et al 1987; Holt et al 1988) and was not affected when the lateral 
hypothalamus was stimulated (Perkins et al 1981; Holt et al. 1987; Iwai et al. 1987). 
There appeared to be a longitudinal inhibitory pathway from the preoptic area 
through the anterior and medial hypothalamus to lower brain areas (Freeman et al. 
1987). Studies of the effect of cooling the preoptic area of the hypothalamus or the 
skin suggest that this pathway was involved in thermoregulatory control of 
nonshivering thermogenesis in brown adipose tissue (Morimoto et al. 1985; Imai-
Matsumura et al. 1987; Imai-Matsumura et al. 1988). Obesity-inducing 
hypothalamic lesions usually impair the hypothalamic control of brown adipose 
tissue thermogenesis in relation to diet. In contrast, leanness-inducing lateral 
hypothalamic lesions either do not alter or even enhance brown adipose tissue 
sympathetic nervous activity (Yoshida et al. 1983; Arase et al. 1987) and 
thermogenic function (Lupien et al 1986; Holt et al. 1988; Park et al. 1988). 
However, data related to SNS activity in obesity were inconsistent. Young and 
Macdonald (Young et al 1992) reviewed 43 studies addressing this issue. According 
to their review, 19 studies found no differences in norepinephrine (NE) between non-
obese and obese subjects, 14 studies found NE lower in obese compared with non-
obese subjects, and 1 studies reported the reverse. Discrepancy between results was 
not thought to be due to the methodology, but age, diet, blood pressure level, gender, 
glucose tolerance, and physical activity might explain the differences in NE values. 
Obesity subtype might also be a factor, as higher SNS activity was noted 
predominantly in subjects with abdominal obesity (Kissebah et al. 1982). 
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1.3.4 Genetics of Obesity 
Obesity is a multifactorial disease with both genetic and environmental components. 
Stunkard studied the body mass index (BMI) of identical and fraternal twins reared 
apart and together. The intrapair correlation coefficients of identical twins reared part 
were similar to those for twins reared together (Stunkard 1991). In other words, 
sharing the same childhood environment did not contribute to the similarity of the 
BMI of twins later on in life. They concluded that genetic influences on BMI might 
account for as much as 70% of the variance. In a study of 12 identical twins who 
were deliberately over-fed, a strong intrapair correlation for increases in the amount 
of intra-abdominal visceral fat was found, with six times more variation between 
pairs than within pairs (Bouchard et al 1990). 
A number of candidate genes have been studied for either association or linkage with 
obesity. Candidate genes can be chosen for their possible effect on body fat 
composition, the anatomical distribution of fat, partitioning of nutrient storage, food 
intake and composition, and energy expenditure (Warden et al 1996). 
1.3.4.1 Brown adipose tissue (BAT) 
It is known that mammals possess at least two types of adipose cells: white 
adipocytes which store triglycerides and can also favour obesity development and 
brown adipocytes which are innervated by a dense sympathetic innervation, and the 
release of NE activates the production of cAMP and free fatty acids (FFA) as 
substrate for the mitochondria (Nicholls 1979; Barnard et al. 1980). Brown fat 
mitochondria have developed a unique uncoupling of the oxidation of fatty acids 
from the production of ATP and can therefore dissipate as heat the energy available 
from the oxidation of substrates (Nicholls 1979). Brown adipocytes differ from white 
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adipocytes by their multilocular appearance (several fat droplets per cell) and their 
numerous tightly packed mitochondria. In fact, brown adipocytes can be distinctly 
identified by the detection of the uncoupling protein (UCP) which is uniquely 
expressed in these cells (Camion et al 1985; Himms-Hagen 1990). Although the 
importance of brown adipose tissue in regulatory thermogenesis in rodents has been 
well documented, its significance in humans is still poorly understood (Lean et al. 
1986). The existence of BAT in humans is now accepted. However most studies 
were made on necropsy material and the conclusions were based on simple 
histological criteria. These studies indicated that BAT is mainly abundant in the 
perirenal region during the first and second decades of human life (Heaton 1972; 
Tanuma et al. 1975; Tanuma et al. 1976; Huttunen et al. 1981). 
Brown adipose tissue has a rich sympathetic innervation, with nerve endings on both 
cells and blood vessels and an extensive network of vascular capillaries. Its 
metabolic activity is regulated primarily by norepinephrine secreted by the nerve 
supply. Brown adipose tissue oxidizes its triglyceride stores when stimulated by its 
sympathetic nerves. The metabolic activity of brown adipose tissue is regulated 
primarily by circulating hormones, such as insulin and epinephrine. The two external 
stimuli that trigger thermogenesis in brown adipose tissue, cold and food ingestion, 
increase sympathetic nervous activity in the tissue (Young et al. 1982). 
1.3.4.2 Uncoupling protein 
BAT mitochondria possess a protein, the uncoupling protein (UCP), which is not 
present in mitochondria of other tissues. The UCPs are inner mitochondrial 
membrane transporters which dissipate the proton gradient, releasing stored energy 
as heat. The UCP has been established as the major, perhaps the sole, component of 
BAT mitochondria that confers upon them their unique thermogenic property, that is 
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of becoming physiologically and reversibly uncoupled (Nicholls et al. 1986). UCP is 
a member of a family of mitochondrial carriers, UCP has a triplicate organization 
with three homologous domains of about 100 amino acids, encoded by two exons 
each. Several UCPs have now been identified including UCPl (expressed in brown 
fat), UCP2 (widely expressed) and UCP3 (mainly expressed in skeletal muscle). 
Variants of the UCP genes may be involved in the aetiology of obesity via an effect 
on thermogenesis. 
1.3.4.3 Uncoupling Protein 1 Gene 
The human uncoupling protein (UCP) 1 gene had been cloned and mapped to the 
long arm of chromosome 4 (q31) (Bouillaud et al 1988; Cassard et al. 1990). An A 
to G polymorphism in the 5'-flanking region of the uncoupling protein 1 (UCPl) 
gene had been identified in Caucasian subjects (Oppert et al. 1994). This UCPl gene 
marker was shown to be associated with an increased capacity for weight gain over 
years (Oppert et al 1994). Uncoupling protein 1 (UCPl) is a 32-kilodalton protein 
located in the inner mitochondrial component of brown adipose tissue (BAT). 
Through a regulation mainly by intracellular free fatty acids, UCPl dissipates the 
electrochemical gradient generated in the electron transfer chain in the mitochondria 
and thereby uncouples the respiration process leading to production of heat instead of 
ATP. A Bel I restriction fragment length polymorphism (RFLP) located in the 5'-
flanking region of the UCPl gene had been found to be associated with increased 
accumulation of body fat in a 12-year prospective study in 64 families from Quebec 
(Oppert et al. 1994; Cassard-Doulcier et al. 1996). This polymorphism site is due to 
an A to G point variation at position -3826 bp in the 5' flanking genie domain of 
UCP (Cassard-Doulcier et al 1996). 
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1.3.4.4 Association of the UCPl Polymorphism and Weight Gain in 
Obesity 
Mutations of the uncoupling protein 1 (UCPl) gene had also been studied in relation 
to weight changes. Two studies with a retrospective study design had found the A to 
G polymorphism in the UCPl gene to predict a larger weight gain (Oppert et al. 
1994; Clement et al 1996). Clement et al. (Clement et al. 1996) found that a high 
prevalence (27%) in French Caucasians of the A to G change variation located in the 
5' flanking domain of the UCP gene was observed with no significant difference 
between morbidly obese patients and non obese subjects, suggesting that the UCP 
gene was not a major gene for obesity. However, when they compared two groups of 
high weight gainers and low weight gainers, the results were that the presence of the 
A to G allelic variant of the UCP gene was shown to be an associated factor of high 
weight gain during adult life (odd-ratio = 1.4, P=0.02). Urhammer et al. performed 
an association study which showed that there was no association between the 
genotype of the polymorphism and the variables listed (Arg/Trp; Ala/Thr; Val/Met; 
Met/Leu; Lys/Asn), in particular no association with BMI, fat mass, or weight gain 
during childhood and adolescence (Urhammer et al. 1997). In Japan, Hayakawa et al. 
(Hayakawa et al 1999) investigated 264 Japanese men aged 30 to 71 years. For the 
A to G polymorphism of the UCPl gene, the frequency of the G allele was 0.51. In 
non-insulin-dependent diabetes mellitus (NIDDM), impaired glucose tolerance 
(IGT), and normal glucose tolerance (NGT), the frequency was 0.57, 0.50, and 0.48, 
respectively, with no significant differences between patterns with various levels of 
glucose tolerance. In non-obese, intermediate, and obese subjects, the G allele 
frequency was 0.44, 0.52, and 0.46, respectively, with no significant differences 
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among the three groups. The BMI was significantly higher in subjects with the G 
allele versus those without it, but other characteristics did not differ. In the Quebec 
Family Study, Oppert et al. (Oppert et al. 1994) showed no relationship was found 
between the proportion of the marker alleles shared by sibs and the squared 
difference of BMI, percent body fat, subcutaneous fat, resting metabolic rate (RMR), 
or the changes in the quantitative phenotypes during the 12-year period of follow-up, 
suggesting absence of linkage. 
1.4 Overview of Genetics of Hypertension 
Essential hypertension represents the upper quintile of the blood pressure distribution 
in the general population and is a major risk factor for morbidity and mortality from 
cardiovascular causes (MacMahon et al. 1990). Studies of families and twins implied 
that 20 to 40 percent of the variance of essential hypertension may have a genetic 
basis (Ward 1990). Epidemiologic studies indicate a continuous distribution of blood 
pressure in the population, and the genetic basis of this disorder appeared to be 
polygenic and therefore did not follow simple Mendelian patterns of inheritance 
(Pickering 1965). It is likely that several genes interact with environmental stimuli to 
produce high blood pressure in susceptible persons (Williams et al 1989). 
1.4.1 The Renin-Angiotensin System 
In adult mammals, the renin-angiotensin system (RAS) regulates arterial blood 
pressure, renal haemodynamics, and fluid and electrolyte homeostasis. The RAS 
cascade is composed of a series of enzymatic reactions culminating in the generation 
of angiotensin peptides, which are responsible for most of the actions of the RAS 
(Peach 1977; Keeton et al 1980). The initial substrate of this cascade, 
angiotensinogen, can be hydrolyzed in the circulation (circulating RAS) and 
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presumably in a variety of tissues (local RAS) (Czau 1984; Campbell 1987). The 
enzyme renin acts on a leucyl-leucine bond of angiotensinogen to yield the 
decapeptide angiotensin I. Angiotensin I is then cleaved by angiotensin-converting 
enzyme (ACE), a carboxyl terminal dipeptidase, to yield the octapeptide angiotensin 
II. Angiotensin II interacts with its receptors, thereby inducing the actions of the 
RAS. Angiotensin II can be processed by enzymes like aminopeptidase [angiotensin 
III (2-8), angiotensin IV (3-8)] and endopeptidase [angiotensin (1-7)] to several 
active or inactive fragments (Peters 1995). In contrast to renin, which is a highly 
specific enzyme for angiotensinogen, ACE degradates bradykinin and is involved in 
the biosynthesis of different neuropeptides such as substance P. The angiotensin 
peptides exert their effects via specific angiotensin receptors (AT receptors). The use 
of specific nonpeptide antagonists led to the identification of two major AT receptor 
subtypes termed ATi and AT2. Most of the known effects are mediated via the ATi 
receptor. The ATi receptor is a G-protein coupled receptor which activates the 
inositol-diacylglycerol cascade and augments intracellular calcium or interacts with 
the adenylate cyclase system. The exact role of the AT2 receptor remains to be 
further elucidated, although there is evidence for a tyrosine kinase activity of the AT2 
receptor and involvement in cell proliferation and in fetal development and it appears 
to have some effects which oppose those mediated through the AT! receptors. 
1.4.1.1 Functions of Renin-Angiotensin System 
The endocrine RAS is subject to feedback regulation. The stimulus is primarily 
hypotension, and once it is compensated the system shuts off. Similarly, in volume-
depleted states, the system is activated for the duration of the initial hypovolaemic 
state, supporting a short-term regulatory profile for endocrine RAS. In contrast, the 
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local RAS activation seems to have both short- and long-term regulatory roles in 
cardiovascular homeostasis, which is achieved by sustained activation of local 
angiotensin and the secondary structural changes in the cardiovascular system. 
Angiotensin II plays a significant role in controlling the growth of vascular smooth 
muscle cells (SMC) and transgenic cardiomyocytes (Cook et al 1995). A direct 
stimulating effect of angiotensin II on vascular myocyte growth had been 
demonstrated by Geisterfer et al. (Geisterfer et al. 1988), who used cultured rat aortic 
SMC and by Campbell-Boswell and Robertson (Campbell-Boswell et al. 1981), who 
used cultured human aortic SMC. Cook et al. (Cook et al. 1995) demonstrated 
growth-promoting properties of angiotensin II in transgenic cardiomyocytes. The 
effect of ACE inhibitors in spontaneously hypertensive rats provides indirect 
evidence implicating angiotensin II as a hypertrophic stimulus. Several mechanisms 
have been proposed for the growth-promoting effects of angiotensin II, such as 
enhanced gene expression and elaboration of platelet-derived growth factor (PDGF) 
(Naftilan et al. 1989), fibroblast-derived growth factor (FDGF), and other cytokines 
(Itoh et al. 1993), which in turn mediate increased messenger RNA and protein 
synthesis in vascular SMC. In addition to the growth promoting effects of 
angiotensin II, evidence exists to support angiotensin Il-mediated transforming 
growth factor-(3 production, which neutralizes the pro-proliferative effects of 
angiotensin (Gibbons et al. 1992). 
1.4.1.2 The Renin-Angiotensin System and Hypertension 
Essential hypertension is a multifactorial and polygenic disorder, and several genes 
are thought to play a role in its pathogenesis. The RAS is one of the important factors 
regulating blood pressure, as well as fluid and electrolyte balance, and may have an 
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important role in the pathogenesis of hypertension. Persistent activation of the RAS 
in the pathogenesis of renovascular hypertension is well documented. However, 10% 
to 20% of subjects with essential hypertension have high plasma renin levels. This 
persistent activation of the RAS in the face of high blood pressure suggests an 
impaired negative feedback system. On the other hand, enhanced tissue-based RAS 
expression and activation that occurs in the face of high blood pressure may explain 
the paradoxical association. 
The pathophysiologic hypothesis is very intuitive. Because the RAS is intimately 
involved in the regulation of blood pressure, a genetic variability in the degree of 
expression of one of its enzymes may account for variability in the blood pressure or 
may play a role in mediating high blood pressure. The genes coding for each protein 
involved in the RAS have been identified and studied for any relation with 
hypertension and other cardiovascular disorders. The renin gene and its 
polymorphism were studied first. In Utah, a careful analysis of a large pedigree with 
a high prevalence for hypertension failed to demonstrate any significant association 
between hypertension and RFLPs in the renin gene (Soubrier et al. 1990). Two other 
studies of a hypertensive population in Europe also failed to show that the renin gene 
was a genetic determinant of hypertension (Naftilan et al. 1989). Other genes such as 
the ACE gene, and ATi gene will be mentioned later. 
1.4.2 Renin 
Renin is the first enzyme in the biochemical cascade of the renin-angiotensin system. 
It is synthesized and stored in the juxtaglomerular cells of the afferent arteriole of the 
kidney and is released into the circulation in response to a variety of stimuli. Renin is 
an aspartyl proteinase. It cleaves its substrate, angiotensinogen, to generate the 
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decapeptide angiotensin I. Renin has been completely purified from various species 
(Cohen 1972; Inagami et al. 1977; Dzau 1979; Galen 1979; Yokosawa 1980). There 
appears to be a high degree of structural conservation between renins of different 
species (Dzau 1982; Corvol 1983). Renal renin is a glycoprotein with a molecular 
weight of 37,000 to 40,000. Its isoelectric point is between 5.2 and 5.8, and the pH 
optimum for reaction with angiotensinogen is 5.5 to 5.6. Studies of the structure of 
mouse submandibular gland renin indicate that renin is composed of a heavy chain 
(molecular weight 31,000) and a light chain (molecular weight 5500) linked by a 
single disulfide bond (Misono 1982). The active site is located in the heavy chain; 
the function of the light chain has not yet been exactly elucidated. Renin is 
synthesized from its mRNA as a preproenzyme (Khairallah 1972; Dzau 1981) and is 
rapidly translocated into the lumen of the endoplasmic reticulum. In the lumen of the 
rough endoplasmic reticulum and Golgi apparatus, prorenin is processed into the 
mature, active enzyme, which is finally packaged and stored in secretory granules. 
The biosynthetic sequence of human renin has recently been characterized [Hsueh, 
1991 #2638; Krieger, 1991 #2642, Paul, 1988 #2640; Pratt, 1987 #2641]. 
Biosynthesis and secretion of human renin has been studied in both renal and 
extrarenal tumor tissue, in normal kidney, and in cultured cells transfected with and 
thus expressing the human renin gene (Pratt et al 1987; Paul 1988; Krieger et al. 
1991). Translation of human renin mRNA results in preprorenin, which then 
undergoes cotranslational removal of the signal peptide, followed by glycoxylation 
during tansfer into the cisternae of the rough endoplasmic reticulum. Within the 
juxtaglomerular cells of the kidney, prorenin appears to be sorted by one of two 
pathways: a regulated pathway mediated by secretory granules, where a thiol pretese 
cleaves the amino terminal of the 43-amino acid prosegment, or a constitutive 
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pathway (Pratt et al. 1987). In man, markedly increased levels of circulating prorenin 
(also called inactive renin) occur both as a normal physiologic response and as a 
response to disease. Prorenin level may participate in the regulation of renal renin 
production. 
The release of renin is influenced by a number of factors (Keeton et al. 1980). The 
major signals controlling renin secretion are (1) renal perfusion pressure, monitored 
by an intrarenal baroreceptor; (2) the adrenergic nervous system, via renal 
sympathetic nerves or circulating catecholamines that act on a beta receptor; (3) 
distal tubular sodium concentration at the macula densa; and (4) other humoral 
signals (potassium, angiotensin II, prostaglandins, and possibly kinins). 
Tobian originally proposed the existence of an intrarenal baroreceptor that regulates 
renin release in response to change in the stretch of the arteriolar wall (Tobian 1960). 
The stimulus-response curve of pressure and renin secretion has recently been 
defined in the conscious dog (Farhi 1982). Renin release is relatively unresponsive to 
the initial 10 to 20 mm Hg reduction from a normal basal blood pressure. The 
threshold pressure is 80 to 90 mm Hg; below the threshold, renin secretion is a steep 
and linear function of renal perfusion pressure. 
The activity of two intrarenal adrenergic receptors (beta and dopaminergic) influence 
renin release. The beta and dopaminergic receptors on the juxtaglomerular cells are 
responsive to both neurally released and circulating catecholamines (Keeton et al. 
1980). Electrical stimulation of renal sympathetic nerves or selective areas of the 
vasomotor center or hypothalamus results in renin release, which is blocked by 
propranolol. Epinephrine and isoproterenol stimulate renin release both in vivo and 
in vitro. Specific dopaminergic nerve endings and receptors have been demonstrated 
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in the kidney. Stimulation of dopaminergic receptors also results in renin release 
(Mizoguchi 1983). 
Sodium also exerts a major influence on renin release. Both intrarenal infusion of 
sodium chloride and an increase in dietary sodium intake are capable of inhibiting 
renin release. Dietary sodium restriction is associated with increased renin secretion. 
There are at least two possible mechanisms by which sodium may influence renin 
release. Sodium may have an indirect effect by changing extracellular sodium 
content and fluid volume (leading to an altered volume or neural signal); or there 
may be, potentially, a direct effect of sodium on the juxtaglomerular apparatus 
(either on the juxtaglomerular cells or on macula densa sensors). Kotchen and 
coworkers have suggested that chloride rather than sodium is responsible for the 
control of renin release via the macula densa (Kirchner 1978). 
1.4.3 Angiotensinogen 
Angiotensinogen is a moderately abundant 55,000-60,000 Da serum glycoprotein 
that is the precursor to the angiotensin peptides and is the only known naturally 
occurring renin substrate. Most angiotensinogen is extracellular, and therefore its site 
of synthesis is most readily determined by detecting its mRNA. Angiotensinogen 
RNA sequences accumulate in liver, fat, and brain and have been detected, albeit in 
small amounts, in a variety of tissues including lung, kidney, ovary, adrenal gland, 
heart, spinal cord, and testes (Campbell et al 1986; Ohkubo et al. 1986). The 
function of angiotensinogen is to act as a circulating renin substrate, and the products 
of the reaction are the (amino terminal derived) decapeptide Ang I and des (Ang I)-
angiotensinogen (Morton 1999). Some of the impetus for studies of angiotensinogen 
gene promoter activity was provided by the body of literature describing 
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developmental and hormonal influences on angiotensinogen gene expression. The 
most studied regulatory phenomenon regarding angiotensinogen is that exerted by 
glucocorticoids. In addition to the unmasking of additional transcription start sites 
upstream of the angiotensinogen gene (Ben-Ari et al. 1989) and exerting a 
permissive effect with acute-phase response mediators (Ron et al. 1990), 
glucocorticoids increase the level of angiotensinogen gene expression. 
Angiotensinogen gene expression is also positively affected by sex steroids. The 
estradiol-indued increase in angiotensinogen gene expression is reflected in elevated 
plasma renin substrate levels seen in women taking oral contraceptives (Skinner et 
al 1969). Androgen treatment of female rats or castrated male rats has been reported 
to increase kidney angiotensinogen RNA levels (Ellison et al 1989). Investigation of 
angiotensinogen (AGT) in adipose tissue began in 1987, when AGT-mRNA was 
found in periaortic brown adipose tissue (BAT) and in cells found within the rat aorta 
wall (Campbell et al, 1987). Subsequently, AGT secretion and AGT-mRNA were 
detected in several rat adipose tissue depots and in adipocytes isolated from rat 
arterial vessel walls, atria, and mesenterium (Cassis et al. 1988; Cassis et al. 1988; 
Naftilan et al 1991). In humans, AGT expression has been demonstrated in adipose 
tissue (Jones et al. 1997; Engeli et al. 1999), in primary, cultured adipocytes, and in 
differentiating preadipocytes (Schling et al. 1999). AGT expression in adipose tissue 
of animal models of obesity and hypertension as well as in obese and hypertensive 
subjects has been investigated with positive (Frederich et al. 1992; Tamura et al. 
1996; Nyui et al 1997; Hainault et al. 1998; Hainault et al. 1999; Van Harmelen et 
al. 1999) and negative results (Harp et al. 1995; Jones et al. 1997; Tamura et al. 
1997; Giacchetti et al. 1999). 
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Several genetic studies have been performed to evaluate the role of the AGT gene in 
essential hypertension after initial positive results were obtained by linkage and 
association in French and Utah families (Jeunemaitre et al. 1992). The study by 
Jeunemaitre and associates (Jeunemaitre et al. 1992) also identified 15 distinct single 
nucleotide polymorphisms in the human angiotensinogen gene. Among them, two 
transversions in exon 2, a T—C substitution that results in conversion of amino acid 
235 from methionine to threonine (M235T) and a C—T substitution that results in 
conversion of amino acid 147 from threonine to methionine (T147M), were 
significantly associated with hypertension in both study cohorts. In addition, 235T, 
but not 147M, was associated with approximately 15% higher circulating plasma 
angiotensinogen concentrations in homozygotes compared with heterozygotes or 
controls. Variant T235 corresponds to the presence of a threonine instead of a 
methionine at residue 235 of the mature protein and occurs at a frequency of 35-40% 
in Caucasians. Another variant, Ml74, is characterized by the presence of a 
methionine instead of a threonine at residue 174; occurring at a frequency of 8-10% 
in Caucasians, it also exhibits significant association with hypertension (Jeunemaitre, 
et al 1992). Rotimi et al. compared the frequency of the 235T and 174M alleles of 
the angiotensinogen gene, between 57 hypertensive African Americans and 130 
normotensive African Americans sampled as part of a community survey of 
hypertension in the Chicago area. They found no evidence that the 235T allele 
confers a risk of hypertension (Rotimi et al 1994). In Japan, the AGT gene was 
examined in a sample of 105 subjects with a systolic BP > 160 mmHg and / or a 
diastolic BP > 95 mm Hg at three or more visits at least 2 wk apart, and in 81 control 
subjects with normal blood pressure. Allele T235 was significantly more common 
among hypertensive subjects than in controls (0.89 vs. 0.75, yj^ = 11.3, P < 0.001); 
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79% of cases and 54% of controls were homozygous for this allele. The frequency of 
allele T235 in normotensive Japanese was much higher than observed in 
normotensive Caucasians (0.75 vs. 0.36, xi^ = 62.1). There was no significant 
difference in the frequency of allele Ml74 among cases and controls (0.11 vs. 0.09, 
Xi = 0.77), its frequency was similar to that observed in Caucasians (Hata et al 
1994). Caulfield et al. using restriction enzymes, determined the frequency of the 
M235T and T174M genotypes in index patients from the 63 families and in 80 
control subjects. The allele frequencies for the two variants were very similar in the 
hypertensive patients and the controls, and neither M235T nor T174M was 
significantly associated with hypertension. Both M235T and T174M were tested for 
linkage by the affected-pedigree-member method in the 63 families, and there was no 
evidence that either polymorphism was linked to hypertension (t-statistic for M235T, 
-0.411, P = 0.68; t-statistic for T174M, -0.86313, P = 0.65). These studies suggested 
that a homozygous threonine allele at codon 235 in ATG (TT/M235T) is more 
frequent among individuals with hypertension than among normotensive subjects 
(Jeunemaitre et al. 1992; Brown et al. 1994; Hegele et al. 1994; Kamitani et al 
1994) and that the TT genotype is associated with an increase of circulating 
angiotensinogen concentration, which may result in hypertension (Jeunemaitre et al. 
1992). In China, Niu et al. analyzed two AGT polymorphisms, M235T and T174M, 
using data on 335 hypertensive subjects from 315 nuclear families and their parents. 
They found no evidence that either allele of M235T or T174M contributes to 
hypertension in this Chinese population (Niu et al. 1999). 
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1.4.4 Angiotensin-Converting Enzyme (ACE) 
The renin-angiotensin system (RAS) plays a key role in the regulation of blood 
pressure as well as in the maintenance of fluid and electrolyte balance. ACE is 
predominantly a membrane-bound ectoenzyme and an integral component of the 
RAS that is responsible for the production of angiotensin II from its inactive 
precursor angiotensin I as well as the degradation of bradykinin to inactive 
fragments. ACE converts the inactive decapeptide angiotensin I to the active 
octapeptide angiotensin II by releasing the C-terminal histidyl-leucine dipeptide. 
ACE is a metalloenzyme that always requires zinc as cofactor and also needs 
chloride ions to cleave most substrates; angiotensin I conversion is absolutely 
chloride dependent, whereas bradykinin hydrolysis is less affected. Human ACE has 
a molecular weight of 150,000 to 180,000, of which 146.6 kD is protein and the 
balance is carbohydrate. The majority of ACE is membrane-bound and is present on 
the plasma membrane of various cell types. ACE is inserted into the membrane by a 
17-amino-acid hydrophobic region near the C-terminus. Proteolytic cleavage near the 
C-terminus results in the release of ACE from the plasma membrane, which happens 
normally in vivo. 
1.4.4.1 Angiotensin-Converting Enzyme Gene 
The human gene that encodes ACE has been cloned and shown to be located on the 
q23 region of chromosome 17 (Bernstein et al. 1988; Soubrier et al 1988). The 
human ACE gene comprises 26 exons and 25 introns. Both somatic and testicular 
ACE isoforms are derived from the same gene via two alternative promoters (Hubert 
et al. 1991; Kumar et al. 1991). The somatic promoter is located in the 5' flanking 
region of the gene, upstream of exon 1, and initiates somatic ACE transcription. The 
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testicular promoter is located within intron 12 of the gene and is responsible for 
transcription of testicular ACE (Howard et al 1990). Somatic ACE is encoded by an 
mRNA of 4.3 Kb, transcribed from exons 1 to 26 of human ACE gene, excluding 
exon 13. On the other hand, testicular ACE is encoded by an mRNA of 3 Kb, 
transcribed from exons 13 to 26, with exon 13 encoding the unique N-terminus of the 
testicular isoform. The insertion/deletion polymorphism within intron 16 of the ACE 
gene is due to the presence or absence of a 287-base pair fragment (Costerousse et al. 
1997). 
1.4.4.2 Association of the ACE I/D Polymorphism with Hypertension 
Previous studies of the relation between the ACE gene I/D polymorphism and 
essential hypertension have been equivocal. Several genetic investigations, such as 
case-control studies, affected sib-pair analyses, and rat cross-experiments, have 
attempted to elucidate the genetic pathogenesis of essential hypertension 
(Jeunemaitre et al. 1992; Kamitani et al. 1994; Sato et al 1997). A major locus for 
high blood pressure (BP/SPl ) is located on rat chromosome 10, which contains the 
rat angiotensin-converting enzyme gene (ACE) locus, according to several rat 
crosses between a genetically hypertensive rat strain and normotensive controls 
(Hilbert et al. 1991： Jacob et al. 1991). However, most human studies have failed to 
identify a positive association between essential hypertension and the ACT: 
polymorphism that is mapped on human chromosomc 17 (Jeunemaitre et al. 1992; 
Migashimori ct al. 1993). Although studies on US and Dutch populations have not 
shown an association between essential hypertension and ACE genotype 
(Jeunemaitre ct al. 1992: Schmidt ct al. 1993). studies on Australian and African-
American populations have shown such association (Zee el al. 1992; Duru et al. 
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1994). Two recent studies describe a linkage between the ACE locus and 
hypertension in a large number of hypertensive sibs (Fornage et al. 1998; O'Donnell 
et al 1998). 
The present Japanese study examines the association between hypertension and ACE 
I/D polymorphism as well as sex specificity in the Japanese population. Data showed 
that in a large number of Japanese subjects (n=5014), the frequency of DD (17.1%) 
in hypertensive men was significantly higher (P<0.0015) than that (11.8%) in other 
mildly hypertensive or normotensive men, and the estimated odds prevalence for 
hypertension (DD vs II) was 1.75 (95% CI 1.21 to 2.53). In contrast, no significant 
association was confirmed in women (odds ratio 1.17, 95% CI 0.79 to 1.72) (Higaki 
et al 2000) O'Donnell et al. showed that in logistic regression analysis, in a data 
sample consisting of 3095 participants, the adjusted odds ratios for hypertension 
among men for the DD and DI genotypes were 1.59 (95% confidence interval [CI], 
1.13 to 2.23) and 1.18 (95% CI, 0.87 to 1.62), respectively, versus II (P-0.02). In 
women, adjusted odds ratios for the DD and DI genotypes were 1.00 (95% CI, 0.70 
to 1.44) and 0.78 (95% CI, 0.56 to 1.09), respectively (P=0.14). In linear regression 
analysis, there was an association of the ACE DD genotype with increased diastolic 
blood pressure in men (age-adjusted P二0.03, multivariate-adjusted P=0.14) but not 
women. In the linkage analyses in 1044 pairs of siblings, by using both ACE D/I and 
a nearby microsatellite polymorphism of the human growth hormone gene, findings 
supported a role of the ACE locus in influencing blood pressure in men but not in 
women (O'Donnell et al. 1998). 
Turner et al. studied a sample of 1875 non-Hispanic white individuals (988 female) 
between 5 and 90 years of age from the general population of Rochester, Minn. They 
concluded that the influence of variation in the ACE gene on interindividual 
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variation in blood pressure is dependent on contexts that are indexed by gender, age, 
and measures of body size (Turner et al. 1999). 
Recently, Celentano et al. (Celentano et al 1999) found that a positive association 
existed between homozygosity for the D allele of the ACE gene and left ventricular 
hypertrophy. They investigated the influence of major cardiovascular risk factors 
(smoking, hypercholesterolemia, diabetic mellitus) on the association between the 
ACE gene I/D polymorphism and echocardiographic left ventricular mass in 225 
patients with sustained hypertension. No difference was found in subjects in whom at 
least 1 major cardiovascular risk factor was present. In the absence of cardiovascular 
risk factors, DD subjects (n=32) exhibited a left ventricular mass index higher than 
non-DD (ID/II) subjects (n=75; P<0.05). After controlling for age and sex, in the 
absence of cardiovascular risk factors, the risk of left ventricular hypertrophy was 
3.8-fold higher in DD than in non-DD patients (odds ratio 3.8; 95% confidence 
interval 1.2 to 12.1, P<0.02). 
1.4.4.3 Association of the ACE I/D Polymorphism with Other 
disease 
There is major disagreement about whether individuals with the ACE D allele are at 
greater risk of cardiovascular disease. The finding by Cambien et al. (Cambien et al 
1992) that classically low-risk individuals (low body mass index and low 
apolipoprotein B) but with the DD genotype are more likely to develop myocardial 
infarction was not confirmed by Ludwig and colleagues (Ludwig et al 1995) or 
Mattu and colleagues (Mattu et al. 1995). The ACE D/D genotype was more 
common in subjects with myocardial infarction who were considered to be at 
reduced risk on the basis of lower body mass index and cigarette consumption, and it 
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was more common in subjects with coronary artery disease and low cholesterol and 
triglyceride levels (Gardemann et al. 1995). 
Agerholm-Larsen et al. showed there was no significant difference in the 
development of ischaemic cerebrovascular disease between genotype classes of the 
ACE gene polymorphism in women or men (Agerholm-Larsen et al 1997). 
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1.4.5 The Angiotensin II Receptor 
Angiotensin, like other peptide hormones, interacts with receptors at the surface of 
its target cells. Three subtypes of receptor have been described, designated AT!, AT2, 
and AT4. Virtually all the well-known actions of Ang II and III are mediated by the 
first type of receptor ATi. AT2 has relatively high affinity for Ang III, and AT4 for 
Ang IV. 
1.4.5.1 Type 1 Angiotensin II Receptor 
The cell-surface angiotensin type 1 angiotensin II receptor (ATiR) is a member of 
the 7-transmembrane G protein-coupled receptor (GPCR) superfamily (Murphy et al. 
1991; Sasaki et al. 1991). It has been cloned from human, rat, mouse, rabbit, pig, and 
dog cDNA. The ATi receptor has a molecular mass of 41 kDa and contains three 
consensus N-glycosylation sites and eight phosphorylation sites that are involved in 
receptor-effector coupling (Sandberg 1994). The ATi receptor is sensitive to GTPyS, 
indicating that it has heterogeneous states of affinity owing to its association with G-
proteins. True subtypes of the AT] receptor, called ATia and ATm, have been 
characterized in rat. They are closely related but are encoded by distinct genes 
located on chromosomes 17 and 2, respectively. They differ in 19 amino acids, 
mainly in the carboxy-terminal region (Sasamura et al 1992), There are two 
additional phosphorylation sites in ATib (Elton et al. 1992). Although ATia and 
AT IB subtypes have identical binding and functional properties, they are 
differentially regulated (Chin et al 1993). A third subtype, ATic, has been described 
in rat placenta and has more than 80% homology to ATia and ATib (Hahn et al. 
1993). In humans, only one single AT! receptor has been reported and is encoded by 
a gene on chromosome 3. The properties of the rat ATia are close to that of the 
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human receptor. An additional and novel type of human ATi receptor has been 
cloned from a placental cDNA library. The AT! receptor is present predominantly in 
vascular smooth muscle cells. It appears pharmacologically distinct from the receptor 
cloned from a human heart cDNA library in its effect on calcium mobilization 
(Konishi et al. 1994). In humans, the AT! receptor is present predominantly in 
vascular smooth muscle cells. 
Several studies suggest that the ATi receptor might be involved in hypertension: (1) 
spontaneously hypertensive rats have an enhanced ATi receptor-mediated renal 
vascular responsiveness to Ang II infusion but not to periarterial renal nerve 
stimulation compared with Wistar-Kyoto rats (Kost et al. 1993); (2) some patients 
with hypertension present with an enhanced pressor responsiveness to infused Ang II 
(Meier et al 1981); (3) in humans, altered ATi receptor function/regulation could 
play a role in non-modulators, a subgroup of hypertensive individuals who fail to 
appropriately modulate renal vascular and adrenal reactivity in response to Ang II 
infusion with changes in dietary sodium (Lifton et al. 1989); and (4) although 
probably a distinct hypertensive phenotype, pregnancy-induced hypertensive patients 
have an enhanced pressor response to Ang II and increased platelet AT! receptor 
number (Grant et al. 1973; Graves et al. 1992). 
1.4.5.2 The Type 1 Angiotensin Receptor Gene 
The type 1 angiotensin receptor (ATi) gene has been located on chromosome 3 in 
humans and is encoded on exon 3 (Ahnve et al 1995). ATi genotypes were 
established by enzymatically amplifying a 120-bp fragment comprising a highly 
informative dinucleotide repeat in the 3' flanking region of the ATi receptor gene 














































in the angiotensin II type 1 receptor gene is associated with the incidence of essential 
hypertension and increased coronary artery vasoconstriction (Bonnardeaux et al. 
1994). Bonnardeaux et al. had performed a linkage study using the affected sib pair 
method and a highly polymorphic marker of the ATi receptor gene. There was no 
evidence for linkage in 267 hypertensive sib pairs analyzed from 138 pedigrees 
(Bonnardeaux et al. 1994). A genetic association study carried out in an independent 
series of 50 hypertensive cases and 122 normotensive controls showed that the 
A1166—C variant was significantly more frequent among the hypertensive cases 
than among the controls (28% versus 16%, P=0.01). The data provide evidence that a 
common genetic variant of the ATi gene locus influences the risk of essential 
hypertension in the Finnish population (Kainulainen et al 1999). Kainulainen et al. 
using linkage analysis also found that common genetic variation at the ATi gene 
locus may modify an individual's risk for developing essential hypertension. They 
analyzed 476 dizygotic and 264 monozygotic concordant hypertensive pairs, when 
allowing for linkage disequilibrium in the analysis, an LOD score of >3 was found in 
a 2-point dominant analysis with the marker A1166->C; and in the multipoint 
analysis, extracting information of all 3 intragenic diallelic markers (A1166->C, 
T573—C, and T-713—G), an LOD score of 4.75 was obtained with the recessive 
model and 5.13 with the dominant model. 
Berge et al. found that ATi gene CC homozygosity appeared to be associated with 
myocardial infarction in Norwegian males. They compared 235 survivors of 
myocardial infarction to 384 controls with respect to distribution of genotypes and 
gene frequencies in the A1166C polymorphism at the AT] locus, and no differences 
in allele frequencies or genotype distribution were observed when all patients were 
compared with all controls. The distributions of male cases and controls in the group 
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differed significantly with respect to genotypic groups, since all male cases and no 
male control had genotype CC (P<0.001), and there was no such difference observed 
among females (P=0.21) (Berge et al. 1997). 
1.4.6 Dopamine 
Dopamine (DA) is an endogenous neurotransmitter catecholamine that also serves as 
the biochemical precursor of norepinephrine and epinephrine. Dopamine modulates a 
variety of physiologic functions including behavior, movement, nerve conduction, 
hormone synthesis and release, ion transport, vascular tone, and blood pressure. 
Most studies of DA have been conducted in the central nervous system and the 
pituitary gland where our knowledge is well advanced (Spano et al. 1978). Only 
during the past decade has DA been characterized as an important modulator of 
blood pressure, sodium balance, and renal and adrenal function through an 
independent peripheral dopaminergic system. Dopaminergic mechanisms in the 
periphery have been studied in greatest detail in the kidney and less well in the 
adrenal glands and vasculature. 
In the kidney, a great deal of evidence suggests a proximal tubular origin of DA 
(Chan 1976; Bsines et al. 1980; Hagege et al 1985; Soares-da-Silva et al 1990; 
Aperia et al 1991; Lee 1993). Aromatic amino acid decarboxylase (AADC) is 
located primarily in the proximal tubule where biochemical conversion of 
dihydroxyphenylalamine (DOPA) to DA has been demonstrated. The main control 
mechanism for renal DA formation is dietary sodium, which is thought to increase 
the concentration of DOPA in the proximal tubular lumen with subsequent uptake in 
proximal tubular cells (Alexander et al. 1974; Ball et al. 1978; Baines et al. 1980; 
Carey et al. 1981; Goldstein et al 1989). Also, sodium can stimulate tubular 
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transport of several aromatic amino acids, including DOPA, thus providing the 
substrate for DA formation by high levels of AADC within the tubule (Ullrich et al. 
1974). It is also possible that the intracellular electrolyte composition may play a role 
in the regulation of DA production, but this requires further study (Bertorello et al 
1988). There are reports of a deficiency in the renal dopamine synthesis and/or 
secretion in various forms of human hypertension. Because endogenous kidney 
dopamine plays an important role in maintaining body sodium homeostasis, renal 
dopaminergic deficiency may contribute to the development and maintenance of high 
blood pressure, at least in a subpopulation of humans with essential hypertension. 
Suppression of dopaminergic activity was also observed in young normotensive 
subjects with an apparent family history of hypertension before any evidence of 
hypertension emerged (limura et al 1990; limura 1996). The infusion of exogenous 
dopamine leads to the augmentation of sodium excretion in the subjects with low-
renin hypertension and in the subjects with a family history of hypertension (limura 
1996). There is also evidence that dietary protein can stimulate renal DA formation, 
probably by serving as a source of tyrosine that can be converted to DOPA, followed 
by renal conversion to DA (Williams et al 1986). Most of the DA appearing in urine 
is nephrogenous, and urinary DA excretion is believed to reflect tubular amine 
production, as renal denervation does not affect DA levels in urine (Baines 1982). 
Dietary sodium appears to be a main determining factor for renal DA synthesis, as 
evidenced by a positive (direct) relationship between urinary sodium and DA 
excretion (Alexander et al. 1974; Ball et al 1978; Carey et al 1981; Goldstein et al. 
1989). The concomitant increase in urinary sodium and free dopamine output after 
salt loading suggests that dietary sodium is a major determinant of renal dopamine 
synthesis. 
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The most significant mechanism of catecholamine release in response to adrenergic 
stimulation is stress, which results in a nerve impulse-mediated increase in tyrosine 
hydroxylase (TH) and dopamine beta-hydroxylase (DBH) activity (Kopin et al 
1989). Most stressful stimuli result mainly in norepinephrine and epinephrine 
release. However, under certain circumstances such as shock, hemorrhage, surgical 
stress, and moderate exercise, DA release may increase in comparable fashion to that 
of norepinephrine and epinephrine. Under these circumstances, the increase in TH 
and AADC activity may exceed that of DBH and phenylethanolanine-N-methyl 
transferase (PNMT), resulting in a relative increase in DA formation and release 
(Carlsson et al 1973; Sole et al. 1982; Bell 1988). According to some investigators, 
it may be possible that the adrenergic nervous system becomes "dopaminergic" when 
activated by stress or exercise (Snider et al 1983; Kuchel et al 1991). However, it 
has been shown that sodium or colloid-induced volume expansion may stimulate TH 
and inhibit DBH activity, leading to a relative overproduction of circulating DOPA, 
which may be converted to DA in the kidney (Alexander et al 1974; Ball et al. 1978; 
Baines et al. 1980; Carey et al. 1981; Goldstein et al. 1989). In terms of the control 
of DA release, as distinct from DA formation, from proximal tubular cells, there is 
virtually no information. Because these cells do not contain secretory granules in 
which DA may be packaged and released by a controlled process, it is likely that DA 
formation leads to DA release proportionately by a constitutive process (Lee 1993). 
Dopamine plays a major role in the regulation of appetite (Smith et al. 1988). The 
most effective drugs used to suppress appetite contain dextroamphetamine, a 
dopaminergic agonist, and a major side effect of dopamine D2 receptor antagonists, 
such as haloperidol, is marked weight gain. Not only do addictive drugs, such as 
cocaine and amphetamines affect the dopaminergic reward pathways of the brain 
41 
(DiChiara et al, 1988), but food does also (Wise et al 1989). Endogenous opioids are 
increased in obesity (Walkowitz et al 1985; Genazzani et al 1986) and dopamine 
plays a role in the regulation of opioid levels (Vermes et al. 1980; Genazzani et al. 
1985). 
1.4.6.1 Dopamine Receptors 
The dopaminergic system depends on an interaction of DA with several specific DA 
receptors (Civelli et al. 1993). In the late 1970s, two DA receptors were identified in 
the brain as the Di and Di receptors (Kebabian et al 1979). Molecular studies have 
demonstrated that DA receptors belong to a large family of G-protein-coupled 
receptors, including rhodopsin, alpha- and beta-adrenergic receptors, muscarinic 
acetylcholine receptors, serotonin receptors, and receptors for a variety of peptide 
hormones (Dohlman et al. 1987; Probst et al 1992). Biochemical and 
pharmacological evidence was developed to support the hypothesis that 
physiological actions of DA were mediated by its interaction with two basic types of 
G-protein-coupled receptors, Di and D2, which stimulate and inhibit, respectively, 
the enzyme adenyl cyclase (Stoof et al 1984). Five of the cloned receptors 
correspond to the classical Di (DIA, DIB, and D5) and D2 (D2 short and D2 long) 
receptors (Bunzow et al. 1988; Dal et al. 1989; Giros et al. 1989; Grandy et al. 1989; 
Monsma et al 1989; Albert et al 1990; Dearry et al. 1990; Monsma et al. 1990; 
Neve et al 1990; Sokoloff et al. 1990; Sunhara et al 1990; Zhou et al. 1990; Van 
Tol et al. 1991). The other two cloned receptors, D3 and D4 are closely related to, but 
clearly distinct from the D2 receptor (Sokoloff et al. 1990; Van Tol et al. 1991). In 
mammals, the Dplike receptors are linked to stimulation of adenylyl cyclase 
(Mackenzie et al 1994). The Di-like receptors that have been cloned are linked to 
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inhibition of adenylyl cyclase (Bunzow et al 1988; Dal Toso et al 1989; Giros et al. 
1989; Monsma et al 1989; Chio et al 1990; Sokoloff et al 1990; Van Tol et al. 
1991; Sibley et al 1992; Jaber et al 1996; Robinson et al 1997), and inhibition of 
Ca2+ channels (Brown et al. 1995; Mei et al. 1995; Jaber et al 1996; Wilke et al 
1998). All the Di-like receptors have been shown to stimulate K+ channels (Sibley et 
al 1992; Jaber et al 1996; Werner et al. 1996), although these receptors have also 
been reported to inhibit potassium currents (Liu et al 1996; Wilke et al. 1998). The 
structural organization of the DA receptors provides useful information with respect 
to their molecular functions. The DIA, DIB, and D5 receptors have no introns and are 
encoded by a single exon (Dearry et al. 1990; Monsma et al 1990; Sunhara et al. 
1990; Zhou et al. 1990). These Di-like receptors are highly homologous, sharing 50 
to 83 percent identity at the amino acid level. In contrast, the Di-like receptors (D2, 
D3, and D4) are encoded by a mosaic of exons and contain introns within their 
protein-coding regions (Bunzow et al. 1988; Dal et al 1989; Giros et al. 1989; 
Gmndy et al 1989; Monsma et al. 1989; Neve et al. 1990; Sokoloff et al 1990; 
Sunahara et al. 1991; Van Tol et al 1991). 
Evidence rapidly accumulated that the anatomical distribution ofDi and D2 receptors 
in rat brain was largely independent (Joyce et al. 1985; Boyson et al. 1986; Dawson 
et al. 1986). In the brain, the highest levels of dopamine D2 receptors are found in 
forebrain regions, including the caudate nucleus, nucleus accumbens, and olfactory 
tubercle (Mansour et al. 1990; Gehlert 1993). The dopamine D2 receptors, messenger 
ribonucluic acids (mRNAs) show differing localizations in the brain, with the D2 
mRNAs located primarily in the basal ganglia (Mansour et al. 1990), the D3 in limbic 
regions, including the ventral striatum (Bouthenet et al. 1991), and the D4 primarily 
in the amygdala and frontal cortex (Van Tol, Bunzow, Guan et al. 1991). 
43 
In peripheral tissues, DA receptors are distributed in the sympathetic nervous system, 
the cardiovascular system, kidney, and adrenal cortex. Most studies of receptor 
distribution to date have relied on ligand binding and pharmacologic studies. 
However, Di-receptor messenger ribonucleic acid (mRNA) has been found by 
polymerase chain reaction (PGR) in isolated proximal renal tubules and D2-receptor 
mRNA in the adrenal cortex (Northern blot) and Ds-receptor mRNA in whole kidney 
(Sokoloff et al 1990; Yamaguchi et al 1993). Pharmacologic and ligand-binding 
studies have demonstrated that the prototype DA-1 receptor is located 
postsynaptically in arterial blood vessels and is associated with vasodilation 
(Goldberg et al. 1978; Goldberg et al. 1986). The DA-2 receptor is located both pre-
and postsynaptically (Goldberg et al 1986). The presynaptic DA-2 receptor inhibits 
catecholamine release from sympathetic neurons (Wolf et al 1987). 
In the kidney, DA-1 receptors are present in the medial layer of all renal vessels from 
the main renal artery to the afferent arteriole (Felder et al 1989). DA-1 receptors 
also are present in the renal proximal tubule, cortical collecting duct, and medullary 
thick ascending limb (Felder et al. 1984; Felder et al. 1988; Felder et al. 1989; Ohbu 
et al 1991). Recent studies using antibodies directed toward the third intra- and 
extracellular loop of the central DIA receptor have demonstrated this receptor in renal 
blood vessels, the juxtaglomerular apparatus, the proximal tubule, and the cortical 
collecting duct but not in the glomerulus (O'Donnell et al 1998). 
Postsynaptic DA-2 receptors have been described in the endothelial and adventitial 
layers of blood vessels, including the renal vasculature (Brodde 1982; Jose et al 
1986; Felder et al 1989; Amenta 1990). The DA-2 receptor has also been localized 
to the glomerulus and in the adrenal zona glomemlose (Felder et al 1984; Missale et 
al, 1986; Felder et al. 1989; Missale et al 1989). A novel DA-2-like receptor (the 
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DA2k receptor) has also been described in inner medullary collecting duct cells (Huo 
et al 1991). The D2 receptor is the major site of effect of many typical and atypical 
neuroleptic drugs and a recent study suggests an increased density of D2 or D2-like 
receptors in the caudate of patients with bipolar disorders (Pearlson et al. 1995). 
1.4.6.2 The Dopamine D! Receptor Gene 
The human Di receptor gene contains at least eight exons, spans at least 50 kilobases 
(kb), and has the unusual feature of a large (greater then 25 kb) intron (intron 1) 
separating the presumed promoter region from the protein-coding region (Gandelman 
et al 1991). The D2 receptor locus has been localized to the llq21 to llq23 region 
of the human genome and a restriction fragment length polymorphism has been 
reported for the enzyme Taq I. Civelli and colleagues cloned the human dopamine D2 
gene in rats and humans and described a TaqI A polymorphism at the 3, end of the 
DRD2 gene (Bunzow et al 1988; Grandy et al. 1989; Blum et al. 1990). In a C to G 
transversion causing a serine-to-cysteine missense mutation at codon 311 of the 
DRD2 gene was identified by Itokawa et al. (Itokawa et al 1993). 
Blum et al. reported that 24 (69%) of 35 alcoholics carried the Al allele of DRD2 
compared with only seven (20%) of 35 nonalcoholics (Blum et al. 1990). Comings et 
al. (Comings et al 1991) described several large samples in which the Al allele may 
have a modifying effect on a wide spectrum of behavioral disorders characterized by 
their familial association with alcoholism or their possible involvement with 
dopaminergic neurotransmission. They found the Al allele was significantly more 
prevalent in alcoholics, being carried by 42 (42%) of the 104 alcoholics they studied, 
similar to results reported by Parsian et al. (Parsian et al. 1991). They suggest that 
the Al allele is likely to modify the expression of alcoholism rather than be a 
45 
necessary or sufficient cause, because most alcoholics do not carry the Al allele, the 
Al allele does not cosegregate with alcoholism in pedigrees, and it is associated with 
other behavioral disorders that do not cosegregate with alcoholism. 
Dopaminergic neurons play an important role in the regulation of appetite, behavior 
and reward pathways. Previous studies showed that the allelic variants of the DRD2 
gene play a major role in the regulation of weight (obesity) and may serve as a risk 
factor in late-onset non-insulin dependent diabetes mellitus (Comings et al 1992). 
David et al. explored the possibility that the different haplotypes of the DRD2 locus 
might be associated with differences in mean weight and height for three reasons, (a) 
The previous studies have suggested that the presence of physiologically important 
alleles of the DRD2 locus played a role in the function of the dopaminergic reward 
pathways with a significant increase in the prevalence of the D2AI allele in severe 
drug abuse. The same pathway plays a role in the regulation of food intake, (b) Their 
studies of DRD2 haplotypes showed that since the 1 haplotype was in partial linkage 
disequilibrium with the D2AI allele and the 4 haplotype was in partial linkage 
disequilibrium with the D2D2 allele, haplotyping would allow a further subdivision 
of D2D2A2 individuals. In their previous study, 100% of 20 obese subjects were 
D2D2A2 homozygotes. (c) Growth hormone is a dopaminergically regulated 
pituitary hormone that plays a role in the control of both weight and height (Comings 
et al 1993). 
Dopamine D2 receptor gene variants have been implicated in the pathogenesis of 
psychiatric disorders. The cys311 allele was found to be present more often among 
156 Japanese schizophrenic patients (5.4%) than 300 normal controls (1.8%). It was 
also noted that the cys311 allele was associated with patients with younger age-of-
onset, more positive symptoms, and positive family history. Hence, it was proposed 
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that the cys311 allele of the DRD2 gene might pose a genetic risk factor for certain 
subtypes of schizophrenia (Arinami et al. 1994). However, this association could not 
be replicated by other Japanese researchers (Nanko et al. 1994). As cys311 was also 
detected in Caucasians, the association between cys311 and schizophrenia was not 
confirmed (Asherson et al 1994; Gejman et al. 1994). An association was proposed 
between cys311 and patients with unknown family history in Caucasians (Shaikh et 
a/. 1994), but it was in contrast to what was found in the Japanese study (Arinami et 
al. 1994), and has not been replicated by other researchers yet. 
2 Aims 
The literature shows hypertension is a particularly common and important risk factor 
in the pathogenesis of coronary heart and cerebrovascular disease in many modem 
societies. In Hong Kong, heart disease is currently the second commonest cause of 
death after cancer. Human essential hypertension is a typical example of a complex 
multifactorial, and polygenic trait. It is most likely that there are several causal 
genes, which together contribute the variation in blood pressure among individuals. 
The renin-angiotensin system influences vascular tone, cardiovascular remodeling, 
and salt and water homeostasis, and this system is closely involved in the physiologic 
regulation of blood pressure. However, a large number of epidemiological data have 
documented that the association between obesity and hypertension is more than can 
be expected by chance alone. 
Three main lines of investigation have been developed so far. These include linkage 
analysis in families segregating for rare, Mendelian forms of hypertension, candidate 
gene approaches, and genome-wide scanning strategies. Of the above approaches, the 
search for single-gene, Mendelian forms of hypertension has been the most 
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successful, resulting in several elegant publications illustrating how a single gene 
mutation leads to the high blood pressure phenotype. 
My study therefore attempts to identify four genes for each sibling. In view of the 
multitude of possible candidate genes involved in the regulation of blood pressure or 
obesity-related hypertension described in literature, it is necessary to be selective. 
Sib-pair linkage analysis was used to detect linkage of the marker loci with blood 
pressure and obesity. As stated above, the genetic components of hypertension may 
lead to a breakdown of the regulatory mechanisms, such as those controlling an 
important regulatory system, the RAS (section 1.4.1, page 19). In an attempt to 
identify this possibility we investigated the role of two genetic markers involving 
components of the RAS. This included the ACE I/D (section 1.4.4, page 29) and 
ATIR Al 166C (section 1.4.5, page 35) gene polymorphisms. We analysed the DRD2 
TaqI gene polymorphism that may modulate blood pressure and fat deposition 
through either common centrally acting or discrete mechanisms. To investigate a 
possible genetic component of obesity-related hypertension, the UCPl A-3826G 
polymorphism (section 1.3.4.3, page 17) of the gene that is involved in the heat 
production was analysed. 
3 Materials and methodology 
3.1 Patient recruitment protocol 
In our study, we recruited patients in the hypertensive clinic in the Prince of Wales 
Hospital. All the patients with their siblings were living in the Hong Kong Special 
Administrative Region of China, and they were of Han Chinese origin, without any 
known ancestors of other ethnic origin. 
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If hypertensive patients were not on medication, they were asked to attend our study 
unit one time for routing screening. Hypertensive patients on one medication, were 
asked to stop medication and give a follow up appointment 2 weeks later at our study 
unit. If on more than one medication, they attended our study unit once a week for 
checking the blood pressure to make sure that the patients were safe from severe 
hypertension, then at the second or the fourth week they underwent the routing 
screening. 
At the last visit to our study unit, subjects were asked to fast for 12 hours, then siting 
blood pressure and pulse were measured in triplicate after 10 minutes resting. Then 
anthropometric measurement was recorded (include body weight, body height, waist 
circumference, hip circumference, skin-fold thickness) and the 24 hour urine sample 
taken over the previous 24 hours was processed. Then blood samples were taken for 
the measurement of biochemical and haematological parameters. 
3.2 Subjects 
Hypertensive patients in our sibling study, had a family history of hypertension, and 
they were aged from 20 to 60 years, and had at least one sibling in Hong Kong. If 
siblings also had hypertension and were on medication, they were asked to stop 
medications just like the probands. All subjects underwent clinical and biochemical 
investigation to exclude those with either secondary hypertension, impaired glucose 
tolerance or type 2 diabetes mellitus. Following withdrawal of antihypertensive 
medication subjects were monitored weekly to check their blood pressure did not 
exceed the upper exclusion limit and confirm that they were not at risk from severe 
hypertension. After the two to four weeks washout period the sitting blood pressure 
was recorded in triplicate after a 10-15 minute resting period. The baseline blood 
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pressure was taken at this time. Anthropometric measurements were made and the 24 
hours urine sample taken over the previous 24 hours was processed. The blood 
samples for routine assays were taken at this time. Probands whose blood pressure 
was less than 140/85 mm Hg was reassigned to the normotensive category. 
In our sibling study, we totally had 96 families consisting of 313 sibling subjects 
(40.3% males). Altogether there were 142 hypertensive subjects and 96 hypertensive 
subjects were probands. The number of maximised pairs and the size of the families 
resulting from these siblings groups are shown below. 
3.2.1 Classification of Hypertension 
We recruited patients according to the definitions given in Table 1 (page 6) below for 
subjects not taking antihypertensive medication. This new definition defines the 
lower limits of hypertension as 140 mm Hg systolic blood pressure and 90 mm Hg 
diastolic blood pressure. The new Guidelines emphasize that the decision to lower 
the elevated pressure in a particular patient is not based on the level of blood pressure 
alone but on assessment of the total cardiovascular risk in that individual 
(Subcommittee 1999). Hypertension is therefore defined as a systolic blood pressure 
of 140 mm Hg or greater and/or a diastolic blood pressure of 90 mm Hg or greater in 
subjects who are not taking antihypertensive medication. This classification of blood 
pressure levels is in adults over the age of 18 years. It must be emphasized that the 
term ‘mild hypertension' does not imply a uniformly benign prognosis, but is used 
simply to contrast with more severe elevations of blood pressure. (Table 3, page 51) 
(Subcommittee 1999). 
50 
Table 3 New (1999) World Health Organization/International Society of 
Hypertension (WHO/ISH) definitions and classification of BP levels  
Category Systolic BP Diastolic BP 
(mm Hg) (mm Hg)  
Optimal BP < 120 < 8 0 
Normal BP < 130 < 8 5 
High-Normal BP 130-139 85-89 
Grade 1 hypertension (mild) 140-159 90-99 
Subgroup: Borderline 140-149 90-94 
Grade 2 hypertension (moderate) 160-179 \ 00-109 
Grade 3 hypertension (severe) >i8o >110 
Isolated Systolic Hypertension 140 < 
Subgroup: Borderline 140-149 < 9 0 
BP= blood pressure “ ‘  
If siblings have no hypertensive history, and systolic blood pressure less than 
130 mm Hg, diastolic blood pressure less than 80 mm Hg, we say they were 
normotensives. 
3.2.2 Definition of Dyslipidaemia 
Dyslipidaemia characterized by high plasma concentrations of triglyceride and low 
concentrations of high-density lipoprotein cholesterol (HDL-c) may be an important 
element in the linkage between hypertension and coronary heart disease. The fasting 
plasma cholesterol and triglyceride criteria used to classify the subject's lipid profile 
are described in Table 4 (page 52) (Bjorntorp et al 1971; Fujimoto et al. 1994; 
James et al. 1997). 
Most commonly, two features, which are closely associated with each other are 
identified as metabolic syndrome criteria: hypertriglyceridaemia and low HDL-c. 
Hypertriglyceridaemia is defined at a fasting triglyceride level of > 2.0 mmol/1. 
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Table 4 Classification criteria for dyslipidaemia based on fasting plasma 
cholesterol and triglyceride levels 
Category Total cholesterol (mmol/L) 
Normti 丨 <5 .2 
Borderline high 5.2 — 6.2 
^ ^ 
Triglycerides (mmol/L) 
Normal < 2.3 
Borderline high >2.3 and < 4.5 
High > 4.5 
HDL-cholesterol (mmol/L) 
Normal 
males > i.o 
females > 1.2 
Borderline low 
males 1 - 1 . 5 
females 1 . 2 - 1 . 7 
Low 
males < \ 
females < 1.2 
LDL-cholesteroI (mmol/L) 
Normal < 3 . 4 
Borderline high 3.4 — 4.1 
^ ^  
Total cholesterol: HDL-cholesterol ratio 
Desirable < 5 
HDL= high density lipoprotein, LDL= low density lipoprotein. ~  
3.2.3 Classification of Diabetes Mellitus 
Diabetes mellitus is a spectrum of metabolic disease characterized by 
hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. 
The chronic hyperglycaemia of diabetes is associated with long-term damage, 
dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, 
and blood vessels. The diagnostic criteria for diabetes mellitus have been modified 
from those previously recommended by the National Diabetes Data Group (NDDG) 
(1979) or WHO (1985). The revised criteria for the diagnosis of diabetes are shown 
in Table 5 (page 53). Three ways to diagnose diabetes are possible, and each must be 
confirmed, on a subsequent day, by any one of the three methods given in Table 5 
(page 53) (2000). The diagnosis of diabetes mellitus should not be based on urine 
tests or capillary blood glucose concentrations. 
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In our study we used fasting plasma glucose (FPG), when the FPG was greater than 
7.0 mmol/L, the patient would not be recruited. 
Table 5 Criteria for the diagnosis of diabetes mellitus 
Symptoms of diabetes plus casual plasma glucose concentration > 200 mg/dl (11.1 mmol/1). Casual is defined as 
any time of day without regard to time since last meal. The classic symptoms of diabetes include polyuria, 
polydipsia, and unexplained weight loss. , 
Or 
FPG > 126 mg/dl (7.0 mmol/1). Fasting is defined as no caloric intake for at least 8 h. 
Or 
2-h PG > 200 mg/dl (11.1 mmol/1) during an OGTT. The test should be performed as described by WHO (1985), 
using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water. , 
In the absence of unequivocal hyperglycaemia with acute metabolic decompensation, these criteria should be 
confirmed by repeat testing on a different day. The third measure (OGTT) is not recommended for routine 
clinical use. 
3.2.4 Definition of Obesity 
Height and weight are the most simple and commonly used measures. A number of 
weight-for-height indices have been developed of which the body mass index (BMI) 
is the most widely used. The World Health Organization consultation on obesity 
proposed a system of classification based on BMI. (Table 6, page 53) (1998) 
Table 6 Classification of weight by BMI in adult 
Classification BMI (kg/in^) Risk of co-morbidities 
Underweight <18.5 Low (but increased risk of other 
‘ clinical problems) 
Normal range 18.5-24.9 Average 
Overweight: > 25 
Pre-obese 25-29.9 Increased 
Obese 1 30-34.9 Moderate 
Obese 2 35-39.9 Severe 
Obese 3 ^ Very severe 
BMI= body mass index. “ — 
Here we used different ranges for the Asia-Pacific region based on risk factors and 
morbidities. In Asians, the cut-offs for overweight (> 23.0 k g W ) and obesity (> 25.0 
kg/m2) are lower than the WHO criteria (Ko et al. 1999; 2000) (Table 7, page 54). In 
our study, when males and females with a BMI > 27.0 kg/m^ and > 25.0 kg/m^, 
respectively, were defined as obese. 
53 
Table 7 Classification of weight by BMI in adult Asians (2000) 
Classification BMI (kg/m^) Risk of co-morbidities 
Waist circumference 
< 90 cm/ 35.4 inch (men) > 90 cm / 35.4 inch (men) 
< 8 0 cm/31 .5 inch (women) > 80 c m / 3 1 . 5 inch (women) 
U — h t <18.5 = = 二 二 f Average — 
Normal range 18 .5 -22 .9 Average Increased 
Overweight: > 23 
At risk 2 3 - 2 4 . 9 Increased Moderate 
Obese I 2 5 - 29.9 Moderate Severe 
Obese II Severe Very severe 
BMI= body mass index. “  
3.2.5 Exclusion Criteria 
Subjects were excluded when they had high fasting glucose levels (> 7.0 mmol/L), 
severe renal dysfunction (plasma creatinine > 200 )Limol/L) or had a history of 
significant cardiovascular disease (stroke, angina and myocardial infarction etc). 
3.3 Routine Assessment 
3.3.1 Blood Pressure 
Blood pressure and pulse were measured by the Critikon Dinamap automatic 
sphygmomnometer (Critikon Inc, CA USA). Blood pressure was measured in 
triplicate at one minute intervals in the sitting position following a 10 to 15 minutes 
resting period using the right arm. The sitting position is a convenient position for 
routine clinical practice and with that it is easier to ensure that the cuff is at the same 
level as the heart. 
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3.3.2 Measurements of obesity 
3.3.2.1 Body mass index 
A widely used measurement in adults is the body mass index (BMI) which is body 
weight (kg) divided by the square of height (meters) (BMI=kg/m^). Males and 
females with a BMI > 27 k g W and > 25 kg/m^ respectively, were defined as 
general obese. 
3.3.2.2 Waist to hip ratio 
The waist to hip ratio is used as a measure of abdominal obesity. Waist 
circumference was measured around the waist in the standing position, some 
measure at the umbilicus, others at a point one-third the distance between the xiphoid 
process and umbilicus. We used the first, because the later one is difficult in the very 
obese with large abdominal obesity. Hip circumference was measured at the levels of 
the greater trochanters through the pubic symphysis. From these data the waist-to-hip 
ratio was calculated. Males and females with a waist-to-hip ratio > 0.90 or > 0.80, 
respectively, were classified as central obese. 
3.3.2.3 Skin-Fold Thickness 
The measurement of skin-fold thickness is a common measure. A digital caliper 
(Skyndex electronic body fat calculator system, Caldwell Justiss and Co Inc, AZ) 
was used to measure skin-fold thickness in 4 sites. Triceps skin-fold was measured 
half way between the acromial and olecranon processes. A fold of skin and 
subcutaneous tissue is pinched between the operator's thumb and forefinger. The 
grip is maintained with the left hand while the right hand opens the calipers and then 
applies them to the fold of skin. Biceps skin-fold thickness was measured in the same 
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place as the triceps skin-fold but at the front of the arm with the hand supinated. 
Subscapular skin-fold thickness was measured at a 45° angle to the vertical at the 
lower angle of the left scapula. Suprailiac skin-fold thickness was measured in the 
horizontal plane just above the iliac crest in the mid axillary line on the left side. The 
triceps and biceps sites measurement represent body fat in the extremities, whereas 
suprailiac and subscapular sites measurement represent truncal body fat. 
3.3.2.4 Skinfold Percentage Fat 
Skinfold percentage fat was calculated from the body density (BD) values using the 
following equation: 
f 4 95 ) Equation 1 %fat= 4.50 xlOO, 
�density J 
Body density was first calculated from the skin-fold thickness values using the 
regression equations described by Dumin and Womersley based on the Caucasian 
population (Table 8, page 56). 
Table 8 Age-adjusted regression equations for the calculation of body density 
from skin-fold thickness data 
Age (years) Body density in males Body density in females 
1.1631-0.0632.log SSF 1.1599-0.0717.log SSF  
30-39 1.1422-0.0544.log SSF 1.1423-0.0632.log SSF 
40-49 1.162-0.0700.log SSF 1.1333-0.0612.log SSF 
Over 50 1.1715-0.0779.log SSF 1.1339-0.0645.log SSF 
SSF= sum of the biceps, triceps, subscapular and iliac crest skin-fold thickness (mm) 
3.3.3 Biochemical measurements 
Blood was taken for the measurement of renal and liver function tests, fasting lipid 
profile, fasting plasma glucose (FPG), urate and complete blood count. 24 hour urine 
sample was collected for the measurement of 24 hour urinary parameters. 
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3.3.3.1 Assays measuring biochemical factors from plasma 
3.3.3.1.1 Plasma electrolytes 
Plasma electrolytes were measured using ion-selective electrodes on a parallel 
multichannel analyser (American Monitor, IND, USA). 
3.3.3.1.2 Plasma urate 
Measurements were based on the uricase method and performed using the Dade 
Dimension clinical chemistry system (Dade International Inc, DE, USA). 
3.3.3.1.3 Plasma creatinine 
Creatinine was measured using the Jaffe method on a Beckman Astra-8 Chemistry 
analyser (Beckman, Brea, CA). The reaction between creatinine and picrate in 
alkaline solution leads to the formation of a coloured complex. The analyser can then 
measure this complex. 
3.3.3.1.4 Fasting plasma glucose 
FPG was measured using a standard glucose oxidase method. 
3.3.3.1.5 Fasting plasma cholesterol 
Total cholesterol was measured enzymatically (Centrichem Chemistry System, Baker 
Instruments Co., Allentown). Initially cholesterol esters are hydrolysed with 
cholesterol esterase and the free cholesterol is then oxidised by cholesterol oxidase. 
The hydrogen peroxide then reacts with a chromogen and the colour change is 
measured at 540 nm. The long term precision of the assay was 3% at 3.3 mmol/L and 
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2.2% at 6.8 mmol/L. HDL-cholesterol was determined following fractional 
precipitation with dextran sulphate-MgCl� and LDL-cholesterol was calculated with 
Friedewald's formula (Saad et al. 1991). 
3.3.3.1.6 Fasting plasma triglyceride 
Triglycerides were measured by the glyceryl dehydrogenase reaction following the 
hydrolysis of the triglyceride (Centrichem Chemistry System, Baker Instruments Co., 
Allentown). The long term imprecision of the assay was 6.9% at 1.02 mmol/L and 
4.6% at 2.18 mmol/L. 
3.3.3.2 Assays measuring biochemical factors from urine 
3.3.3.2.1 Urinary electrolytes 
Urinary electrolytes were measured using the same methods as for the plasma 
(section 3.3.3.1.1). 
3.3.3.2.2 Urinary creatinine 
Urinary creatinine was measured using the same method as for the plasma (section 
3.3.3.1.3). 
3.3.3.2.3 Urinary albumin concentration 
Urinary albumin concentration was measured by immunoturbidimetry (Ogihara et al. 
1995). The lowest detection limit was 2.5 mg/1 and inter- and intra-assay CVs were 
less than 5%. 
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3.4 Extraction of DNA from blood specimen 
The protocol for DNA extraction was: 1. 10 ml peripheral venous blood was 
collected, then centrifuged at 3000 rpm, 4°C for 10 mins and the plasma was 
aspirated off. 2.12 ml of lysis buffer (lOmM K H C O 3 , 155mM N H 4 C I , 0.1 mM 
EDTA) was added to the blood cells and placed on ice for 15 mins, then centrifuged 
at 3000 rpm at 4°C, and the supernatant was then decanted. 3. The cell pellet was 
resuspended in 12 ml lysis buffer and step 2 was repeated. 4. The cell pellet was 
> 
resuspended in 3 ml of TE buffer, then 600 jil of 10% SDS and 50 |LI1 proteinase K 
(20 mg/ml) was added and incubated at 60°C water bath overnight. 5. 1.2 ml of 6M 
NaCl was added to the overnight digested sample with vigorous shaking for a few 
seconds, then the sample was centrifuged at 3000 rpm at 4�C for 10 mins. 6. The 
supernatant was decanted to a clean test tube and 1 ml of TE equilibrated phenol was 
added and mixed well. 7. 1 ml of chloroform was then added and mixed well. The 
mixture was centrifuged at 3000 rpm at 4°C for 10 mins and the upper aqueous layer 
was transferred to a new test tube. 8. 2 ml of chloroform was added and mixed well 
o 
and it was then centrifuged at 3000 rpm at 4 C for 10 mins, and the upper aqueous 
was transferred to a new test tube for precipitation of DNA. 9. Two volumes of ice 
cold absolute alcohol were added and the tube was placed on a nutator and DNA 
started to precipitate as a stringy mass. 10. The precipitated DNA was transferred to 
a 1.5 ml eppendorf tube and washed with 1 ml 70% alcohol, then the DNA was 
pelleted to the bottom of the eppendorf tube and the alcohol was drained off. 11. The 
DNA was briefly dried by SpeedVac for 10 mins, and then thoroughly dissolved in 
200 — 400|al TE and the optical density (OD) at 260 nm and 280 nm were measured 
to determine the quantity and quality of the DNA. A ratio of 1.8 was regarded as 
good quality. 
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3.5 Polymerase Chain Amplification protocols 
3.5.1 Uncoupling protein 1 gene polymorphism 
In a population from Quebec, with a rather low percentage of obese subjects, an 
association between the rare 8.3kb allele of the Bell restriction fragment 
polymorphism site in the human UCP gene and the capacity for fat gain over time 
was reported (Oppert et al. 1994). This polymorphic site is due to an A to G point 
variation at position -3826 bp in the 5' flanking genie domain of UCP (Cassard-
Coulcier 1996). PGR assays contained 1 ng DNA, 0.6 \iM each of forward and 
reverse primer (primers were: forward primer, 5'-CTT GGG TAG TGA CAA AGT 
AT-3'; reverse primer, 5,-CCA AAG GGT CAG ATT TCT AC-3'), 10 mM Tris-Hcl 
(pH 8.3), 3 mM UgCh, 50 mM KCl, 0.1 mM of each dNTP, and 1 unit of Taq 
polymerase. The PGR amplification of the region containing the Bell UCP variant 
was carried out in final reaction volume of 10 |LI, then performed in a thermocycler 
(GeneAmp PGR System 9600, Perkin Elmer Corporation, Foster City, CA). The 
reaction mixture was initially denatured at 95°C for 3 min, followed by 36 cycles of 
denaturation (94 C, 1 min), annealing (52°C, 1 min), and extension (72°C, 1 min), 
with a final extension for 10 min at 72°C. The 470 bp amplified product was digested 
o 
at 37 C for 12 h with 6 units of Bell restriction enzyme, and the fragments resolved 
on a 2% agarose gel. 
Two fragments were produced by digestion of the PGR fragment; a 250 bp and 220 
bp fragments. A G mutation homozygosity (GG) resulted at the disappearance of 
the digested products. Heterozygotes (AG), containing the A -> G mutation yield the 
470 bp band, as well as the 250 and 220 bp bands. 
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Figure 4 Visualisation of the ethidium bromide stained UCPl gene A-3826G 
polymorphism PCR RFLP product on a 2% agarose gel 
i m i i i i m i i i m i ^ ^ m 
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3.5.2 Angiotensin-Converting Enzyme insertion-deletion 
polymorphism 
The angiotensin-converting enzyme plays a key role in the renin angiotensin system. 
A frequent insertion and/or deletion (I/D) polymorphism, characterized by the 
presence or absence of a 287-base-pair fragment in intron 16 of the human ACE gene 
has been identified (Perusse et al 1991; Rigat et al. 1992). DNA was extracted from 
white blood cells, as mentioned before (section 3.4, page 59). Ing of genomic DNA 
was added to 10|al of the PGR master mix (10 mM Tris-HCl, 3 mM MgCl2, 50 mM 
KCl pH 8.3, 0.1 mM dNTP, 0.6 [iM of each primer (the primers used were: sense 
oligo 5,-CTG,GAG,ACC,ACT,CCA,TCC,TTT,CT-3' and antisense oligo 5'-
GAT,GTG,GCC,ATC,ACA,TTC,GTC,AGA,T-3，）and 1 U Taq polymerase per 
sample. DNA amplification was then performed in a thermocycler (GeneAmp PGR 
System 9600, Perkin Elmer Corporation, Foster City, CA). The reaction mixture was 
initially denatured at 94 C for 2 min, followed by 30 cycles of denaturation (94 C, 1 
min), annealing (58°C, 1 min), and extension (72�C, 1 min), with a final extension for 
o  
10 min at 72 C. The reaction products were separated by electrophoresis on 2% 
agarose gels, and DNA was visualized by ethidium bromide staining under 
ultraviolet light. PGR amplification revealed a combination of a 490-base-pair 
product and /or 190-base-pair product depending on the presence or absence of the 
insertion fragment. Thus, each sample revealed 1 of 3 electrophoretic patterns: a 490-
base-paire band corresponding to I/I genotype, a 190-base-pair band corresponding 
to D/D genotype, or a combination of 490- and 190-base-pair bands corresponding to 
I/D genotype. 
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Figure 5 Visualisation of the ethidium bromide stained angioteiisin-converting 
enzyme insertion/deletion polymorphism PGR product on a 2% agarose gel 
Full-







3.5.3 Angiotensin type 1 receptor gene A1166C polymorphism 
Blood sampling and DNA extraction were performed as mentioned before (section 
3.4, page 59). The 10|LI1 reaction volume contained lOmM Tris-HCl, 3mM MgCl�，50 
mM KCl, pH 8.3, 0.1 mM each dNTP，0.1 |LIM of each primer [the A1166C 
polymorphism at the ATIR locus was examined using the following primer pair: 5'-
ATA,ATG,TAA,GCT,CAT,CCA,CC-3， (sense strand of DNA) and 5'-
GAG,ATT,GCA,TTT,CTG,TCA,GT-3’ (antisense strand of DNA)], 1 U Taq 
polymerase andl ng DNA. After an initial denaturation step at 94�C for 2 min, 30 
cycles of PCR consisting of 94°C for 1 min, 60�C for 1 min, and 72�C for 1 min 
were carried out. A final extension step at 72°C for 10 min ended the PCR. The 546 
base pair cDNA fragment was obtained, spanning the region 1057-1602 base 
pairs. 10|il of the reaction product was then exposed to 5 U of Ddel (Gibco BRL, Life 
Technologies, Gaithersburg, MD USA) for 16 h at 37°C. After exposure to the 
restriction enzyme, ATIR products were submitted to electrophoresis in 2% agarose 
gel and DNA fragments were visualized by ethidium bromide staining. Two bands of 
435 base pairs and 111 base pairs were indicative of the presence of the A1166C 
allele. 
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Figure 6 Visualisation of the ethidium bromide stained angiotensin II type 1 
receptor A1166C gene polymorphism PCR RFLP product on a 2% agarose gel 
Full-
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3.5.4 Dopamine D2 receptor TaqI polymorphism 
The dopamine D2 receptor gene TaqI A polymorphism was examined by PCR, 
similar to that previously described (section 3.4, page 59). PCR were done under the 
following procedures: 15 mM MgCb, 50 [iM dNTP, 50 mM KCL, 10 mM Tris/HCL, 
150 nM of each primer and 1 U Taq polymorphism (Boehringer Mannheim, 
Germany) in a final volume of 10 |LI1. The PCR condition were: 5 minutes at 94�C, 
then 30 cycles of 94C, 1 minute, 56°C, 1 minute, and 72°C, 1 minutes. The 310 bp 
fragment PCR product was then digested with 5 U TaqI restriction enzyme 
(Boehringer Mannheim, Germany) in a final volume of 20 )LI1 for 6h at 65�C. The 
digestion products were visualised on a 2% agarose gel with ethidium bromide 
staining. The Al allele remained undigested with the 310 bp fragment, the A2 allele 
produced bands 180 bp and 130 bp in size. 
3.5.5 Dopamine D2 receptor TaqI polymorphism 
The dopamine D2 receptor gene TaqI A polymorphism was examined by PCR, 
similar to that previously described (section 3.4, page 59). PCR were done under the 
following procedures: 15 mM MgCl�,50 |LIM dNTP, 50 mM KCL, 10 mM Tris/HCL, 
150 nM of each primer and 1 U Taq polymorphism (Boehringer Mannheim, 
Germany) in a final volume of 10 j^ l. The PCR condition were: 5 minutes at 94 C, 
then 30 cycles of 94°C, 1 minute, 56°C, 1 minute, and 72°C, 1 minutes. The 310 bp 
fragment PCR product was then digested with 5 U TaqI restriction enzyme 
(Boehringer Mannheim, Germany) in a final volume of 20 ii\ for 6h at 65°C. The 
digestion products were visualised on a 2% agarose gel with ethidium bromide 
staining. The Al allele remained undigested with the 310 bp fragment, the A2 allele 
produced bands 180 bp and 130 bp in size. 
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Figure 7 Visualisation of the ethidium bromide stained dopamine 1)2 receptor 
gene TaqI polymorphism PCR RFLP product on a 2% agarose gel 
EBB 
• • I 
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3.6 Statistical analysis 
3.6.1 Paired sample T test 
A statistical test of the null hypothesis is performed to determine if two population 
means are equal. It is used when the observations for the two groups can be paired in 
some way. (For example, when the same person is observed before and after a 
treatment.) Pairing is used to make the two groups as similar as possible. Observed 
differences between the groups can then be attributed more readily to the variable of 
interest. In this study, one affected and one unaffected sib within a family were 
formed a pair, each family was independent. 
3.6.2 Conditional Logistic Regression 
The Conditional Logistic Regression Model is used to model matched binary data 
most often matched-retrospective, such as case-control data. The matching may 
either be by design. The data are matched to avoid having to estimate a large number 
of fixed effect parameters corresponding to the baseline responses (set effects) for 
the sets induced by the matching. 
In our data, data available for each pair: 
Affected siblings 不⑷， . . . . ， x f 
Unaffected siblings �X ^ ^ 
Let the difference ； = x } � )- 对 ) ， 少 ， = 到 。 ) _ 对 ) = -力】） 
To perform a logistic regression with ...., , 
prob (tends to have case) = r—, 1 ^ 
1 + exp卜(Z i^j^ i 十…+ ^ 少^“). 
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3.6.3 Linkage analysis 
Genetic studies of hypertension are difficult because genetic and environmental 
variables are often confounded. One methodology for demonstrating a genetic 
contribution to disease traits is linkage analysis. Linkage is a convincing indicator of 
genetic influence, as it is unlikely that linkage between behavioral traits and genetic 
polymorphisms would result solely from environmental effects (Haseman et al 
1972). Linkage analysis aims to extract all available inheritance information from 
pedigrees and to test for coinheritance of chromosomal regions with a trait. In 
principle, one can use either parametric methods, which involve testing whether the 
inheritance pattern fits a specific model for a trait-causing gene, or nonparametric 
methods, which involve testing whether the inheritance pattern deviates from 
expectation under independent assortment. 
3.6.3.1 Allelic frequency and genotypic distribution 
The frequency of an allele i in the population is defined as the probability that a 
haplotype (a particular haploid combination of alleles in a defined region of a 
chromosome or a genome) carries the allele i. 
The chi square test was used to identify differences in the genotype or allele 
distribution of each gene polymorphism between hypertensive and normotensive 
sibs. Statcalc (Epilnfo version 5.0, 1990) was used for the chi square analyses. 
3.6.3.2 Hardy-Weinberg equilibrium 
Genotypic frequencies can be obtained by simple counting in the population. For a 
gene with n alleles, there are n (n+l)/2 possible genotypes. The relationship between 
gene frequency and genotypic frequency for a single gene at the population level can 
69 
be used to infer the genetic status of the gene in the population, relative to expected 
equilibrium. 
A population is in equilibrium (often called Hardy-Weinberg equilibrium) if the gene 
and genotypic frequencies are constant from generation to generation. This implies 
that the allelic frequency and genotypic frequency have a simple relationship. That 
is, for a two-allele model where Pa and Pa are allelic frequencies for alleles A and a, 
respectively and Paa, Pah and PAA are genotypic frequencies for genotypes AA, Aa 
and aa, respectively 
Equation 2 P^ = Pj 
Equation 3 = 
Equation 4 P^ ^ = P^ 
Or ” a 
Equation 5 (P, ^ P j = P] + + P^ 
If the frequency of the allele is 0.01, then 99% of the rare alleles are expected to be 
carried by heterozygotes. The relative frequencies of heterozygotes and homozygotes 
carrying a rare allele are even more different. For example, if Pa = 0.1, the ratio 
between the expected heterozygous frequency and homozygous frequency (PAA) is 
Equation 6 ^ ^ 2 P , ( 1 - P J ^ 2 ( 1 - P J ^ 
Paa Pi P, 0.1 -
The heterozygotes carrying the rare allele are 18 times more frequent than the 
homozygotes carrying the rare allele in the population. If the rare allele has a 
frequency of 0.01, then the heterozygotes are 198 times more frequent than the 
homozygotes. When a rare allele is in a population, most likely it is carried by 
heterozygotes. 
In our study, we already have the population allele frequencies of the ACE gene 
polymorphism (Table 33, page 102), the ATIR gene polymorphism (Table 37, page 
104) and DRD2 gene polymorphism (Table 40, page 107) in Hong Kong Chinese, 
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after using this method, we found that our sibling data were in the Hardy-Weinberg 
equilibrium. For the UCPl gene polymorphism, no other study have shown the 
population allele frequencies in Hong Kong Chinese or Chinese, so we have to use 
the Japanese data (Table 25, page 94), because they all are Asian. We found that the 
UCPl gene polymorphism was also in the Hardy-Weinberg equilibrium. 
3.6.3.3 Parametric analysis 
The LOD (logio [odds ratio]) score linkage analysis is the most widely used approach 
to parametric linkage analysis (Morton 1955); computer programs to carry out LOD-
score calculations are available (Ott 1991; Terwilliger et al. 1994). The program can 
compute LOD scores for arbitrary pedigrees under particular models of inheritance, 
allowing the user to specify allele frequencies at the disease locus and penetrances 
for liability classes (including age- and sex-dependent penetrances). The program 
also allows the user to test for linkage under genetic heterogeneity by using an 
admixture model to estimate the proportion of linked families. Alternatively, the user 
can specify the admixture parameter. The classical critical LOD score of 3 therefore 
can be interpreted as stating the estimated value of c (the recombination fraction) 
(say we choose c= 10%) is 1000 times more likely than the null hypothesis that c = 
50% for the given (marker and pedigree) data. 
3.6.3.4 Nonparametric analysis 
Because parametric linkage analysis can be highly sensitive to misspecification of 
the linkage model (Clerget-Darpoux 1998), nonparametric analysis is a key tool for 
all but the simplest of traits. The nonparametric methods make no assumptions about 
the mode of inheritance of a given genetic trait and have been valuable in mapping 
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susceptibility genes for which the mode of inheritance is unclear (Davies et al. 1994; 
Hashimoto et al. 1994). 
The heterozygous parent is informative for linkage analysis, in that we can determine 
whether each child received an allele from the same parental chromosome (or same 
grandparental gamete). The term identity by descent (IBD) refers to this information. 
In the case of a homozygous parent, each child receives the same allele, but we do 
not know whether these came from the same grandparent. The term identical by state 
(IBS) describes the situation where two relatives carry the same allele, regardless of 
whether it was inherited from a common ancestor or not. In our study, we used the 
IBS method, because we only recruited siblings and we did not type the parents. 
In ambiguous cases, we will often calculate the probabilities of identity by descent. 
For example, if one parent is BB and the other bb, then the probability that both 
children carry the B allele is 100%. The probability that the B allele in one child is 
identical by descent with the B allele in the other child is 50%. Identity by descent, 
or IBD is useful in that it extends to other types of relatives, and probabilities can be 
estimated when particular individuals (such as parents) are not typed at the marker. 
If a disease occurs late in life, both parents of an affected-sib-pair are likely to be 
dead. It is still possible to work out the IBD probabilities for the sibs. If we know the 
marker allele frequencies, and assume panmixia, Hardy-Weinberg equilibrium etc, 
we can obtain the expected IBDs by adding up the probabilities under each possible 
mating type that could give rise to that pair. (Table 9, page 73) 
The IBS values test, is based on fitting the observed frequencies in each of the three 
IBS categories (2, 1, or 0) to the frequencies expected for "unlinked" marker and 
disease loci. Under the null hypothesis, the goodness of fit statistic has a chi-square 
distribution with 2 degrees of freedom. 
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Table 9 Expected IBP sharing when parental genotypes are unknown 
Sib pair 二 = 二 IBD=0% IBD=50% IBD=100% Mean IBD 
aa,aa a2(l+a)2/4 a2/(l+a)2 2a/(l+a)2 l / ( l+a)2 l7(I+i) 
ab, ab ab(l+a+b+2ab)/2 2ab/(l+a+b+2 (a+b)/(l+a+b+2ab i/(i+a+b+2ab) ( 2+a+b)/( 2+ 2a 
ab) ) \ , +2b+4ab) 
aa, ab a2b(l+a) a/(l+a) l /( l+a) 0 l/(2+2a) 
aa, bb a2b2/2 1 0 0 0 
ab, bb ab2(l+b) b/(l+b) l /( l+b) 0 l/(2+2b) 
bb, bb b2(l+b)2/4 b2/(l+b)2 2b/(l+b)2 l /(l+b)2 l / ( i+b) 
Population frequency of that type of family in the population assuming random mating and HWE. Each letter represents the 
population frequency of that allele in the general population. 
The mean IBS value test, tests if the mean IBS value of the sample is equal to the 
expectation of the mean IBS value ( / / ) for a diallelic marker locus, when the marker 
and the disease are unlinked = and there is no linkage disequilibrium between 
the marker and disease loci, i.e., /r 二 c = 為 ) .Thus if n ” �a n d n^ are the 
observed numbers of sib pairs (in a sample of size n) that share 2, 1, and 0 marker 
alleles IBS (respectively), the null hypothesis of marker and disease "unlinked" will 
be rejected whenever 
Equation 7 f J 2 ” 2 + )/" - _ 
“BS , �� 11/ 
4^2 + -(2^2 +nj 
is larger than the appropriate value of the t distribution with n-\ degrees of 
freedom. 
In the ASP method (section 3.6.3.4.1, page 74), Lange (Lange 1986) suggested that if 
two affected sibs have the same marker genotypes, we call them marker concordant 
(state A). If their marker genotypes share no common alleles, we call them marker 
discordant (state C). Finally, if they are neither marker concordant nor discordant, we 
call them half-marker concordant (state B). For extremely polymorphic loci, these 
conditions correspond fairly closely to the sibs sharing two, zero, or one gene 
identical by state. 
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3.6.3.4.1 The affected sib pair (ASP) method 
This method is used where one trait A is dichotomous (affected or unaffected), with 
unknown penetrances and allele frequencies for the underlying trait locus. The other 
locus B is a codominant marker (ideally). When the marker gene is Hardy-Weinberg 
equilibrium, the null hypothesis is that there is no distortion of segregation due to 
linkage between the trait locus and the marker locus. The Suarez method is suitable 
for only extracting one affected sib-pair of each family with identity by descent 
(IBD) (Suarez et al 1979). It can use one unaffected sib in the sib-pair with IBD to 
do the linkage analysis. Lange (Lange 1986) suggested an alternative approach for 
ASPs with untyped parents, identical by state (IBS) affected sib-pair linkage 
analysis. This approach can also be easily generalized to other types of relatives. 
We have mentioned IBS sharing in the previous section. The idea now is to compare 
the expected and observed number of affected sib-pairs falling into each of these 
three categories by a chi-square test. If there is a significant deviation between 
observed and expected numbers, then the only viable conclusion is segregation 
distortion caused by close linkage of a disease predisposing locus with the marker 
locus. 
The aim of the ASP method is to examine the pairs of affected relatives for how their 
phenotypes at the marker locus deviate from what is expected under the assumption 
that the trait and the marker locus segregate independently: the null hypothesis. 
The procedures of the ASP method are: 
1. Assume that there are n codominant alleles (Al, A2...., An), with known 
population frequencies Pi, P2 , Pp. 
2. Linkage equilibrium is assumed between the marker locus and the trait, which 
means the marker allele plays no role in determining trait expression. 
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3. X is the number of marker alleles shared in common by the two individuals of a 
sib pair. It generally adopts the following conventions: if the individuals are 
(A1A2) and (A3A4), then X=0, whereas (A1A2) and (A1A3) is example of X=l, 
and (A1A2) and (A1A2) is an example ofX-2 . 
4. ki is simply the mean or expected i.b.d. sharing under the null hypothesis, which 
is the probability that the two individuals have i gene i.b.d. at the marker locus 
for i=0,\,2. For full sibs, the expected i.b.d. distribution for a single marker is 
ko=l/4, k尸 1/2, k2=l/4, where kj is the probability of sharing i alleles i.b.d.. 
5. Tij (i=0,l,2 and j=0,l,2) is the probability of i alleles i.b.s. when j alleles are i.b.d. 
at the marker locus. In the terms of the allele frequencies, when Hardy-Weinberg 
equilibrium is assumed, these are given by: 
Too = S P i P J - Pi - pJ+ E p^ - Pi Y , 
i 
i^J i 
Tn = , 
/ 
i^J ‘ 
� 2 1 = 1 > , 2 , 
i 
6. The probability distribution of X is: 
p[ j f = o] = " o r � �， 
i l z = i] = V;�+y^ir i i , 
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7. The Pearson's x statistic is used for testing the goodness of fit between the 
observed and expected distribution of X. The test for a particular type of 
relative pair will be based on this table. 
Identity by state allele sharing 
i b s = 1 0 0 % i b s - 5 0 % i b s = 0 % 一 
Observed count O2 — ^ o^ ^ 
Expected count E2 E] E ^ ~ n 
3.6.3.4.2 The affected pedigree member (APM) method of linkage 
analysis 
Weeks and Lange (1988, 1992) developed the affected-pedigree-member method 
(APM). The APM method is a nonparametric method that uses identity-by-state 
(IBS) status to test for linkage as indicated by increased marker similarity between 
affected relative pairs. Since the APM statistic uses IBS information in lieu of IBD 
information (and so only uses marker information on the affected individuals), it 
completely ignores unaffected genotypes; this information is used by many affected-
sib-pair methods. Pedigree data on gene-disease association often include marker 
information from unaffected pedigree members, and so the affected-pedigree-
member method is extended to allow this information from unaffected pedigree 
members to be incorporated into the test statistic (Weeks et al. 1992). 
In the Weeks and Lange method, a pair of genes is IBS if they are the same, 
regardless of whether this identity is due to common descent. We can define such an 
IBS match between a pair of genes a and b via the Kronecker delta: 
Equation 8 Sia^b) = { ‘ " an? are ihs 
1 V ' / I 0 if a and h are not ihs 
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For individual i, denote the two genes at the marker locus by Gix and Gjy, and for 
individual j , denote the two genes at the marker locus by Gjx, and Gjy. Weeks and 
Lange (1998) proposed to measure the genie concordance between individuals i and 
j at the marker locus as 
Equation 9 
Zij is the expected probability of a match in state conditional on the observed marker 
genotypes of i and j. The / is a weighting factor which incorporates the population 
frequencies of the marker alleles into the measure. Each f is some decreasing 
function of the frequency of its subscripted allele, the rationale being that a match 
across a pair of individuals for a rare allele is more striking evidence for association 
between disease and genotype than would be the case for common alleles. Weeks 
and Lange propose / 少 = w h e r e p � i s the population frequency of the 少 th 
allele at the marker locus. Lange et al. was inclined to use this function instead of the 
function f{p) = 1. Their tentative conclusion is that f{p) = J / ^ represents a good 
compromise between ignoring allele frequency (i.e., f{p) = 1) and strongly 
weighting by allele frequency (i.e. f{p) = y^^^) and incorporating important 
information about allele frequencies. This choice represents a compromise (Weeks et 
al 1988). 
The sum Z = Y^nj^u taken across all possible pairs of affected individuals measures 
the degree of genie concordance at the marker locus within the population of affected 
individuals. Large positive values for T = [Z - E{Z)]/^VAR{Z) indicate untenability 
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of the null hypothesis, where E{Z) and Var{z) are, respectively, the mean and 
variance of Z under the null hypothesis of no association between marker and 
disease. Since Z is a sum of random variables Z , none of which can be extremely 
large or small, the distribution of T is approximately standard normal. Large values 
of T are therefore those exceeding the standard, normal deviates corresponding to 
the upper 0.05 or 0.01 percentiles (for further details, see Weeks and Lange 1988) 
(Weeks et al 1988). 
The set of individuals under analysis are number 1 to n. Let the data set contain s 
affected and t unaffected individuals for whom marker genotype information is 
available. Define an index set {“(/):/ = l”",s} containing the indices of the typed, 
affected individuals. An index set {^ 0")： j = for the typed, unaffected 
individuals is likewise defined. Let {pm： m = 1,"., r} be the population frequencies 
of the r alleles at the marker locus and define c, = Y ' f p and c. = Y ' f n^ 
Under the null hypothesis of no association between disease and marker genotype, 
for the affected individuals, we get for the unaffected 
individuals, we get 五 = 取州力 = 价 2 + ( � 1 . 么 is the 
kinship coefficient of individuals i and j and is defined as the probability that an 
allele drawn at random from individual i is IBD with an allele drawn at random from 
individual j at the same gene locus. The variances of the Z are the second central 
moments of the test statistics under the null hypothesis and are defined as 
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f � 
/< i<s k<l^s 
、 * J 
/=1 M k=l 1=1 
� �‘ J 
c � 
(3). C o v ( Z ” Z j = - 对 Z X Z J . 
}<j<s k=l 1=1 
The observed variable Z for affected individuals and for unaffected individuals are 
Z j 二 and Zb = S m ，respectively. The observed variable 
2Z Z 
Z for affected-unaffected sib pair is Z仙=——~^ ——^. 
小 - 1 ) St 
For the affected-affected sib pairs, the test statistic is T, = ^^ 一五(义乂) 
For the affected-unaffected sib pairs, the test statistic is 
仙、^lVar{Z,)l{s-\Y -,Var{Z,)/4t' - C o v ( Z , , Z , - 1 ) • 
Here the T value showed us that in the normal distribution, under the null hypothesis, 
how many deviations there are between the observed allele frequency and the 
expected. 
3.6.3.4.3 Quantitative traits linkage analysis 
Quantitative traits linkage analysis (QTL) is designed to screen for genetic linkage 
on the basis of sib-pair quantitative phenotypes, with the advantage of being able to 
screen a large number of traits in a relatively short amount of time. It can be used for 
detecting linkage between each of a set of marker loci and putative trait loci without 
assuming a genetic model. For our data is a set of sibships, the allele frequencies 
have been calculated. The function of the QTL method are: 1). For each sib pair and 
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each locus, QTL method will estimate the proportion (TT) of alleles IBD, that the sib 
pair shares at that locus, assuming the pair is randomly sampled, pairs inconsistent 
with Mendelian inheritance are automatically eliminated. 2). Regress the sib-pair 
trait difference square (Y) on the estimated proportion (TT) of alleles IBD to detect 
possible linkage between the trait and marker locus. 3). Estimate all possible marker-
marker locus correlations to determine linkage groups and to order loci. 4). In the 
case of a dichotomous trait, test whether the proportion of alleles shared IBD is equal 
to 1/2 for full sibs, or 1/4 for half sibs, separately for concordant affected, concordant 
unaffected, and discordant sib pairs. 
The statistic for testing linkage is the estimated regression coefficient divided by its 
standard error. For large samples, it has been shown that this statistic has an 
approximate standard normal distribution. For smaller samples, the t-distribution 
may be used. Although the sib pairs are pairwise independent, they are not jointly 
independent, and the number of degrees of freedom for the t-distribution is 
problematic. In this method, the effective sample size is used to determine the 
degrees of freedom, rather than the total number of sib pairs in the analysis. When 
performing the analysis on only full sib pairs, the effective sample size is defined as: 
二M ), where M. for the z-th sibship and is the 
number of full sibs in the /-th sibship, i = 1,2,3,"., Only full-sib pairs are used in 
the linear regression analysis. The simple linear regression model is 
a + Pn丨• j is sib pair j . where a = a； + Icj] and p = -la] • cf] is the 
genetic variance at the locus, the cr； is a function of the environmental variance, the 
environmental covariance between sibs, and any order effect. 
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4 Results 
4.1 Description of the characteristics of in siblings 
4.1.1 Siblings and sib-pairs 
Data for 313 subjects were collected from 96 families in Hong Kong. There were 2 
sibs in 39 families, 3 sibs in 23 families, 4 sibs in 14 families, 5 sibs in 14 families, 6 
sibs in 4 families，7 sibs in 1 family and 9 sibs in 1 family respectively, and hence 
449 sib -pairs were considered in total (Table 10, page 81). 
Table 10 The number of family size and maximised pairs 
Family size 2 3 4 5 6 7 9 T ^ 
(possible pairs) (1) (3) (6) (10) (15) (21) (36) Numbers 
Number of families 39 23 14 14 4 1 1 96 
Number of pairs ^ ^ 84 140 60 21 36 449 
4.1.2 Demographic characteristics 
The mean age for the whole set of subjects was 39.51 土 0.43 years. Among them 
there were 133 with hypertension, of whom the mean age 士 standard deviation was 
42.03 土 6.81 years. There were 148 normotensive ones, of whom, mean age 土 
standard deviation was 37.24 士 6.78 years. 
Besides, there were 32 subjects with systolic blood pressure in the range of (130, 
139) mm Hg and diastolic blood pressure in the range of (80, 89) mm Hg. In the 
following data analysis, these 32 siblings were excluded because it could not be 
ascertained whether they were subject to hypertension or not. Therefore, 281 siblings 
were considered in terms of two groups, hypertensive and normotensive. For all the 
109 males, the mean age 士 standard deviation was 40.2 ±7.18 years and 42.12 士 6.59 
years for the 66 hypertensive males and 37.26 ±7.11 years for the 43 normotensive 
males respectively. For the 172 females, the mean age 士 standard deviation was 
39.07 士 7.18 years, and 41.94 土 7.06 years for the 67 hypertensive females, and 
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37.24 土 6.67 years for the 105 normotensive females, respectively. (Table 11, page 
82) 
The trend that blood pressure increases with age is clearly showed in our sibling data. 
Blood pressure rose continuously in both men and women. The mean blood pressure 
of males was higher than that of females (Figure 8; Figure 9, page 82). 
Figure 8 Trends of average systolic blood pressure with age for sibling data 
1 I III _?_灘_穩纖賺 
C - J 'if " I I I I I I T T •； 
n c i4n - ；- -- T - � women 
O S “ / (n=172) 
(f) * 
> 3 120 >:�:�仏丨…'、丨〜丨〜、-：？；? - men 
C W 110 V c-："：：；-. / V ‘ 产 : ” 乂 
S > ： 「、\、、、、、：、、〜、、」、、、.、：、:'、、;、、、: 、衫> V； (U n c tJ- ^ n n � - - - \ - - - r - . : � � �>、、-；； v - -^ luu i 1 1 1—h 1 1 r — 
20- 25- 30- 36- 40- 45- 50- 55-
25 30 35 40 45 50 55 60 
Age (years) 
Figure 9. Trends of average diastolic blood pressure with age for sibling data 
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Table 11 Mean age and SD of siblings 
Total Hypertensive Normotensive  
Number Mean age Number Mean age Number Mean age 
^ 40.2±7.18 ^ 42.12±6.59 43 37 26±7 11 
Female 172 39.07±7.18 67 4 ^ 4 ± 7 . 0 6 105 37.24±6 67 
SD= standard deviation.  
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A previous study showed that body weight and mortality from all causes were 
directly related among the middle-aged in North America (Manson et al 1995; 
Stevens et al. 1998). In our data，the age of siblings was mainly between 35-50 years 
old. In males, 67% siblings were in the age of 35-50 years old, 23.8% younger than 
35 years old and 9.2% older than 50 years old. In females, about 66.9% siblings were 
in the age of 35-50 years old, 23.8% younger than 35 years old and 9.3% older than 
50 years old. In total, there were 188 siblings in the age of 35-50 years, 67 siblings 
younger than 35 years old, and about 26 siblings older than 50 years old (Table 12, 
page 83). 
Table 12 Distribution of age, gender and blood pressure in siblings 
Age rvears^  Males Females 
Age (years) 町 NT Total HT NT T ^ ^ 
1 0 ( 1 5 . 2 % ) 1 6 ( 3 7 . 2 % ) 2 6 ( 2 3 . 8 % ) 1 0 ( 1 4 . 9 % ) 3 1 ( 2 9 . 5 % ) 4 1 (23 8%) 
35 < age < 5 0 48 (72.7%) 25 (58.1%) 73 (67.0%) 46 (68.7%) 69 (65.7%) 115(66 9%) 
2 50 8 (12.1%) 2 (4.7%) 10 (9.2%) 11(16.4%) 5(4.8%) 16 (9 3%) 
Total ^ 43 m 67 105 172 
HT 二 hypertensive; NT- normotensive. ‘~“   
4.1.3 Relationship to age and gender 
4.1.3.1 Hypertension versus age and gender 
Data showed that the ratios of hypertensive versus normotensive were 38.5%: 61.5%, 
65.8%:34.2% and 80%:20% respectively, for three age groups of males. That is this 
ratio increased with age for males. Data also showed similar trend for females 
(24.40/0 vs 75.6%, 40% vs 60%, 68.75% vs 31.25%, respectively). However, the 
ratios were lower for females than males. 
4.1.3.2 Central obesity versus age and gender 
Similarly, these siblings were divided into groups of central obese and non-central 
obese, according to the waist to hip ratio. Table 13 (page 84) showed that for males, 
the ratios of central obese versus non-central obese were 30.8%:69.2%, 47.9%:52.1% 
and 70%:30% respectively for three age groups. That is, this ratio increased with age 
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for males. Table 13 (page 84) also showed a similar trend for females and the ratios 
were also lower for females than males so that males seemed to have more central 
obesity. 
Table 13 Distribution of central obese and non-central obese siblings in each age 
group  
Males Females 
Age (years) Central Non-central ^ , , , Non-central ：：；^ 
obese obese Total Central obese Qbese Total 
^ 8 (30.8%) 18(69.2%) Ye 8(19.5%) 33 (80.5%) 4 1 ^ 
35 < age < 5 0 35 (47.9%) 38 (52.1%) 73 33 (28.7%) 82 (71.3%) 115 
7 (70%) 3 (30%) 10 8(50%) 8 (50%) 16 
4.1.3.3 General obesity versus age and gender 
These siblings were divided into groups of general obese and non-general obese, 
according to BMI. Table 14 (page 84) showed that the ratios of general obese versus 
non- general obese were 38.5%:61.5%, 42.5%:57.5% and 30%:70% respectively for 
three age groups. That is, the ratio for mid-age males reached the highest level. 
However, Table 14 (page 84) showed a different pattern for females that this ratio 
increases with age and is higher than males. That is, females seemed to have more 
obesity by BMI. 
Table 14 Distribution of general obese and non- general obese siblings in each 
age group 
Males Females  
Age (years) General Non- general “ ； “ Non- eeneral  
obese obese �ota丨 General obese Total 
^ 10(38.5%) 16(61.5%) 26 19(46.3%) 22 (53 7%) 41 
35 < age < 50 31 (42.5%) 42 (57.5%) 73 52 (45.2%) 63 (54 8%) 1 15 
� () 3(30%) 7 (70%) 10 13(81.25%) 3(18.75%) 16 
4.1.3.4 Hypertension-central obesity versus age and gender 
Combining the two factors of hypertension and central obesity, and comparing the 
group of hypertension and central obese with the group of normotension and non-
central obese (“healthy”），the ratios were 25%:75%, 60%:40%, 77.8%:22.2% 
respectively for males (Table 15, page 85), and 7.4%:93.6%, 26.3%:73.7% and 
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70%:30% respectively for females (Table 15, page 85). It seemed that the risk of 
hypertension and central obesity increased with age and the risk for males seemed to 
be higher than females. 
Table 15 Distribution of hypertensive central obese and healthy siblings in each 
age group 
Males Females 
Age (years) ™ NT andiron- Total HT and N T a n d N o n -
obese central obese central obese central obese 
^ 4 ^ 2 5 ^ 12 (75%) 16 2 (7.4%) 25 (93%) TH 
35 < age < 5 0 30 (60%) 20 (40%) 50 20 (26.3%) 56 (73.7%) 56 
7 (77.8%) 2 (22.20/0) 9 7(70%) 3 (30%) 3 
HT= hypertensive; NT二 normotensive; Healthy siblings = normotensive non-central obese siblings. 
4.1.3.5 Hypertension- general obesity versus age and gender 
Combining two factors of hypertension and general obesity, and comparing the 
group of hypertension and general obese with the group of normotension and non-
general obese ("healthy"). Table 16 (page 85) showed a similar pattern as Table 15 
(page 85) except the ratios of age > 50 years was not higher for males than females, 
which may be caused by the small sample size. 
Table 16 Distribution of hypertensive general obese and healthy siblings in each 
age group 
Males Females 
Age (years) HT and general NT and Non- ^ , HT and NT and 
obese general obese Total al obese Non-general Total 
obese 
^ 6(33.3%) 12 (66.7%) 18 8 (28.6%) 20 (71.4%) 28 
35 < age < 5 0 26 (56.5%) 20(43.5%) 46 29 (38.7%) 46(61.3%) 75 
」 0 3 ( 6 0 % ) 2 ( 4 0 % ) 5 9 ( 9 0 % ) 1 ( 舰 ) 10 
HT= hypertensive; NT= normotensive; healthy siblings = normotensive non-obese siblings.  
4.1.4 Relationship to anthropometric indices 
4.1.4.1 Large proportion of obesity 
In these siblings, there was a large proportion of general obesity. In the females, 
48.80/0 of them had a high BMI (BMI > 25kg/m^), 58.7% had a high WHR (WHR > 
0.80), 47.1% had waist circumference over 80cm and 36.0% had hip circumference 
over 100cm (Table 17, page 86). In the males, 68.8% of them had a high BMI (BMI 
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^ 25kg/m2), 45.9% had high WHR (WHR > 0.90), 44.0% had waist circumference 
over 90cm and 48.6% had hip circumference over 100cm (Table 17, page 86). The 
skinfold thickness data showed that 84.3% of the females had their percentage body 
fat over 30%, and 88.1% males had their percentage body fat over 20%. Comparing 
females and males, the abnormal rate of BMI for males was higher than that for 
females while the abnormal rate of WHR for females was higher than that for males. 
This suggest that the pattern of body fat deposition between female and male might 
be different. 
Table 17 Means and standard deviations of anthropometric indices 
Total Males Females  
Index ~ Abnormal ~ A b n o r m a l ~ ~ Abnormal 
Mean土 SD �at io (%) Mean土SD ratio (%) Mean土SD ratio (。/。） 
BMI ( k g W ) 25.2+3.81 26.2±3.49 ^ 24.7±3.94 4 0 
WHR 0.85±0.07 53.7 0.89±0.05 45.9 0.81±0.07 58.7 
Waist (cm) 83.0±10.26 45.9 89.1±8.81 44.0 79.6±9.53 47.1 
Hip (cm) 98.3±6.89 40.9 99.6±6.23 48.6 97.8±7.23 36.0 
body fat (%) 30.5±6.41 85.8 33.8±4.75 88.1 35.01±4.14 84.3 
SD= standard deviation; BMI= body mass index; WHR= waist-to-hip ratio. “ 
4.1.4.2 Hypertension versus anthropometric indices 
Table 18 (page 86) showed that the gender specific means and abnormal rates of all 
anthropometric indices in the group of hypertensive were consistently greater than 
those in the group of normotensive. 
Table 18 Distribution of the anthropometric indices between HT and NT 
siblings 
— MT (n=65) NT (n=105) 
Term M c a n t S D •^卜 二 1 Mean土SI) 
rate (%) rate (%) 
Females “ ~ 
BMI (kg/nr) 26.8±3.79 68.7 23.2±3.23 36.2 
0.84±0.07 74.6 0.79±0.06 4X.6 
Waist (cm) 84.6±(入23 70.1 76.1±8.08 32.4 
I lip (cm) 100.6±7.44 44.X 95.77±6.27 30.5 
Percentage body fat 35.4±5.18 ^ 32.8±4.2 81.0 
M a l e s 一 “    
27.3±3.38 77.3 24.3±2.99 55.8 
0.91 ±0.05 62.1 0.X6±0.04 20.9 
Waist (cm) 91.7±8.81 59.1 20.9 
" ' P (cm) 100.7±6.65 60.6 97.2±5.17 30.2 
Percentage bod\ fat 26.5±48.3 97.0 23.5±5.01 74.4 
standard deviation; BMI= body ma5s index: \\ }1R= uaist-to-hip ratio; 117 = h\ pcricnsive; NT= 
normoicnsivc. ‘ “ ‘ 
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4.1.5 Relationship to biochemistry indices 
4.1.5.1 Large proportion of dyslipidaemia 
Table 19 (page 88) showed that 47.3% of the siblings had abnormal total cholesterol 
(over 5.2 mmol/L), 31.3% of the siblings had abnormal HDL-c (below 1.0 mmol/L in 
males; below 1.2 mmol/L in females), and 45% of the siblings had abnormal LDL-c 
(over 3.4 mmol/L). However, only 11.5% of the siblings had abnormal triglyceride 
(over 2.0 mmol/L). 
There were some differences between females and males. In males, more than half 
had total cholesterol (54.8%) and LDL-c (57.1%) increased, and about 16.7% males 
had abnormal triglyceride. However, in the females, they mainly had increased total 
cholesterol (42.2%), decreased HDL-c (33.2%) and increased LDL-c (36.9%). (Table 
19, page 88) 
Table 20 (page 88) showed that the rates of abnormal metabolic disorders in 
hypertensive siblings were higher than normotensive siblings, regardless whether is 
males or females. 
4.2 Association between disease traits and covariates in discordant 
sib pairs 
4.2.1 Association between blood pressure and covariates in 
discordant sib-pairs 
In our data, all the siblings had a family history of hypertension. To find the 
association between blood pressure and all the covariates measured, siblings were 
paired into discordant hypertensive-normotensive pairs within each family. Each 
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sibling was only used once in this analysis. Consequently, there were 93 discordant 
sib-pairs being analysed. 
Table 19 Mean and standard deviation and proportion with abnormal values 
for biochemical and haematological parameters in siblings 
Index Total (n-281) Males (n=109) Females (n=172) 
M±SD AR M土 SD AR M±SD AR 
TC (mmol/L) 5.2+1.04 ^ 7 3 5.4±1.1 5.1 土 1.0 i l T " 
TG (mmol/L) 1.4±1.4 11.5 1.7±1.32 16.7 1.2±1.43 8.0 
HDL mmol/L) 1.3±0.38 31.3 1.2±0.30 28.6 1.4士0.4 33.2 
LDL (mmol/L) 3.3+0.94 45 3.5±1.0 57.1 3.1±0.87 36.9 
P creatinine Omol/L) 69.5±16.3 1.9 83.9土 12.9 0.8 59.8士 10.0 2.7 
P sodium (mmol/L) 141±1.6 0 142士 1.45 0 141+1.61 0 
P potassium (mmol/L) 4.2±0.45 14.7 4.3±0.47 11.1 4.2±0.43 17.1 
P urate (mmol/L) 0.30±0.08 8.3 0.36±0.07 13.5 0.26土0.06 4.8 
P bilirubin (lamol/L) 9.5士3.92 8.9 10.97±4.37 16.7 8.55±3.24 3.7 
Haemoglobin (g/dl) 13.9±1.57 4.5 15.2±1.03 0.8 12.9士 1.11 7.0 
HCT ratio 0.40+0.04 2.2 0.44±0.03 1.6 0.38±0.03 2.7 
MCV (fL) 86.7±7.01 9.9 87.5+6.57 6.3 86.1±7.26 12.3 
Platelet (xlOE9/L) 246.7+50.67 0 236.1+48.4 0 253.9+51.0 0 
Blood white cell (xlOE9/L) 6.4±1.50 3.2 6.54士 1.54 1.6 6.3士1.47 4.3 
U mACR (mg/mmol creatine) 3.8±14.56 43.0 2.2±5.1 57.9 4.9士 18.4 32.7 
U AER (i^g/min) 28.8+104.5 21.5 20.4+54.2 23.9 34.3+126.9 20 
TC= total cholesterol; TG= triglyceride; HDL= high density lipoprotein; LDL= low density lipoprotein; plasma; U= 24 
hour urine; M = mean, AR = abnormal ratio (%) , 
Table 20 Mean, standard deviation and proportion with abnormal values for 
biochemical and haematological parameters 
Males Females 
Index HT(n=66) NT (n=43) HT (n=67) NT (n=lQ5) 
M±SD AR M±SD AR M±SD AR M±SD AR 
TC (mmol/L) 5.6±1.05 ^ 5.2±1.11 4 1 9 5.3±1.0 ^ 2 2 4.9士 1.0 3 6 2 ~ 
TG (mmol/L) 1.8±1.4 21.2 1.2±0.6 4.7 1.7±2.11 17.9 1.0±0.79 2.9 
HDL mmol/L) 1.1±0.26 28.8 1.3±0.33 23.3 1.3±0.32 44.8 1.5±0.41 28.6 
LDL (mmol/L) 3.6+0.90 62.1 3.5士 1.18 51.2 3.4士0.76 47.8 3.0±0.92 28.6 
P creatinine 
(^mol/L) 85.0±13.6 1.5 82.8士 11.1 0 59.4±10.9 4.5 59.6±9.6 1.9 
P sodium (mmol/L) 142±1.5 0 142±1.3 0 141±1.7 0 141 士 1.5 0 
P potassium … … „ , ^ 
(mmol/L) 4.3±0.48 1：).2 4.4±0.37 4.7 4.1±0.47 26.9 4.3±0.38 11.4 
P urate (mmol/L) 0.38±0.07 18.2 0.34±0.06 4.7 0.28±0.07 7.5 0.25±0.05 1.9 
I) bilirubin 
(l_imol/L) n .5±4.0 18.2 10.4±3.8 16.3 8.56±3.77 6.0 8.48±2.71 1.0 
Haemoglobin (g/dl) 15.5土0.88 0 15.0±1.13 2.3 13.1 土 1.13 6.0 12.9±11.1 8.6 
HCT ratio 0.45土0.03 1.5 0.44±0.03 2.3 0.38±0.03 3.0 0 38±0 03 2 9 
MCV (fL) 88.0±5.03 3.0 87.6±6.75 7.0 85.1 土6.87 14.9 86.9±7.2 10.5 
Platelet (X10E9/L) 236.5±48.8 0 238土48.6 0 262±54.2 0 245.4±47.8 0 
Blood white cell ^ „ ^ 
(X10E9/L) 6.78±1.58 3.0 6.43±1.53 0 6.42±1.38 3.0 6.14±1.39 3.8 
U m A C R … ， 
(mg/mmol creatine) 2.8±6.64 24.2 1.04±1.43 2.6 10.3±29.3 42.6 1.6±3.33 3.3 
U AER (^ig/min) 28.3±72.3 34 9.3±12.3 9.7 74.6土202 44.0 9.7±22.2 4.2 
TC= total cholesterol; TG= triglyceride; HDL= high density lipoprotein; LDL= low density lipoprotein; P= plasma; U= 24 hour 
urine; M = mean, AR = abnormal ratio (%). ， 
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Table 21 (page 90) showed, the affected siblings were significantly older than 
healthy siblings about 2 years on average; more metabolic disorders occurred in the 
hypertensive siblings, and there were difference in plasma sodium, plasma 
potassium, plasma urate, plasma creatinine and lipid profile; body fat distribution 
was also highly related with blood pressure such that BMI (increased 3 kg/m^), WHR 
(increased 0.05), waist circumference (increased 8 cm) and four sites of SFT were 
significantly higher in the hypertensive siblings (p < 0.05). 
Table 20 (page 88) showed the covariates, which were related to hypertension and 
were roughly selected by paired T tests in hypertensive discordant sib-pairs. Based 
on the results of the above table, Table 22 (page 91) showed that BMI, plasma 
potassium and plasma urate are significantly related to blood pressure between 
hypertensive and normotensive siblings (p - 0.038, odds ratio 二 1.699; p < 0.001, 
odds ratio 二 0.029 with coefficient = -3.556; p = 0.013, odds ratio = 1.6E+08, 
respectively) after adjusting for age and gender. So this indicated that BMI, plasma 
potassium and plasma urate were associated with blood pressure within 
hypertensive-normotensive sib-pairs. 
4.2.2 Association between general obesity and covariates in 
discordant sib-pairs 
In our data, we found that general obesity was highly related to hypertension, and 
there were more than half the siblings with obesity. 142 siblings were paired into 
discordant obese sib-pairs with each sibling only used once. General obesity was 
defined by BMI. The paired sample T test was used to analyse these data. Table 23 
(page 92) showed that the obese siblings were significantly older than non-obese 
siblings about 2 years on average; BMI was significantly related to blood pressure; 
89 
more metabolic disorders occurred in the obese siblings, such as differences in 
plasma sodium, plasma urate, plasma creatinine, fasting glucose and lipid profile. 
According to the results from Table 23 (page 92), the discordant sib-pairs data were 
analysed by Conditional Logistic Regression. The results showed that only 
triglycerides were significantly related to general obesity between affected siblings 
and unaffected siblings (p = 0.031, odds ratio = 1348.9, 95% CI 1.9-9.3E+05) after 
adjusting for age and gender. It indicated that high triglycerides was associated with 
general obesity. 
In our data, central obesity was defined by WHR. 126 siblings were paired into 63 
central obese discordant sib-pairs. Table 23 (page 92) showed that the central obese 
siblings were significantly older than non-central obese siblings. Blood pressure was 
significantly higher in the central obese siblings. Only plasma potassium and 
triglyceride were found to be significantly different between affected and unaffected 
siblings (p = 0.003, p = 0.029 respectively) after adjusting for age and gender. 
Table 21 Association between blood pressure and covariates in discordant sib-
pairs (Analysed by paired t test)  
Factor Normotensive Hypertensive N P 
Age (years) " 3 8 ± 6 . 5 40.8±6.2 ^ ^ o M 
Sodium (mmol/L) 141+1.6 142±1.7 92 0.015 
Potassium (mmol/L) 4.3±0.40 4.1±0.48 92 0.001 
Urate (mmol/L) 0.28±0.07 0.33±0.09 90 ^ Q ^ l 
Creatinine (|amol/L) 64.7±14.4 71±17.5 93 0.005 
TC (mmol/L) 5±1 5.4±1 93 " p ^ 
HDL-c (mmol/L) 1.4±0.4 1.2±0.3 93 
LDL-c (mmol/L) 3.1±1 3.4±0.9 89 " Q ^ j T 
TG (mmol/L) 1.2±0.9 1.8±2.0 93 
Glucose (mmol/L) 4.9±0.4 5.2±1.0 93 p ^ 
BMI (kg/m^) 24.1±3.4 27.0±3.7 93 
Waist circumference (cm) 79.7±8.8 87.7士 10.0 93 <0.001 
Waist-to-hip ratio 0.82±0.06 0.87±0.07 93 ^ Q ^ 
Midarm circumference (cm) 28.2±2.9 30.7+3.3 89 <0.001 
Subscapular SFT (mm) 18.0+6.0 20.9土6.0 93 <0:001 
Triceps SFT (mm) 16.4+6.9 17.2±7.7 93 0.338 
Biceps SFT (mm) 10.3±5.2 11.6±5.7 93 0.034 
Iliac SFT (mm) 21.1±7.9 22.9±9.1 93 
Percent body fat 31.0±6.5 31.3+7.0 93 
U Potassium (mmol/day) 48.6±28.7 47.1±17.4 76 0.699 
U Sodium (mmol/day) 175.3±77.3 196.3+84.5 77 0.108 
U mACR (mg/mmol creatinine) 1.26±1.16 9.3±27.1 75 0.010 
N= number of sibling pairs; SFT= skinfold thickness; BMI= body mass index; T O total cholesterol; 1G= triglyceride. HDL= 
high density lipoprotein; LDL= low density lipoprotein; P= plasma; U= 24 hour urine; mACR= mean albumin-to-crktinine 
ratio. 
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Table 22 Association between blood pressure and covariates in hypertensive 
discordant sib-pairs (Analysed by Conditional Regression)  
95% C I 
Factors Coefficient p-value Odds ratio  
Lower Upper 
^ 0038 Lm iWi IMl 
Plasma potassium -3.556 <0.001 0.029 0.004 0.236 
Plasma urate 18.870 0.013 1.6E+08 55.194 4.4E+14 
Plasma creatinine -0.078 0.065 0.925 0.852 L005 
With age and gender adjustment. "“ 
According to the positive results from Table 23 (page 92), the discordant sib-pairs data 
for centrally obesity was analysed by Conditional Logistic Regression. The results 
showed that only triglyceride were significantly related to central obesity between 
affected and unaffected siblings (p = 0.01, odds ratio = 4.96, 95% CI 1.5-16.6) after 
adjusting for age and gender. So in our data, triglycerides may mainly predict central 
obesity within discordant central obese sib-pairs. 
4.2.3 Association between obesity related hypertension and 
covariates in combined discordant sib-pairs 
90 siblings were paired into obese and hypertension combined discordant sib-pairs. 
The affected siblings were significantly older than unaffected siblings, about 3 years 
on average. More metabolic disorders occurred in the affected siblings, such as 
differences in plasma potassium, plasma urate, plasma creatinine, urinary ACR and 
lipid profile. (Table 24, page 93) 
The obese and hypertensive discordant sib-pairs data were also analysed by 
Conditional Logistic Regression with the covariates significant in the Table 24 (page 
93). No significant relationship was found between the covariates and obese-
hypertension within the combined discordant sib-pairs. 
76 siblings were paired into 38 central-obese hypertensive discordant sib-pairs. The 
paired sample T test was used to analyse the relationship between covariates and 
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central obese combined hypertension. Table 24 (page 93) showed that the affected 
siblings were significantly older than unaffected siblings, about 3 years on average. 
Plasma potassium, plasma urate, lipid profile (total cholesterol, triglyceride, HDL) 
and fasting glucose were significant different between affected and unaffected 
siblings. 
According to the results from Table 24 (page 93), the Conditional Logistic 
Regression was used to analyse the combined discordant sib-pairs data. The results 
showed that only plasma urate was found to have a significant relationship with 
central obese-hypertension between affected and unaffected siblings (p = 0.02, odds 
ratio = 3.6E+06, 95% CI 14.3-9.1E+11) after the adjustment for age and gender. 
Table 23 Association between obesity and covariates in general (n=71) + 
centrally (n=63) obese discordant sib-pairs using paired t test 
Factor General Non-general ~ Central Non-central ~ 
Obese obese obese obese  
Age (years) 38±6.9 40.4士6.8 0.004 40.2+6.6 38.4±7.0 0.050 
Systolic BP (mm Hg) 122±17.3 141±21.2 <0.001 137±21.0 123±16.4 
Diastolic BP (mm Hg) 72+13.3 87±15.3 <0.001 84±14.8 75±13.4 " o o o T 
MAP (mm Hg) 90+13.6 106+16.6 <0.001 103±16.3 92±13.7 0.001 
Pulse (beat/min) 71±9.2 73±10.7 0.216 73±9.7 72±9.0 
Sodium (mmol/L) 141.2±1.84 141.7±1.57 0.050 141.4±1.85 141.3±1.56 0.763 
Potassium (mmol/L) 4.3±0.39 4.2+0.47 0.142 4.1±0.48 4.3±0.39 0.003 
Urate (mmol/L) 0.28士0.06 0.33±0.07 <0.001 0.30±0.08 0.30±0.07 
Creatinine (|imol/L) 66.7±14.1 74.2±18.3 0.003 66.6±16.7 71.8±16.7 0.085 
TC (mmol/L) 4.9±1.0 5.4±1.1 0.004 5.2±0.9 5.1±1.0 0.203 
HDL-c (mmol/L) 1.5土0.4 1.2±0.3 < 0 . 0 0 1 1.3±0.3 1.4±0.4 0 . 2 2 5 
LDL-c (mmol/L) 3.1±1.0 3.5+0.9 0.011 3.3±0.8 3.2±1.1 0.547 
TG (mmol/L) 0.9±0.5 1.9+2.1 <0.001 1.6±2.1 1.0+0.4 0.029 
Glucose (mmol/L) 4.9±0.4 5.2±1.1 0.023 5.1±1.1 4.9±0.4 o l s O 
Waist (cm) 75.6±6.6 89.5±8.7 ^ 0 0 0 1 88.0±9.3 78.3±8.4 <0.001 
Waist-to-hip ratio 0.81±0.07 0.88土0.06 <0.001 0.88±0.06 0.81±0.06 
Subscapular SFT (mm) 16.3±4.4 22.4士6.2 <0.001 21.1±5.2 16.4±4.5 <0.001 
Triceps SFT (mm) 14.9土5.3 18.2土8.1 <0.001 18.1±7.2 13.6±5.4 ^OOm 
Biceps SFT (mm) 8.7±2.9 12.2±5.9 <0.001 11.6±4.7 8.6±3.9 
Iliac SFT (mm) 19.7±6.7 24.4士9.1 <0.001 23.6±8.7 19.5±7.2 ^ O Q ^ 
Percent body fat 29.8±5.7 31.9土7.0 33.2±6.2 28.0±5.7 ^Q^om 
U Potassium (mmol/day) 45.1±15.6 47.9±16.8 0.225 47.0±16.7 44.5±15.4 0.303 
U Sodium (mmol/day) 170.5±65.8 190.0±74.0 0.096 189.6±84.8 173.9±68.1 0.222 
U mACR (mg/mmol �� — . . 
creatine) 1.23±1.30 8.13±27.10 ^ 4 9 8.48±28.0 1.48±1.63 0.064 
Haemoglobin (g/dl) 13.6±1.4 14.2±1.5 0.009 13.6±1.4 14.0土 1.5 0.118 
HCT ratio 0.40士0.04 0.41±0.04 0.013 0.40±0.04 0.41±0.04 0 145 
MCV(fL) 87.1±6.7 87.0±5.8 0.826 85.4±7.0 86.5±8.0 0 328 
Platelet (M0E9/L) 240.9±54.8 249.0±53.7 0.331 256.4±47.6 246.0±44.5 0 196 
White cell (*10E9/L) 6.34+1.48 6.66±1.30 0.125 6.29士 1.30 6.54土 1.55 0.307 
N= number of sibling pairs; SFT= skinfold thickness; BMI= body mass index; TC= total cholesterol- TG- triglyceride- HDL= 
hi吵 density lipoprotein; LDL= low density lipoprotein; plasma; U二 24 hour urine; mACR= mean albumin-to-creatinine 
ratio. 
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Table 24 Association between obesity related hypertension and covariates in 
general (n=45) +centrally (n=38) obese-hypertension discordant sib-pairs using 
paired t test 
Factor General Non-general Central- Non-central 
obese + HT obese + NT obese + HT obese + NT  
Age (years) 41.0±6.7 37.8±7.0 0.002 41.2+6.6 38.3±6.8 0.007 
Systolic BP (mm Hg) 151.7±15.0 114士7.8 <0.001 149士 14.6 116±8.1 <0.001 
Diastolic BP (mm Hg) 94士 10.2 67士7.7 <0.001 93土 10.3 69士8.1 <0.001 
MAP (mm Hg) 115+10.5 84+7.4 <0.001 U3±11.0 86士7.7 <0.001 
Pulse (beat/min) 74士11.6 72±9.4 0.357 74士 13.3 73±9.3 0.468 
Sodium (mmol/L) 141.8±1.83 141.2±1.87 0.069 141.7±2.04 141.1±1.43 0.072 
Potassium (mmol/L) 4.2±0.51 4.3+0.35 0.027 4.1 土0.53 4.3±0.37 0.041 
Urate (mmol/L) 0.34土0.07 0.27±0.06 <0.001 0.32士0.08 0.28±0.06 
Creatinine (iimol/L) 73.2±19.1 64.9土 13.3 0.011 70.1±18.7 68.6±16.5 0.717 
TC (mmol/L) 5.5士 1.0 4.9±1.0 0.002 5.4±1.0 4.9±1.0 0.009 
HDL-c (mmol/L) 1.2±0.3 1.5±0.4 < 0 . 0 0 1 1.2士0.3 1.5土0.5 
LDL-c (mmol/L) 3.5±0.8 3.0±1.1 0.016 3.4+0.8 3.1±1.2 O J ^ 
TG (mmol/L) 2.2±2A 0.8土0.3 <0.001 2.3+3.0 0.9+0.4 0.004 
Glucose (mmol/L) 5.3±1.3 4.9±0.4 0.045 5.3±1.4 4.8士0.4 0.034 
Waist (cm) 91.8±8.6 74.7士6.7 <0.001 90.9+9.3 75.7士7.3 <0.001 
Waist-to-hip ratio 0.89+0.06 0.80+0.07 <0.001 0.89士0.06 0.79±0.06 <0.001 
Subscapular SFT (mm) 23.5±6.3 16.2±4.8 <0.001 21.5±5.4 15.2±3.6 <0.001 
Triceps SFT (mm) 19.5±8.1 15.6±5.3 0.001 17.6土7.4 13.1 士4.7 0.002 
Biceps SFT (mm) 13.1±6.1 9.0土2.9 <0.001 11.4±4.5 7.8+2.2 <0.001 
Iliac SFT (mm) 25.8+9.7 20.0+6.8 <0.001 22.9+8.2 18.0±5.6 
Percent body fat 32.7+7.3 30.3±5.9 0.059 31.8±6.8 27.8士5.3 
U Potassium ,广 , 
(mmol/day) 46.6±17.0 42.2±12.4 0.159 45.6±16.8 43.1 士 13.7 0.451 
U Sodium (mmol/day) 192.4±74.3 162.9±55.6 0.066 199.0±98.6 184.3±73.6 0.465 
U mACR (mg/mmol 
creatine) 12.18±33.69 1.21±1.34 變 13.97±36.59 1.22±1.47 0.055 
Haemoglobin (g/dl) 14.2±1.5 13.4±1.3 0.008 13.8±1.6 13.6±1.6 0.681 
HCT ratio 0.41±0.04 0.39+0.04 0.007 0.40±0.04 0.40±0.04 0.631 
M C V ( f L ) 85.9 土6.5 87.1±7.4 0.284 84.5±7.3 87.0±8.1 0.085 
Platelet (*10E9/L) 255.1±54.8 234.9±49.3 0.059 252.9±54.7 236.2±42.0 0.166 
White cell (*10E9/L) 6.58±1.20 6.31±1.56 0.287 6.41+1.35 6.25+1.54 0.603 
HT= hypertensive; NT二 normotensive; N= number of sibling pairs; SFT= skinfold thickness; BMI= body mass index; TC= 
toml cholesterol; TG= triglyceride; HDL= high density lipoprotein; LDL= low density lipoprotein; P= plasma; U= 24 hour 
urine; mACR= mean albumin-to-creatinine ratio. ’ 
With age and gender adjustment. 
4.3 Description of the analysis of the polymorphisms of 4 genes 
which might be related to hypertension and obesity 
4.3.1 The uncoupling protein 1 gene 
There were many studies which identified the UCPl gene A-3826G polymorphism in 
diverse populations. In Caucasians, such as Finns, Danish and French, they all have 
lower G allele frequencies. In Asia, the only data we were aware of was in Japanese 
men and they had a significantly higher G allele frequency than Caucasians (Table 
25, page 94). We did not find any other studies having been done on this gene 
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polymorphism for populations in Chinese. In our study, this gene polymorphism had 
been identified in 96 hypertensive families，including 281 hypertensive and 
normotensive siblings. The frequencies of the genotypes and alleles of this 
polymorphism were not significantly different between the Hong Kong Chinese 
siblings in our data set and those in the Japanese report = 0.26, p = 0.99), and 
between the males in our data set and the males in the Japanese report (x^ 二 0.88, p = 
0.93). 
Table 25 Genotype and alleles frequencies of the uncoupling protein 1 gene 
A3826G polymorphism in ethnically diverse populations 
Population Number of Genotype frequency (%) Allele frequency (%) 
Studies Subjects AA AG GG A G 
Japanese (Hayakawa et al. “ ~ “ ~~ “ 一 
1999) 1 214 males 26.2 49.5 24.3 50.9 49.1 
French (Oppert et al. 1994; “ ^ 40 8 72 ^ 
Clement et al. 1996) 230 obese 54.8 37.8 7.4 ~ f i J ^  
Finnish (Valve et al. 1998) 2 — ^ ^ ！ ^LZ 18.3 
170 obese 53 42 5 7 3 ^ 26.2 
Danish (Urhammer et al. “ ^ “ 
1997) 1 379 56.2 36.9 6.8 74.3 25.7 
4.3.1.1 Comparison of A-G polymorphism in terms of hypertension 
or obesity 
Table 26 (page 95) showed the frequencies of the UCPl A-3826G polymorphism 
genotypes/alleles comparing hypertensive and normotensive siblings had no 
significant difference. For comparison of genotype/allele frequencies between 133 
hypertensive and 148 normotensive siblings, p = 0.423 and 0.84, respectively; for the 
comparison between 66 HT males and 43 NT males, p = 0.48 and p = 0.34, 
respectively; for the comparison between 67 HT females and 105 NT females, p = 
0.44 and 0.45 respectively; for the comparison between 48 mid-age HT males and 25 
mid-age NT males, (22.9% vs 32%; 60.4% vs 52%; 16.7% vs 16%, 53.1% vs 58%: 
46.90/0 vs 42%, for genotype AA, AG and AG, allele A and G, respectively) p = 
0.695 and 0.56 respectively; for the comparison between 46 mid-age HT females and 
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69 mid-age females, (21.7% vs 27.5%; 60.9% vs 53.6%; 17.4 vs 18.8 for genotype 
AA, AG and GG, 52.2% vs 54.3%; 47.8% vs 45.7% for allele A and G, respectively) 
p = 0.72 and 0.75 respectively. 
In our hypertension discordant sib-pairs, 81 hypertensive discordant sib-pairs were 
used to examine the relationship between the UCPl genotype and hypertension. The 
Conditional Logistic Regression was used to analyse the relationship. The results 
showed that no significant relationship was found between this gene polymorphism 
genotype and blood pressure after adjustment for age and gender (AG vs AA, 
coefficient = 0.2, odds ratio: 1.25, 95% CI 0.4-3.5, p= 0.67; GG vs AA, coefficient = 
0.7, odds ratio = 1.97，95% CI 0.4-10.1, p = 0.4). It indicated that this gene 
polymorphism may not be related to hypertension. 
Table 26 The UCPl gene A-G polymorphism genotype/allele frequencies of 
hypertensive and normotensive siblings 
C . n n f y p . . / 一 Total Males Females 
1 二 HT m HT OT HT 
(n=133) (n=148) (n=66) (n=43) (n=67) NT(n=105) 
^ 32 (24.1%) 40 (27%) 16 (24.2%) 15 (34.9%) 16 (23.9%) 25 (23.8%) 
AG 74 (55.60/0) 71 (48%) 36 (54.5%) 20 (46.5%) 38 (56.7%) 51 (48.6%) 
9 G 27 (20.3%) 37 (25%) 14(21.2%) 8 (18.6%) 13 (19.4%) 29(27.6%) 
A 138(51.9%) 151 (51%) 68 (51.5%) 50 (58.1%) 70 (52.2%) 101 (48.1%) 
G 128(48.1%) 145(49%) 64(48.5%) 36(41.9%) 64(47.8%) 109(51.9%) 
Total siblings: = 1.42 (2df), p = 0.423. 'odds ratio = 1.04 (0.73<OR<1.46, 95% CI.)，p = 0.84. “ 
Males: = 1.45 (2df), p = 0.48. *odds ratio = 0.77 (0.43<OR<1.37, 95% CI.), p = 0.34. 
Females: x^ = 1.66 (2df), p = 0.44. *odds ratio 二 1.18 (0.75<OR<1.86, 95% CI.), p = 0.45. 
HT= hypertensive; NT= normotensive. 
Table 27 (page 96) showed similar results for the comparison between 128 general 
obese and 153 non- general obese siblings and there were no significant differences 
either p = 0.47, p = 0.91, respectively, where the general obesity was defined by 
BMI. 
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Table 27 The UCPl gene A-G polymorphism genotype/allele frequencies of 
general obese and non-general obese siblings 
Total Males Females  
Genotypes/ General Non- general 门 , 、， Non-
lleles Obese obese General Non- general General general 
(n=128) (n=153) obese (n=44) obese (n=65) obese (n=84) obese 
^ (n=88) 
AA 35 (27.3%) 37 (24.2%) 15(34.1%) 16 (24.6%) 20 (23.8%) 21 (23.9%) 
AG 61(47.7%) 84 (54.9%) 18 (40.9%) 38 (58.5%) 43 (51.2%) 46 (52.3%) 
GG 32 (25%) 32 (20.9%) 11(25%) 11(16.9%) 21(25%) 21 (23.9%) 
A 131(51.2%) 158(51.6%) 48 (54.5%) 70(53.8%) 83 (49.4%) 88 (50%) 
G 125 (48.8%) 148(48.4%) 40(45.5%) 60(46.2%) 85 (50.6%) 88 (50%) 
Total siblings: f = 1.49 (2df), p 二 0.474. 'odds ratio = 0.98 (0.69<OR<1.39, 95% CI.), p = 0.91. 
Males: = 3.25 (2df), p = 0.197. *odds ratio = 1.03 (0.58<OR<1.84, 95% CI.), p = 0.92. 
Females: = 0.03 (2df), p = 0.984. *odds ratio = 0.98 (0.63<OR<1.52, 95% CI.), p = 0.91. 
Table 28 (page 96) showed similar results for the comparison between central obese 
and non-central obese. The only exception is shown in Table 29 (page 97), the 
difference in the A to G polymorphism between mid-age central obese males and 
mid-age non-central obese males were statistically significant, p = 0.025 and 0.035 
for genotype and allele respectively. It seemed that the UCPl gene A to G 
polymorphism might have some relationship to central obesity in this small 
subgroup. 
Table 28 The UCPl gene A-G polymorphism genotype/allele frequencies of 
central obese and non-central obese siblings 
Total Males Females 
G e 二 广 s / Central o b e s e N o n - c e n t r a l Central obese N o n - c e n t r a l C i H t i ^ N o n - c e n t r a l 
Heles obese obese obese obese 
( ) (n=182) (n—5U) (n=49) (n=123) 
^ 24 (24.2%) 48 (26.4%) 13 (26%) 1 8 ( 3 0 . 5 % ) 1 1 ( 2 2 . 4 % ) 3 0 (24.4%) 
AG 53 (53.5%) 92 (50.5%) 24 (48%) 32 (54.2%) 29 (59.2%) 60 (48 8%) 
GG 22(22.2%) 42 (23.1%) 13 (26%) 9(15.3%) 9(18.4%) 33 (26 8%) 
A 101(51%) 188(51.6%) 50 (50%) 68 (57.6%) 51(52%) 120 (48 8%) 
G 97(49%) 176(48.4%) 50(50%) 50(42.4%) 47 (48%) 126 (51.2%) 
Total siblings: f = 0.25 (2df), p = 0.885.平 odds ratio = 0.97 (0.68<OR<1.40, 95% CI.), p = 0.89.   
Males: x^ = 1-95 (2df), p = 0.38. *odds ratio = 0.74 (0.42<OR<1.30, 95% CI.), p = 0.26. 
Females: = 1.82 (2df), p = 0.4. *odds ratio = 1.14 (0.69<OR<1.87’ 95% CI.), p 二 0.59. 
142 siblings were paired into 71 general obesity discordant sib-pairs. The 
Conditional Logistic Regression was used to analyse the relationship between the 
UCPl polymorphism genotype and general obesity in the discordant sib-pairs. The 
results showed that there was no significant relationship between this gene 
polymorphism genotype and general obesity after adjustment for age and gender (AG 
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vs AA，coefficient = -0.38, odds ratio 二 0.7, 95% CI 0.3-1.6, p 二 0.4; GG vs AA, 
coefficient = 0.09, odds ratio = 1.1, 95% CI 0.2-5.2, p 二 0.9). 
Table 29 The UCPl gene A-G polymorphism genotype/allele frequencies of 
central obese and non-central obese siblings in age between 35y to 50y 
35 < Age < 50 
Genotypes/Alleles Males Females 
Central obese Non-central obese Central obese Non-central obese 
( " -35) (n-38) (n=33) (n=82) 
^ 7 (20%) 12(31.6%) 7(21.2%) 22 (26.8%) 
AG 18(51.4%) 24 (63.2%) 21 (63.6%) 44 (53.7%) 
GG 10 (28.6%) 2 (5.3%) 5(15.2%) 16(19.5%) 
A 32 (45.7%) 48 (63.2%) 35 (53%) 88 (53.7%) 
G 38 (54.3%) 28 (36.8%) 31 (47%) 76 (46.3%) 
Males: = 7.4 (2df), p = 0.025. 'odds ratio = 0.49 (0.24<OR<1.00，95% CI.), p = 0.035. 
Females: x^ = 0.95 (2df), p = 0.621. *odds ratio = 0.98 (0.53<OR<1.80, 95% CI.), p = 0.93. 
126 siblings were paired into 63 central obesity discordant sib-pairs. The Conditional 
Logistic Regression was used to analyse the relationship between the UCPl 
polymorphism genotype and central obese in the discordant sib-pairs. The results 
showed that there was no significant relationship between this gene polymorphism 
genotype and central obesity after adjustment for age and gender (AG vs AA, 
coefficient = 0.3, odds ratio = 1.3，95% CI 0.5-3.8, p = 0.6; GG vs AA, coefficient = 
1.02, odds ratio = 2.8, 95% CI 0.6-12.9, p = 0.2). 
The results of the Conditional Logistic Regression indicated that this gene 
polymorphism might not be related to obesity. 
43.1.2 Comparison of A-G polymorphism in terms of HT and 
obesity 
Table 30 (page 98) showed there was no significant difference of the A-G 
polymorphism between hypertensive general obese subjects and normotensive non-
general obese ones. Table 31 (page 98) showed similar results for the comparison 
between hypertensive central obese and normotensive non-central obese. 
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Table 30 The UCPl gene A-G polymorphism genotype/allele frequencies of 
hypertensive obese and healthy siblings 
Total Males Females 
H T and obese NT = n o n - " " " " ^ N T and non- “丁 ^ N T and non-
(n=81) (n=川 1) obese (n=35) obese (n=34) obese (n=67) 
^ 22 (27.2%) 27 (26.7%) 11 (31.4%) 11 ( 3 2 . 4 % ) 1 1 (23.9%) 16(23.9%) 
AG 39(48.1%) 49 (48.5%) 15 (42.9%) 17 (50%) 24 (52.2%) 32 (47.8%) 
GG 20 (24.7%) 25 (24.8%) 9 (25.7%) 6(17.6%) 11 (23.9%) 19 (28.4%) 
A 83(51.2%) 103(51%) 37(52.9%) 39 (57.4%) 46 (50%) 64(47.8%) 
G 79(48.8%) 99(49%) 33 (47.1%) 29(42.6%) 46(50%) 70(52.2%) 
Siblings: = 0 (2df), p= 1.0. ‘ odds ratio = 1.01 (0.65<OR<1.56, 95% CI.), p = 0.96. “ 
Males: = 0.71 (2df), p = 0.7. *odds ratio = 0.83 (0.4<OR<1.72, 95% CI.), p = 0.60. 
Females: < = 0.31 (2d0, p = 0.856. *odds ratio = 1.09 (0.62<OR<1.93, 95% CI.), p = 0.74. 
HT= hypertensive; NT= normotensive; obese = general obese. 
Table 31 The UCPl gene A-G polymorphism genotype/allele frequencies of 
hypertensive central obese and healthy siblings 
Total Males Females 
Genotypes/ HT and c e n t r a l H T and n o n - H T and c e n t r a l N T and n o n - H T and c e n t r a l N T and non-
lleles obese central obese obese central obese obese central obese 
(n=69) (n=118) (n=41) (n=34) (n 二 28) (n=84) 
^ 16 (23.2%) 32 (27.1%) 10 (24.4%) 12(35.3%) 6 (21.4%) 20 (23.8%) 
AG 36 (52.2%) 54(45.8%) 20 (48.8%) 16(47.1%) 16(57.1%) 38 (45 2%) 
GG 17(24.6%) 32 (27%) 11 (26.8%) 6 (17.6%) 6 (21.4%) 26 (31%) 
A 68 (49.3%) 118(50%) 40 (48.8%) 40 (51.3%) 28 (50%) 78 (46 4%) 
G 70(50.7%) 118(50%) 42(51.2%) 38 (48.7%) 28 (50%) 90 (53.6%) 
Total siblings: f = 0.74 (2df), p = 0.692. 'odds ratio = 0.97 (0.62<OR<1.51, 95% CL), p = 0 . 8 9 . ^ " 
Males: = 1.46 (2df), p = 0.483. *odds ratio = 0.9 (0.46<OR<1.76, 95% CI.), p = 0.75. 
Females: f = 1.34 (2dQ, p = 0.513. *odds ratio - 1.15 (0.6<OR<2.21, 95% CI.), p = 0.64. 
HT= hypertensive; NT= normotensive. 
90 siblings were paired into 45 general obese-hypertensive discordant sib-pairs. The 
Conditional Logistic Regression was used to analyse the relationship between the 
general obese-hypertension and the UCPl polymorphism genotype in discordant sib-
pairs. The results showed that there was no significant relationship between this gene 
polymorphism genotype and general obesity related hypertension after adjustment 
for age and gender (AG vs AA, coefficient = -0.3, odds ratio = 0.7, 95% CI 0.2-2.6, p 
0.6; GG vs AA, coefficient = 0.5, odds ratio = 1.6, 95% CI 0.2-16.1, p = 0.7). 
78 siblings were paired into 36 central obesity-hypertension discordant sib-pairs. The 
results showed that there was no evidence of relationship between this gene 
polymorphism and central obesity-hypertension after adjustment for age and gender 
(AG vs AA, coefficient = -0.05, odds ratio = 0.9, 95% CI 0.2-4.4, p = 0.9; GG vs 
AA, coefficient = 0.4, odds ratio = 1.5, 95% CI 0.2-10.2, p = 0.7). 
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4.3.1.3 Comparison of characteristics among different genotypes 
There was a trend for hip circumference, triceps SFT, iliac SFT and percentage body 
fat to be higher in GG homozygotes, in contrast to AA homozygotes. Table 32 (page 
100) showed the percentage body fat, plasma sodium and 24 hour urine potassium 
were significantly different between GG and AA homozygotes; the systolic blood 
pressure, HDL cholesterol, plasma sodium, plasma MCV and 24 hour urine 
creatinine were significantly different between AG and AA; the weights, hip 
circumference, BMI, triceps SFT and plasma MCV were significantly different 
between AG and GG (p < 0.10). 
There were 74.4% siblings with the G variant including AG and GG genotypes. The 
data showed that systolic blood pressure, percentage body fat, HDL cholesterol, 
plasma sodium and 24 hour urine creatinine were significantly different between the 
groups with and without the G allele (p < 0.10). 
4.3.2 The angiotensin-converting enzyme gene 
The genotype frequencies of the angiotensin-converting enzyme gene I/D 
polymorphism (ACE I/D) in our data set did not differ from those described in the 
Japanese reports (Higashimori et al 1993; Morise et al 1994; Nakai et al 1994； 
Ohishi et al. 1994; Yorioka et al 1995; Doi et al 1996; Maguchi et al. 1996; 
Nakauchi et al. 1996; Ohno et al. 1996; Kario et al 1997), y^ = 4.69, p = 0.095. 
There was also no significant difference between the genotype frequencies in 183 
Hong Kong Chinese from the general population (Thomas et al. 1996; Thomas et al 
1997) and in 281 Hong Kong Chinese hypertensive siblings in our data, y^ = 0.47, p 
=0 .789 . However, there were significant differences between the genotype 
frequencies in our data and those of other Asia Chinese 
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Table 32 Demographic characteristics of subjects with GG or AG versus AA 
genotype of the UCPl gene  
Characteristics A ^ G variant of UCPl gene P-value* 
^ AA GG/AA AG/ AA AG/GG 
No. of subjects 64 145 72 
Age (years) 3 8土8 40±7 39±7 
Systolic BP (mmHg) 127±20 134+23 128±18 0.572 0.037 0.177 
Diastolic BP (mmHg) 77.5±16 81±16 78±15 0.521 0.117 0.444 
Map (mmHg) 95±17 99±18 96土 16 0.552 0.120 0.421 
Pulse (beat/min) 72+8 72±10 74±10 0.330 0.346 0.833 
Weight (kg) 65.8±13.0 63.3士 10.9 65.8±13.9 0.483 0.216 0.044 
Height (m) 1.60±0.08 1.59+0.08 1.60+0.08 0.696 0.533 0.298 
Waist (kg) 83.1+11.3 82.4+9.3 84.1 士 11.3 0.855 0.200 0.165 
Hip (cm) 99.3±6.6 97.6±6.3 98.7土8.1 0.456 0.285 0.062 
Waist-to-hip ratio 0.84±0.08 0.84±0.07 0.85±0.08 0.597 0.392 0.831 
BMI (kg/m^) 25.6±4.25 24.9±3.41 25.5±4.18 0.501 0.331 0.091 
Biceps SFT (mm) 10.4土4.8 9.8+4.5 10.0±4.5 0.834 0.505 0.382 
Triceps SFT (mm) 17.0士7.2 15.5土6.6 15.1+5.9 0.114 0.899 0.093 
Subscapular SFT (mm) 19.0±6.4 18.4±5.7 18.9±5.0 0.800 0.363 0.248 
Iliac SFT (mm) 21.9±8.5 21.0±8.2 21.0±6.9 0.605 0.848 0.440 
Percentage body fat 31.1+6.3 30.9+6.5 29.3土6.2 0.073 0.123 0.565 
TC (mmol/L) 5.2士 1.0 5.2士 1.1 5.2±1.1 0.694 0.755 0.880 
TG (mmol/L) 1.2+1.1 1.4±1.5 1.5±1.3 0.454 0.665 0.659 
HDL (mmol/L) 1.3±0.4 1.4±0.4 1.3土0.4 0.358 0.044 0.381 
LDL (mmol/L) 3.3士0.9 3.3±1.0 3.3±1.0 0.508 0.930 0.501 
P sodium (mmol/L) 141.6±1.7 141.4+1.5 141.0士1.7 0.012 0.060 0.225 
P potassium (mmol/L) 4.2+0.4 4.2+0.4 4.2±0.5 0.695 0.764 0.854 
P urate (mmol/L) 0.3士0.1 0.3土0.9 0.3±0.1 0.358 0.761 0.166 
P creatinine (|_imol/L) 66.7±15.3 69.4+15.7 70.6士 18.6 0.321 0.835 0.405 
U creatinine (mmol/d) 8.8±3.1 9.4+3.3 10.6±4.6 0.052 0.045 0.705 
U sodium (mmol/d) 167.7±78.0 175.0+69.8 189.9±88.7 0.327 0.310 0.850 
U potassium (mmol/d) 41.1+14.8 46.2±17.4 50.1 士32.9 0.060 0.305 0.223 
U albumin (mg/L) 18.3+52.3 23.1±106.5 43.5+170.7 0.352 0.265 0.971 
U AER (iig/min) 23.4±77.5 25.3+102.4 46.7±144.3 0.365 0.215 0 916 
U mACR o … 
(mg/mmol creatinine) 3.3±8.3 4.0士 16.2 7.0±23.2 0.334 0.253 0.958 
BP = blood pressure; SFT- skinfold thickness; BMI= body mass index; TC= total cholesterol; TG= triglyceride; HDL- h i g h ~ 
density lipoprotein; LDL= low density lipoprotein; P= plasma; U= 24 hour urine; mACR= mean albumin-to-creat丨nine ratio. 
*By multiple comparison after ANCOVA 
populations such as Taiwanese (Jeng et al. 1997) ,义=6.35, p = 0.042, mainland 
Chinese populations (Jian et al. 1996; Thomas et al 1996; Thomas et al. 1997), y^ = 
8.36, p = 0.015, and Singapore Chinese populations (Lee 1994), y^ = 6.23, p = 0.044. 
(Table 33, page 102) 
4.3.2.1 Comparison of the A C E I/D polymorphism in terms of H T 
In our hypertensive families, there was no significant difference in the frequencies of 
the ACE I/D polymorphism genotypes/alleles between hypertensive and 
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normotensive siblings. No significant difference was found in the ACE I/D 
polymorphism genotypes/alleles between 66 hypertensive males and 43 
normotensive males. Also, no significant difference was found in this gene 
polymorphism genotypes/alleles between 67 hypertensive females and 105 
normotensive females. (Table 34, page 102) 
The Conditional Logistic Regression was used on the basis of 84 hypertensive 
discordant sib-pairs to analyse the relationship between this gene polymorphism and 
blood pressure. In the analysis the DD genotype showed a significantly higher risk 
for hypertension than II did after adjustment for age and gender, the estimated odds 
ratio was 6.98 (coefficient 1.9, 95% C.I.: 1.01-48.12, p = 0.05). 
4.3.2.2 Comparison of characteristics among different genotypes 
Table 35 (page 103) showed that the age was slightly less in the group of DD 
homozygotes. Comparing DD and II homozygotes, the triglyceride, plasma platelet 
and plasma white cell were significantly higher in the DD genotypes. Between ID 
and DD genotypes, no significant differences were found in the parameters. 
However, the systolic blood pressure was slightly higher in the group of DD 
genotypes (135 土 11 mmHg for DD versus 130 ± 20 mmHg for ID). 
24 hour urine was collected to measured the albumin excretion rate (AER). 
Normoalbuminuria was classified as an AER < 20 f^g/min, increased albuminuria as 
an AER > 20 |^g/min(Mogensen et al 1995). We divided siblings into hypertensive 
normoalbuminuria/increased albuminuria and normotensive 
normoalbuminurial/increased albuminuria. The ACE gene genotype and allele 
frequencies between hypertensive albuminuric and hypertensive normoalbuminuric 
or normotensive normoalbuminuric were compared. Although there was no 
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significant difference (Table 36, page 103) one could see a trend towards a higher 
frequency of the DD genotype and D allele in the hypertensive albuminuric than 
normoalbuminuric and a trend of a higher DD genotype and D allele frequency in the 
increased albuminuria siblings than normoalbuminuric siblings. 
Table 33 Genotype and allele frequencies of the angiotensin-converting enzyme 
gene I/D polymorphism in ethnically diverse populations 
Ethnic ‘ “ Number of Genotype frequency A l l ^ 
group Population W frequency (%) 
Studies Subjects H ID DD I D ~ 
PRC (Jian et al. 1996; Thomas et ： ~  
a/. 1996; Thomas W 义 1997) ^ 284 46.4 38.4 15.1 65.7 34.3 
� Hong Kong (Thomas et al. 1996; “ 71 ‘ 
Ghmcsc T h o L s . r i l 9 9 7 ) ^ 183 38.8 48.1 13.1 62.8 37.2 
Singapore (Lee 1994) 1 190 50.0 40.0 10.0 70.0 30.0 
Taiwan (Jeng etal. 1997) 1 110 40.0 40.0 20.0 60.0 40.0 
Korea (Oh era/. 1996) 2 446 23.5 47.1 29.4 47.1 52.9  
Japan (Higashimori etal. 1993; “ . ‘ 
Morise et al. 1994; Nakai et al. 
Other Asian 1994; Doi et al. 1996; Maguchi et , , 
al. 1996; Nakauchi a/. 1996; ^ 1^45 41.2 43.9 14.9 63.2 36.8 
Ohno et al. 1996; Kario et al. 
1997) 
US white (Marian et al. 1993; ‘ 
Raynolds et al. 1993; Beohar et 
al. 1995; Lindpaintnerefa/. 1995; 7 3093 20.1 49.1 30.8 44.7 55.3 
Ludwig et al. 1995; Bloem et al. 
Caucasians 1996; Foy et al. 1996) 
FinlandfKupari et al. 1994; “ _ 
Kicma eta/. 1996) 1 86 29.1 40.7 30.2 45.5 54.5 
Denmark (Rasmussen et al. 1996; ~~ ” 
Agerholm-Larsen etal. 1997) 2 6414 23.9 48.6 27.4 48.3 51.7 
Table 34 The ACE gene I/D polymorphism genotype/allele frequencies of HT 
and NT siblings 
r. .nn.yp.c/Ai Total Males Females 
eles ^ ^ HT Wf HT NT  
(n=133) (n=148) (n=66) (n=43) (n=67) (n=105) 
^ 53 (39.8%) 54 (36.5%) 25 (37.9%) 15(34.9%) 28 (41.8%) 39 (37 1%) 
ID 61(45.9%) 79 (53.4%) 34(51.5%) 24 (55.8%) 27 (40.3%) 55 (52 4%) 
DD 18(13.5%) 13(8.8%) 7(10.6%) 4 (9.3%) 11 (16.4%) 9 ( 8 6%) 
.1 167 (63.3%) 187 (64%) 84 (63.6%) 54 (62.8%) 83 (62.9%) 133 (64 6%) 
D 97 (36.7%) 105 (36%) 48 (36.4%) 32 (37.2%) 49 (37.1 %) 73 (35.4%) 
Total siblings: r = 2.43 (2d0, p = 0.297. "odds ratio = 0.97 (0.67<OR<1.39, 95% CI.)’ p 二 0.85. 
Males: yj = 0.2 (2df)’ p = 0.9. 'odds ratio = 0.96 (0.53<OR<1.76，95% CI.), p = 0.90. ’ 
Females: = 3.64 (2df)，p = 0.2.. odds ratio = 0.93 (0.58<OR<1.50, 95% CI.), p = 0.75. 
HT= hypertensive; NT= normotensive. ‘ 
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Table 35 Demographic characteristics of subjects with DD or ID versus II 
genotype of the ACE gene  
ACE gene  
Characteristics ^ ~ “ DD vs. I I I D vs. I I I D vs. DD 
P P P 
No. of subjects 31 140 107 
Age (years) 39+6 39±7 40±7 
Systolic BP (mmHg) 135±22 130土20 131+22 0.153 0.897 0.121 
Diastolic BP (mmHg) 81±14 80士 16 79+16 0.256 0.405 0.531 
Map (mmHg) 100+17 98+17 97+17 0.267 0.606 0.421 
Pulse (beat/min) 71±10 73±11 72土8 0.636 0.133 0.144 
Weight (kg) 66.2±12.5 65.3士 12.9 63.3+11.3 0.131 0.325 0.361 
Height (m) 1.61±0.08 1.60±0.08 1.59±0.08 0.103 0.157 0.447 
Waist (kg) 83.4土 11 83.2±11 83.0±9.1 0.619 0.945 0.641 
Hip (cm) 98.5土9.0 98.3±6.8 98.3±6.4 0.804 0.898 0.736 
Waist-to-hip ratio 0.84±0.07 0.84±0.08 0.84±0.07 0.609 0.924 0.643 
BMI (kg/m^) 25.6±4.01 25.3±3.96 25.1±3.61 0.397 0.698 0.537 
Biceps SFT (mm) 10.8±5.4 10.1±4.3 9.6±4.7 0.197 0.303 0.510 
Triceps SFT (mm) 16.3±6.2 15.5±6.5 16.0士6.9 0.865 0.693 0.667 
Subscapular SFT (mm) 18.2±5.5 18.5±5.8 19.1±5.8 0.565 0.679 0.747 
Iliac SFT (mm) 20.6士8.5 20.5±7.0 22.4±8.9 0.258 0.102 0.921 
Percentage body fat 31.0士6.3 30.0+6.8 31.0±6.1 0.857 0.602 0.601 
TC (mmol/L) 5.0±1.0 5.3±1.1 5.2±1.0 0.362 0.630 0.212 
TG (mmol/L) 1.8士2.8 1.4士 1.2 1.2+0.9 0.024 0.235 0.121 
HDL (mmol/L) 1.4±0.3 1.3±0.4 1.4士0.3 0.931 0.234 0.494 
LDL (mmol/L) 3.1±0.9 3.3士 1.0 3.3±0.9 0.271 0.769 0.187 
P sodium (mmol/L) 141 土 1.7 141±1.6 142±1.6 0.640 0.011 0.236 
P potassium (mmol/L) 4.2±0.4 4.2±0.4 4.2+0.4 0.688 0.721 0.857 
P urate (mmol/L) 0.3±0.08 0.3±0.08 0.3±0.08 0.399 0.522 0.211 
P creatinine (|imol/L) 70.7±17.1 69.5±15.0 68.3±18.1 0.186 0.728 0.258 
P haemoglobin (g/dl) 13.6±1.7 13.9±1.7 13.9±1.4 0.264 0.515 0.468 
P HCT (ratio) 0.40+0.04 0.41±0.05 0.41±0.04 0.234 0.637 0.360 
P MCV (fL) 86.8±6.8 86.0±7.5 87.8±5.3 0.422 0.603 
P platelet (xlOE9/L) 257.8±42.6 251.1±52.6 236.1±49.0 0.039 0.020 0.543 
P white cell (X10E9/L) 6.8士 1.3 6.4±1.6 6.2±1.4 0.036 0.206 0.182 
U creatinine (mmol/d) 9.9±3.6 9.8±3.7 9.9+3.4 0.851 0.447 0.481 
U sodium (mmol/d) 197.9±66.5 186.4±76.1 169.3±75.8 0.057 0.170 0.286 
U potassium (mmol/d) 45.3±16.4 46.3±23.2 45.6±15.3 0.979 0.792 0.847 
U albumin (mg/L) 10.6±9.3 30.0±121.0 28.2±129.5 0.627 0.803 0.518 
U AER (lag/min) 15.5±13.6 35.6±130.9 28.0±98.0 0.722 0 544 0 461 
U m A C R • 
(mg/mmol creatinine) 2.3±2.0 5.5±20.9 4.1+14.4 0.764 0.457 0.445 
BP = blood pressure; SFT= skinfold thickness; BMI= body mass index; T O total cholesterol; T O triglyceride. HDL= h i g h ~ 
density lipoprotein; LDL= low density lipoprotein; P= plasma; U= 24 hour urine; mACR= mean albumin-to-creatinine ratio. 
Table 36 The ACE gene I/D polymorphism genotype and allele frequencies in 
hypertensive and normotensive siblings with and without albuminuria 
n p n n f y p . / . i i a i . ( � / „ )_ _ Hypertcnsive Normotensive 
Total Normo Albuminuria Total Normo Albuminuria 
n ^ 38 146 ^ 6 
n 40.2 40.7 42.1 37 44.3 33.3 
ID 46.2 47.5 42.1 54.1 48.5 50.0 
DD 13.6 11.9 15 .8”* 8.9 7.2 16.7 
I 64 64.4 63.2 75.6 68.6 58.3 
D 36 35.6 36.8*’" 24.4 31.4 41.7 
p > 0.05 vs. hypertensive normoalbuminuria group; " p> 0.05 vs. normotensive normoalbuminuria group 
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4.3.3 The angiotensin type 1 receptor gene 
The ATIR A1166C polymorphism has been described in Caucasians (Bonnardeaux 
et al. 1994; Tiret et al. 1994; Castellano et al. 1996; Tiret et al. 1998), Japanese 
(Nakauchi et al 1996) and Chinese populations (Thomas et al. 1996; Thomas et al. 
1997), which include mainland Chinese and Hong Kong Chinese (Table 37, page 
104). The C allele frequency was higher in the Caucasians (28.6%). In our sibling 
data, the C allele frequency was 4.7%, which was not significantly different from the 
Hong Kong population data. 
Table 37 Genotype and allele frequencies of the angiotensin II type 1 receptor 
gene A1166C polymorphism in ethnically diverse populations 
r e i Allele 
Ethnic group Populations Number of frequency^(%) frcqQuency 
(0,0) 
Studies Subjects AA AC CC A C 
PRC (Thomas et al. 1996; ； ；"： "； 
Chinese Thomas a/. 1997) 1 155 92 8 0 69.1 3.9 
Hong Kong (Thomas et al. 1996; , … … 
T h o L s / a / . 1 9 9 7 ) ! 100 91 9 0 95.5 4.5 
Japanese Japan (Nakauchi et al. 1996) 1 258 84.1 15.5 0.4 91.9 8.1 
(Bonnardeaux et al. 1994; Tiret 
Caucasians et al. 1994; Castellano et al. 5 1917 50.5 41.8 11 71 4 28 6 
1996; Tiret et al. 1998) . • 
4.3.3.1 Comparison of the ATIR A1166C polymorphism in terms of 
HT 
Table 38 (page 105) showed the frequencies of the ATIR A1166C polymorphism 
genotype/alleles between hypertensive and normotensive siblings and there were no 
significant differences. 
The Conditional Logistic Regression was used on the basis of 84 hypertensive 
discordant sib-pairs to analyse the relationship between this gene polymorphism and 
hypertension in discordant sib-pairs. The results showed that there was no significant 
evidence of a relationship after adjustment for age and gender (AA vs AC, 
coefficient = -0.5, odds ratio = 0.6, 95% CI, 0.1- 2.5, p = 0.49). It indicated that this 
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gene polymorphism might not play any important role in the development of 
hypertension. 
Table 38 The ATIR gene A1166C polymorphism genotype/allele frequencies of 
HT and NT siblings  
一 ^o ta l Males Females — 
lleies ^ ^ HT K f HT m 
(n=133) (n-148) (n=66) (n=43) (n=67) (n=105) 
^ 121 (91%) 131(88.5%) 63 (95.5%) 41 (95.3%) 58 ( 8 6 . 6 % ) 9 0 (85.7%) 
AC 11 (8.3%) 15(10.1%) 3 (4.5%) 2 (4.7%) 8(11.9%) 13 (12.4%) 
A 253 (95.8%) 277 (94.9%) 129 (97.7%) 84 (97.7%) 124 (93.9%) 193 (93 7%) 
C 11(4.2%) 15(5.1%) 3(2.3%) 2(2 .3%) 8(6.1%) 13 (6.3%) 
Total siblings: odds ratio = 1.26 (0.52<OR<3.07, 95%CI.), p = 0.58.，odds ratio = 1.25 (0.53<OR<2.96, 95% CI) p = 0 59 
Males: odds ratio = 0.98 (0.13<OR<8.55, 95% CI.), p = 0.98. *odds ratio = 1.02 (0.12<OR<7.72, 95% CI.), p = 0 98 
Females: odds ratio = 1.05 (0.38<OR<2.97, 95% CI.), p = 0.92. *odds ratio = 1.04 (0.39<OR<2.85，95% CL), p = 0.93. 
HT= hypertensive; NT= normotensive. ‘ 
4.3.3.2 Comparison of characteristics among different genotypes 
In these sibling data, there were 26 siblings with the AC genotype, versus 252 
siblings who were AA homozygotes. All the parameters were compared between the 
two genotypes and no significant difference was found. There was a trend showing 
higher systolic blood pressure (131±21 vs 129±23 mm Hg), higher diastolic blood 
pressure (80±16 vs 74士 15 mm Hg) and lower HDL cholesterol (L3±0.4 vs 1.5±0.4 
mmol/L) in subjects without the C allele than those with the C allele. (Table 39, page 
107) 
4.3.4 The Dopamine D2 receptor gene 
Many studies have identified this gene polymorphism in different populations. There 
was a frequency of 46.5% of the Al allele in Hong Kong Chinese (Thomas et al. 
2000). In this sibling study, there was a frequency of only 42.7% of the Al allele, 
similar to that described in the Japanese population (Arinami et al. 1994). (Table 40, 
page 107) 
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4.3.4.1 Comparison of the DRD2 gene TaqI polymorphism in terms 
o fHT 
Table 41 (page 108) showed the frequencies of the DRD2 TaqI polymorphism 
genotypes/alleles comparing hypertensive and normotensive siblings had no 
significant differences. For the comparison between 66 hypertensive males and 42 
normotensive males, p 二 0.96 and p = 0.89, respectively; for the comparison between 
65 hypertensive females and 101 normotensive females, p = 0.18 and p = 0.84, 
respectively. 
To examine the relationship between this gene TaqI polymorphism and blood 
pressure in the discordant sib-pairs for hypertension, the data were analysed by the 
Conditional Logistic Regression on the basis of 81 hypertensive discordant sib-pairs. 
The results showed that there was no significant relationship between this gene 
polymorphism and blood pressure after adjustment for age and gender (A1A2 vs 
A I M , coefficient = -0.9, odds ratio = 0.4, 95% CI 0.1-1.5, p = 0.2; A2A2 vs A I M , 
coefficient = -0.9, odds ratio = 0.2, 95% CI 0.1-1.6, p = 0.2). 
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Table 39 Demographic characteristics between subjects with C variant and 
without C variant of the ATIR genotype  
A T l R gene  
Characteristics AC A A “ 
(n=26) (n二252) ^ • 
Age (years) ~ 41+7 
Systolic BP (mmHg) 129±23 131±21 0.592 
Diastolic BP (mmHg) 74±15 80±16 0.077 
Map (mmHg) 94±18 98±17 0.214 
Pulse (beat/min) 69±7 73±10 0.112 
Weight (kg) 61.8±12.9 64.9±12.2 0.975 
Height (m) 1.57±0.077 1.60±0.082 0.827 
Waist (kg) 81.8土 10.0 83.2±10.3 0.993 
Hip (cm) 97.3±9.6 98.4±6.6 0.599 
Waist-to-hip ratio 0.84±0.071 0.85±0.073 0.488 
BMI (kg/m') 25.0±4.0 25.3±3.8 0.937 
Biceps SFT (mm) 10.5±3.9 9.9±4.7 0.825 
Triceps SFT (mm) 16.3±6.8 15.7±6.6 0.422 
Subscapular SFT (mm) 19.4±6.4 18.6±5.7 0.787 
Iliac SFT (mm) 22.3土9.4 21.1±7.8 0.916 
Percentage body fat 32.5+6.6 30.3+6.4 0.854 
TC (mmol/L) 5.4±1.丨 5 2±i .o 0.248 
TG (mmol/L) 1.2士0.9 1.4±1.4 0.643 
HDL (mmol/L) 1.5±0.4 1.3±0.4 0.094 
LDL (mmol/L) 3.4土 1.1 3 3±0.9 0.528 
P sodium (mmol/L) 141 土 1.6 141±1.6 0.741 
P potassium (mmol/L) 4.2±0.5 4.2±0.4 0.676 
I) urate (mmol/L) 0.29±0.073 0.30±0.081 0.451 
P creatinine (|.imol/L) 66.3±14.7 69.5±16.7 0.431 
' 'haemoglobin (g/dl) 13.2+1.4 13.9±1.6 0.313 
1) HCT (ratio) 0.38±0.036 0.41 ±0.045 0.148 
l ) M C V ( f L ) 87.4±5.0 86.7±6.8 0.464 
platelet (xl{)i-:9/L) 260.8±42.4 244.6±51.3 0.174 
white ccll (xl()|-:9/L) 6.5±1.3 6.4±1.5 0.552 
U creatinine (mmol/d) 8.5±3.4 l().()±3.6 0.428 
U sodium (mmol/d) 166.5±65.2 182.6±76.3 0.724 
U poiassium (mmol/d) 4().8±16.6 46.5±20.() 0.242 
IJ albumin (mg/I.) 6.9±6.7 29.7土 125.1 0.312 
8.8±8.4 32.�)±I16.4 0.269 
IJ niAC'K (ing/niniol creatinine) 1.3±l.l ;5()±18l 0 ^44 
m) = bliHxl pressure; SIT 二 skin fold thickncss; B‘\ll= hotJ> mass index, 1 C= total cholcslcrol; T(i 二 triglyceride: HDI = high 
ilcnsit> lipoprotein; 1.1)1 = lou density lipoprotein; 1'= plasma; U= 24 hour urine; mAC.R二 mean albumin-to-crcatininc ratio; 
AC'R = albumin: creatinine ratio ’ 
Table 40 Genotype and allele frequencies of the dopamine 1)2 receptor gene 
Tag I polymorphism in ethnically diverse populat ions 
Number of Genotype frequency (。 /。） f � r e ( i u ( m c y 
Population “ — 
Studies Subjects A1A1 A1A2 A2A2 Al A 2 
Hong Kong (Thoma.s cf al. 2()()()) I 3K3 21.7 49 6 28.7 TfTl 5 3 X " 
l aiwan (Chen ct al 1996) ， YL  
41 12.2 5 3 ; 3.U 39 61 
Japan (Armami ci al. 1994) | “ ^ ~ 
US Black (Noble ci al 1994; (ioklman ‘ — ‘  
c i a l - 54 13 5 1 9 35 2 3H 9 61.1 
Chcv cnnc (Cioklman ci al. 1 9 9 3 ) 1 J2 ^ ， 
Jemcz l)iieMo ((ioldmari t ’ / ‘ “ 丨州’ 丨 TjTh J^ ^ ^ "j-y" 
Thi-s 讯 1 2-4 r 9 49.6 32.5 42.7 57.3 
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Table 41 The DRD2 TaqI polymorphism genotype/allele frequencies of 
hypertensive and normotensive siblings 
Total Males Females 
J e s HT NT HT NT HT NT 
(n 二 133) (n=148) (n=66) (n=42) (n=65) (n-101) 
^ ^ 27 (20.3%) 22 (14.9%) 14(21.2%) 8(18.6%) 13 (19.4%) 14(13.3%) 
A1A2 59 (44.4%) 77 (52%) 33 (50%) 22 (51.2%) 26 (38.8%) 55 (52.4%) 
A2A2 45 (33.8%) 44 (29.7%) 19(28.8%) 12 (27.9%) 26 (38.8%) 32 (30.5%) 
A l 113(43.1%) 121 (42.3%) 61 (46.2%) 38 (45.2%) 52 (40%) 83 (41.1%) 
A2 149(56.9%) 165 (57.7%) 71(53.8%) 46(54.8%) 78(60%) 119(58.9%)  
Total siblings: f = 2.38 (2df), p = 0.3. 'odds ratio = 1.03 (0.73<OR<1.47, 95% CI.), p = 0.85. 
Males: = 0.09 (2df), p = 0.96. 'odds ratio = 1.04 (0.58<OR<1.87, 95% CI.), p = 0.889. 
Females: = 3.39 (2df), p = 0.18. *odds ratio = 0.96 (0.59<OR<1.54, 95% CI.), p = 0.84. 
HT= hypertensive; NT= normotensive. 
4.3.4.2 Comparison of the DRD2 gene TaqI polymorphism in terms 
of general obesity or central obesity 
Table 42 (page 108) showed the frequencies of the DRD2 TaqI polymorphism 
genotypes/alleles between general obese and non-general obese siblings had no 
significant differences. For comparison of genotype/allele frequencies between 128 
obese and 153 non-obese siblings, p = 0.19 and p = 0.10, respectively; for the 
comparison between 44 obese males and 65 non-obese males, p =0.197 and p = 0.92, 
respectively; for the comparison between 84 obese females and 88 non-obese 
females, p = 0.98 and p = 0.91, respectively. There were no significant differences 
between this gene polymorphism and general obese in each age group for males and 
females. 
Table 42 The DRD2 TaqI polymorphism genotype/allele frequencies of general 
obese and non- general obese siblings 
— Total Males Females 
Ileles Obese Non-obese Obese Non-obese Obese Non-obese 
(n=128) (n=153) (n=44) (n-64) (n-82) (n=84) 
^ ^ 25(19.5%) 24(15.7%) 9 (20.5%) 13 (20%) 16(19%) 11 (12 5%) 
A1A2 55 (43%) 81(52.9%) 20 (45.5%) 35 (53.8%) 35(41.7%) 46 (52.3%) 
A*2A2 46 (35.9%) 43 (28.1%) 15(34.1%) 16 (24.6%) 31 (36.9%) 27 (30 7%) 
Al 105 (51%) 129 (43.6%) 38 (43.2%) 61 (47.7%) 67 (40.9%) 68 (40 5%) 
*A2 101(490/0) 167 (56.4%) 50 (56.80/0) 67 (52.3%) 97 (59.1%) 100 (59.5%) 
Total siblings: = 3.35 (2df), p = 0.19. 'odds ratio = 1.35 (0.93<OR<1.95，95% CI.), p 二 0 10   
Males: 1.19 (2df), p = 0.55. 'odds ratio = 0.83 (0.47<OR<1.49’ 95% CI.), p = 0.52. 
Females: = 2.67 (2df), p = 0.26. 'odds ratio = 1.02 (0.64<OR<1.61，95% CI.), p = 0.94. 
Obese 二 general obese. 
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Table 43 (page 109) showed the frequencies of the DRD2 TaqI polymorphism 
genotypes/alleles between central obese and non-central obese had no significant 
difference. 
The results of Conditional Logistic Regression on the basis of 69 obese discordant 
sib-pairs showed that there was no evidence of relationship between this gene 
polymorphism and general obesity in the discordant sib-pairs after adjustment for age 
and gender (Table 44, page 109). 
Table 43 The DRD2 TaqI polymorphism genotype/allele frequencies of central 
obese and non-central obese siblings 
Total Males Females 
Genotypes/AI Central obese Non-central Central obese Non-central Central obese Non-central 
eles (n=99) obese (n=50) obese (n=48) obese 
(n=182) (n=58) (n=118) 
A I M 22 (22.2%) 27 (14.8%) 10 (20%) 12 ( 2 0 . 3 % ) 1 2 (24.5%) 15(12.2%) 
A1A2 38 (38.4%) 98 (53.8%) 24 (48%) 31 (52.5%) 14 (28.6%) 67 (54.5%) 
A2A2 38 (38.4%) 51 (28%) 16 (32%) 15 (25.4%) 22 (44.9%) 36 (29.3%) 
A l 82 (41.8%) 152 (43.2%) 44 (44%) 55 (47.4%) 38 (39.6%) 97 (41.1%) 
A2 114(58.2%) 200(56.8%) 56(56%) 61(52.6%) 58 (60.4%) 139(58.9%) 
Total siblings: f = 7.26 (2df), p = 0.026. 'odds ratio = 0.95 (0.65<OR<1.37, 95% CI.)，p = 0.76. “ 
Males: = 0.52 (2df), p = 0.77. *odds ratio = 0.87 (0.49<OR<1.55), p = 0.6. 
Females: ^ = 10.79 (2df), p = 0.0045. * odds ratio = 0.94 (0.56<OR<1.57, 95% CI.), p = 0.8. 
The results of Conditional Logistic Regression on the basis of 61 central obese 
discordant sib-pairs showed that there was a significant relationship between the 
AlAl genotype and increased central obesity after adjustment for age and gender 
(Table 45, page 110), so the AlAl genotype might have a higher risk for central 
obesity than A1A2 and A2A2 genotypes. The odds ratio of A1A2 vs. AlAl was 0.18 
(p = 0.06), and that of A2A2 vs. AlAl was 0.12 (p = 0.038). 
Table 44 Association between the DRD2 TaqI polymorphism and general 
obesity in the discordant sib-pairs (Analysed by Conditional Logistic 
Regression) 
Factor Coefficient p-value Odds ratio 95% C.I.  
Lower Upper 
A 1 A 2 : A 1 A 1 -1.0293 O J m O ® 1 2 ^ 
A2A2 : A l A l -0.6990 0.3434 0.4971 0.1171 2.1107 
With age and gender adjustment. ‘~“ 
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Table 45 Association between the DRD2 TaqI polymorphism and central 
obesity in the discordant sib-pairs (Analysed by Conditional Logistic 
Regression) 
Factor Coefficient p-value Odds ratio , 95o/o C.I. 
Lower Upper 
A1A2 : A I M -1.6925 0.0641 0.1841 0.0307 1.1045 
A2A2 : A l A l -2.1267 0.0378 0.1192 0.0160 0.8871 
With age and gender adjustment. ~ — ”" 
4.3.4.3 Comparison of the DRD2 gene TaqI polymorphism in terms 
of general obesity/central obesity and HT 
The differences between general obesity related hypertension and "healthy siblings" 
(no hypertension and no obesity) were compaired. Table 46 (page 110) showed the 
frequencies of the DRD2 TaqI polymorphism genotypes/alleles between general 
obese-hypertensive and non- general obese normotensive siblings had no significant 
differences. For comparison of genotype/allele frequencies between 81 general 
obese-hypertensive and 101 non- general obese normotensive siblings, p = 0.134 and 
P 二 0.90, respectively; for the comparison between 35 general obese-hypertensive 
males and 34 non- general obese normotensive males, p = 0.74 and p = 0.75, 
respectively; for the comparison between 46 general obese-hypertensive females and 
67 non- general obese normotensive females, p = 0.12 and p = 0.92, respectively. 
There was no significant relationship between this gene polymorphism and general 
obese-hypertension in each age group for males and females. 
Table 46 The DRD2 gene TaqI polymorphism genotype/allele frequencies of 
hypertensive obese and healthy siblings 
Total Males F e n ^ 
Genotypes/ , NT + non- ； NT+ Non-
lleles +obese • HT+obese HT+obese NT+non-obese 
(n=81) (n=101) (n=35) ^ 3 4 ' ("=46) (n=67) 
^ ^ 18 (22.2%) 15(14.9%) 7 6 11 (23.9%) 9(13.4%) 
A1A2 35 (43.2%) 57 (56.4%) 17 19 18(39.1%) 38 (56.7%) 
A*2A2 27 (33.3%) 25 (24.8%) 11 8 16(34.8%) 17 (25 4%) 
*A1 71 (44.4%) 87(44.8%) 31 31 40 (44.4%) 56 (43.8%) 
A2 89 (55.6%) 107 (55.2%0 39 35 50 (55.6%) 72 (56.3%) 
Total siblings: x' = 4.01 (2df), p = 0.134. 'odds ratio = 0.98 (0.63<OR<1.53, 95% CI.)’ p = 0.90   
Males: = 0.6 (2df), p = 0.74. *odds ratio = 0.9 (0.43<OR<1.86, 95% CL), p = 0.75. 
Females: x' = 4.19 (2df), p = 0.12. * odds ratio = 1.03 (0.58<OR<1.84, 95% CI.), p = 0.92. 
Obese = general obese. 
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Table 47 (page 111) showed the frequencies of the DRD2 TaqI polymorphism 
genotypes/alleles between central obese-hypertensive and non-central obese 
normotensive siblings had no significant difference. For comparison of 
genotypes/alleles between 69 central obese-hypertensive and 118 non-central obese 
normotensive, p = 0.05 and p = 0.96, respectively; for the comparison between 41 
central obese-hypertensive males and 33 non-central obese normotensive males, p = 
0.9 and p = 0.85, respectively; for the comparison between 28 central obese-
hypertensive females and 84 non-central obese normotensive females, p = 0.014 and 
P 二 0.88; for the comparison between 4 young-age central obese-hypertensive males 
and 11 young-age non-central obese normotensive males, p = 0.033 and p = 0.065, 
respectively, but the numbers in this comparison are too small to reach any 
meaningful conclusion. 
The results of Conditional Logistic Regression on the basis of 45 general obese-
hypertensive discordant sib-pairs showed (Table 48, page 112) that there was no 
significant relationship either between this gene polymorphism and general obesity 
related hypertension after adjusting for age and gender (p = 0.44 and 0.56). 
Table 47 The DRD2 TaqI polymorphism genotype/allele frequencies of 
hypertensive central obese and healthy siblings 
Total Males Females 
Genotypes/ HT + central NT + non- HT+ central NT+ N o n - H T + central NT+ n o n - ~ 
lldes obese central obese obese central obese obese central obese 
(n=69) (n=118) (n=41) (n=33) (n=28) (n=84) 
A l ^ 15(21.7%) 15(12.7%) 8 ( 1 ^ 6(17：6) 7 (25%) 9 (10 7%) 
A1A2 28 (40.6%) 67 (56.8%) 20(48.8) 18(52.9) 8 (28.6%) 49 (58 3%) 
A*2A2 25 (36.2%) 31(26.3%) 13(31.7) 9(26.5) 12 (42.9%) 22 (26 2%) 
*A1 58 (42.6%) 97 (42.9%) 36(43.9) 30(45.5) 22 (40.7%) 67 (41 9%) 
A2 78 (57.4%) 129(57.1%) 46(56.1) 36(54.5) 32 (59.3%) 93 (58.1%) 
Total siblings: = 5.83 (2df), p = 0.054.，odds ratio = 0.99 (0.63<OR<1.56, 95% CL), p = 0.96. 
Males: x^ = 0.26 (2df), p = 0.9. *odds ratio = 0.94 (0.46<OR<1.9, 95% CI.), p = 0.85. 
Females: = 8.52 (2df), p = 0.014. *odds ratio = 0.95 (0.49<OR<1.87，95% CL), p = 0.88. 
HT= hypertensive; NT= normotensive. ‘ 
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Table 48 Association between the DRD2 TaqI polymorphism and general obese-
hypertension in discordant sib-pairs (Analysed by Conditional Logistic 
Regression) 
Factor Coefficient p-value Odds ratio 95% C.I.  
Lower Upper 
A 1 A 2 : A 1 A 1 -0.6399 0.4402 0.5273 0.1038 2.6783 
A2A2 : A I M -0.6133 0.5563 0.5415 0.0702 4.1781 
With age and gender adjustment. “ ~ 
However, the results of Conditional Logistic Regression on the basis of 39 central 
obese-hypertensive discordant sib-pairs showed (Table 49, page 112) that the AlAl 
genotype was significantly related to central obese-hypertension after adjusting for 
age and gender (p = 0.05, 0.08). 
Table 49 Association between the DRD2 TaqI polymorphism and central obese 
hypertension in discordant sib-pairs (Analysed by Conditional Logistic 
Regression) 
Factor Coefficient p-value Odds ratio 95% C.I.  
Lower Upper 
A1A2:A1A1 -2.7603 O ^ 0 M 3 3 O m ^ 
A2A2 : A l A l -2.7274 0.0791 0.0654 0.0031 1.3724 
With age and gender adjustment. “ 
We combined hypertensive and normotensive siblings and compared the frequency 
of genotypes with the A2 allele (A1A2 + A2A2) and without A2 (AlAl) for blood 
pressure, obesity parameters, and biochemistry parameters. Analysis of covariance 
(ANCOVA) was used to adjust for the differences in age and gender. The results 
showed that there were significant differences in WHR and triglycerides between 
these two allele groups (p=0.01, p=0.006, respectively). WHR was higher in the 
homozygotes AlAl group. Triglycerides were also higher in the homozygotes AlAl 
group. There was no difference in blood pressure, BMI, biceps SFT, triceps SFT, 
iliac SFT, subscapular SFT, and percentage body fat between these two groups. 
However, four SFT and percentage body fat were higher in the group with the A2 
allele than in the group without A2 allele. For the lipid profile, only triglycerides 
were significantly different between these two groups, but HDL-cholesterol was 
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lower in the AlAl group, LDL-cholesterol and total cholesterol were higher in the 
Al Al group than in the group with A2 allele. 
The A2A2 and genotype AlAl and A1A2 and AlAl genotype were compared 
respectively by Analysis of Covariance (ANCOVA), with age and gender 
adjustment. Between A2A2 and AlAl groups, there were significant differences in 
percentage body fat and triglycerides (p=0.045, p=0.021, respectively), and 
percentage body fat was lower and triglycerides were higher in the AlAl 
homozygotes groups. Between A1A2 and AlAl groups, there were significant 
difference in WHR and triglycerides (p=0.003，p=0.007, respectively) and WHR and 
triglyceride were higher in the AlAl homozygotes group. (Table 50, page 113) 
Table 50 Demographic characteristics of subjects with A1A2 or A2A2 versus 
A lAl genotype of the DRD2 gene 
DRD2 gene 
“ A1A2 A l ^ ~ 
Characteristics A2A2 A1A2 A l A l Vs Vs 
(n=89) (n=136) (n=49) A l A l A l A l 
P P 
Age (years) 40+8 ‘ 
Systolic BP (mmHg) 133+22 129+22 134±17 0.322 0.963 
Diastolic BP (mmHg) 80±17 78±16 82土 13 0.369 0.823 
Weight (kg) 64.4+11.6 64.7±12.7 65.5土 12.4 0.863 0.909 
Height (m) 1.59+0.085 1.60±0.081 1.60+0.079 0.343 0.622 
Waist-to-hip ratio 0.85±0.073 0.84+0.073 0.87±0.067 0.114 
BMI (kg /m) 25.5+3.72 25.1±3.94 25.6±3.68 ^ 0.961 
Biceps SFT (mm) 11.1±5.4 9.4+4.0 9.6+4.3 0.611 0 120 
Triceps SFT (mm) 17.4士7.2 15.1+6.3 15.0+6.1 0.867 0.101 
Iliac SFT (mm) 22.8±7.9 20.1±7.9 21.5±7.8 0.243 0.509 
Subscapular SFT (mm) 20.4±6.0 17.6±5.6 18.7士4.9 0.322 0.104 
Percentage body fat 32.1±6.80 29.9±5.89 29.5±6.93 0.634 0:045 
TC (mmol/L) 5.19±1.01 5.14+1.05 5.44±1.11 0.128 0 2 2 7 
TG (mmol/L) 1.31+0.85 1.23+1.43 1.88+1.81 0.021 
HDL (mmol/L) 1.34±0.40 1.34+0.35 1.24+0.38 H l s 0 2 1 7 
LDL (mmol/L) 3.26+0.97 3.30±1.01 3.37+0.82 0.828 0.678 
P sodium (mmol/L) 141+1.44 141±1.74 142+1.51 0.194 0.530 
P potassium (mmol/L) 4.29±Q.44 4.21±0.44 4.15+0.43 0.382 0.051 
BP = blood pressure; SFT= skinfold thickness; BMI- body mass index; TC- total cholesterol; TG= triglyceride- H D L ^ g h 
density lipoprotein; LDL= low density lipoprotein; P= plasma. 
4.4 Sib pair linkage analysis 
In this study three qualitative traits were analyzed for genetic linkage at four 
independent loci. The first was hypertension, the other two were general obesity and 
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central obesity. General obesity was defined as BMI over 25kg/m^ in females, over 
27kg/m in males; central obesity was defined as WHR over 0.85 in females, over 
0.90 in males, respectively. 
4.4.1 Linkage between each gene and hypertension in our data 
Allele-sharing analysis is a kind of nonparametric technique, in which, related 
individuals with a disorder are studied. The sharing of the same allele by all affected 
members of a pedigree is calculated and compared with what is expected by chance. 
This can be done either in families with affected siblings, called the sib-pair analysis, 
or in large multi-generational pedigrees, called affected pedigree analysis. Here the 
sib-pair program [0.99.9 (26-Jul-2000), by David L Duffy], and the program of 
Statistical Analysis for Genetic Epidemiology (S.A.G.E. release 3.1)/SIBPAL were 
used to perform analyses of qualitative-trait and quantitative trait for our data. 
Linkage was assessed among the 96 families, with 133 hypertensive sibs and 148 
normotensive sibs. 
4.4.1.1 Genetic linkage of the marker near the UCPl gene locus to 
hypertension 
The human UCP gene is located in the chromosome 4 (q31). A A->G (-3826) 
polymorphism in the 5'-flanking region of the UCPl gene has been identified in 
Caucasians. We could not find any evidence of linkage between this UCPl gene 
polymorphism and hypertension through ASP, APM and qualitative linkage analysis 
by the SAGE program. However, the evidence of linkage between this gene and 
systolic blood pressure, and diastolic blood pressure had been found by quantitative 
linkage analysis (QTL). 
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In the ASP analysis, among the 44 affected-affected sibling pairs, 22 pairs of IBS 
were sharing 2, 22 pairs was IBS were sharing 1, and no pairs of IBS sharing 0. It 
showed that the observed mean of IBS sharing was less than expected, and the 
with df equals 2 was equal to 5.1, p = 0.078. No evidence of linkage was therefore 
showed between this gene and hypertension. 
Affected-affected sib pairs and affected-unaffected sib pairs were analysed by the 
APM analysis, respectively. In affected-affected sib pair APM analysis, negative T 
values in three weighting functions were obtained in 30 families. It indicated that no 
association was present. Then in the affected-unaffected sib pair APM analysis，the 
total number of families was 77, results showed all the T values were positive, no 
evidence of linkage was present either (Table 51, page 115). 
Table 51 Linkage between the UCPl gene and hypertension in Hong Kong 
Chinese by APM method 
Weighting Affected-Affected sib-pairs Affected -Unaffected sib-pairs 
f 酣 - T value P 她 e T value ^ ^ 
f { p ) = 1 -1-685 ^ 0.8290 ^ Tl 0.7588 
f { p ) = \ / - y l p -1.696 30 0.9711 0.399 77 0.5624 
f { p ) = y p -1.705 0.9651 ^ Tl 0.5769 
By the SAGE SIBPAL program, linkage was analysed through qualitative traits and 
quantitative traits. In the linkage analysis of qualitative traits, 176 effective sib pairs 
were used and no linkage evidence was found between hypertension and the UCPl 
gene polymorphism (51% mean IBS sharing, T=0.68, p=0.75). 
From the quantitative traits linkage analysis within 183 effective sib pairs, the results 
(Table 52, page 116) indicated that there was linkage between systolic blood pressure 
with this gene, 51% mean IBS sharing, T = -1.94, p = 0.027. Another quantitative 
trait was diastolic blood pressure, with the same effective number of sib pairs and 
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mean IBS sharing as systolic blood pressure traits, T value was -1.45, p = 0.07, so it 
also showed a trend of linkage between diastolic blood pressure and this gene. 
Table 52 Linkage between the UCPl gene and systolic BP/diastolic BP in Hong 
Kong Chinese by quantitative trait linkage analysis 
Quantitative „ Effective Mean IBS ^ , „ , , 
traits number of charms. T value P value Intercept Slope  
sib pairs ^  
Systolic BP UCPl m M n T ^ o W i 1070.69 -535 9 
Diastolic BP UCPl 183 0.512 -1.446 0.075 563.15 -218.8 
BP= blood pressure. “ “ 
4.4.1.2 Genetic linkage of the angiotensin-converting enzyme gene 
locus to hypertension 
The I/D polymorphism of the ACE gene, which is located on the q23 region of 
chromosome 17, was used to test the linkage with the hypertension trait. In the 
affected sib pair analysis, 43 sib pairs were used, including 22 sib pairs of IBS 
sharing 2, 18 sib pairs of IBS sharing 1 and 3 sib pairs of IBS sharing 0. The 
observed IBS sharing was 0.72, which was less than expected IBS sharing 0.79. The 
full sib Chi-square test, showed no evidence of linkage of this gene with 
hypertension [z^ = 3.3 (df = 2), p = 0.19]. 
In APM linkage analysis (Table 53, page 117), three weighting functions on the basis 
of the affected-affected sib pairs in 29 families did not indicate evidence of linkage 
of this gene and hypertension (p>0.05). Similar results were obtained on the basis of 
unaffected-affected sib pairs from 75 families that there was no significant evidence 
of linkage between this gene and hypertension. 
The results of sib pair linkage analysis with the SAGE (SIBPAL) program, did not 
show any trend of linkage between this gene and hypertension either. Where the total 
pairs of siblings was 176, the mean IBS sharing was 50%, T value was 0.42, P equals 
0.66. 
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Table 53 Linkage between the ACE gene and hypertension in Hong Kong 
Chinese by APM method  
Weighting Affected-affected sib-pairs Unaffected-affected sib-pairs 
function T value P v a 丨 ue T value 二 , 
/(/>)=： 1 -1.032 29 0.8566 -0.105 75 0.5352 
f { p ) = ^ l 4 p - 1 1 1 4 29 0.8443 -0.349 75 0.4586 
f { p ) = V P -0.998 ^ 0.7787 -0.550 75 0.4728 
In the quantitative traits linkage analysis (Table 54, page 117), 180 effective sib pairs 
were analysed, there was neither a trend of linkage between systolic blood pressure 
and this gene (T=0.02, p=0.5) nor between diastolic blood pressure and this gene, 
(T=0.89, p-0.8). 
Table 54 Linkage between the ACE gene and systolic BP/diastolic BP in Hong 
Kong Chinese by quantitative trait linkage analysis 
Quantitative 广 Effective Mean IBS 
traits Gene number of sharing T value P value Intercepts Slopes  
sib pairs 运 
Systolic BP A ^ 796.169 Y W 
Diastolic BP ACE 180 0.500 0.887 0.812 364.670 168.355 
BP= blood pressure. 一 “ 
4.4.1.3 Genetic linkage of the angiotensin type 1 (ATI) receptor gene 
locus to hypertension 
The A1166C ATiR polymorphism was used to detect the linkage between this gene 
and hypertension. The results of ASP linkage analysis, on the basis of 43 affected sib 
pairs, including 36 pairs of IBS sharing 2, 7 pairs of IBS sharing 1 and 0 pairs of IBS 
sharing 0, showed that observed mean IBS sharing (0.92) was less than the expected 
(0.96), the ；If2 二 2.8, df =1, p = 0.25. That is, there is no evidence to support the 
association between this gene and hypertension. 
From the APM linkage analysis (Table 55, page 118), on the basis of affected-
affected sib-pairs and unaffected-affected sib-pairs, we could not find any evidence 
of linkage between the ATIR gene and hypertension either. 
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Table 55 Linkage between the ATiR gene and hypertension in Hong Kong 
Chinese by APM method  
Weighting Affected-affected sib-pairs Unaffected-affected sib-pairs 
一丨卯 T value p�^丨ue T value p 
f { p ) = 1 -0.448 29 0.7371 -0.618 75 0.1498 
f { p ) = - \ [ p -1.920 29 0.9064 -1.549 75 0.0871 
j \ p ) = V P -1-394 29 09318 -0.550 75 0.2037 
176 sib pairs analysed by the SAGE (SIBPAL) program showed that T = 0.59，p = 
0.7, and hence there is also no evidence of significant linkage between this gene and 
hypertension. 
The quantitative traits linkage between systolic blood pressure/diastolic blood 
pressure and this gene was also analysed with the SAGE (SIBPAL) program. In the 
180 sib pairs, T > l , p > 0.89 (Table 56, page 118), so that there were no evidence of 
linkage between this gene and systolic blood pressure/diastolic blood pressure. 
Table 56 Linkage between the ATiR gene and systolic BP/diastolic BP in Hong 
Kong Chinese by quantitative trait linkage analysis 
Quantitative „ Effective Mean IBS ^ . „ . 
traits e number of sharing T value P value Intercepts Slopes  
sib pairs 呂 
Systolic BP ATjR 0 4 % Ll^l o m 48T?76 641.58 
Diastolic BP AT.R 0.496 1.240 0.892 277.60 345.22 
BP= blood pressure. “ ‘ “ 
4.4.1.4 Genetic linkage of the dopamine D2 receptor gene locus to 
hypertension 
The TaqI A polymorphism at the 3' end of the DRD2 gene, which localized to the 
llq21 to llq23 region of the human genome was used in the test for linkage. In 
affected sib pair analysis, the number of sib pairs is 43 pairs, including 25 pairs of 
IBS sharing 2, and 17 pairs of IBS sharing 1, and 1 pair of IBS sharing 0. The 
observed mean IBS sharing 0.78, was less than the expected mean IBS sharing 0.79, 
because observed mean IBS sharing was less than expected, Chi-square with 2 df 
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equals 0.2, p = 0.9, so that there was no evidence of linkage present between this 
gene and hypertension in affected sib pairs. 
The affected pedigree member linkage analysis was also used to detect linkage 
between this gene and hypertension (Table 57, page 119). In the affected-affected sib 
pairs, there was no any significant linkage between hypertension and this gene with 
weighting functions f{p) = \ (T=1.03，p=0.17), f{p)=\/^ (T=0.99, p=0.32) and 
Ap) = Vp (丁=0.92， p=0.30). However, in affected-unaffected sib pairs, the analysis 
showed evidence of significant linkage between this gene and hypertension with T 
values of the three weighting functions all being negative and p-values all much less 
than 0.05. 
Table 57 Linkage between the DRD2 gene and hypertension in Hong Kong 
Chinese by APM method  
Weighting Affected-affected sib-pairs Affected-unaffected sib-pairs 
functions — ； 
T v a 丨此 P 她 e T va.ue p 
/ 0 ^ ) = 1 ^ ^ 0.1716 T w ^ 0.0355 
f { p ) = ^ l 4 P 0.996 29 0.3202 -1.863 73 0.0132 
f { p ) = \ l p 0.920 29 0.2945 -1.868 73 0.0123 
At the same time, the results of qualitative traits linkage analysis by the SAGE 
(SIBPAL) program showed there might be a linkage between this gene and 
hypertension (T=-1.43, p=0.07). The effective number of sib pairs was 176. The 
mean allele sharing was 49.8%. 
In the quantitative trait linkage analysis of this gene and systolic blood 
pressure/diastolic blood pressure, the results did not show any evidence of 
association (Table 58, page 120). 
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Table 58 Linkage between the DRD2 gene and systolic BP/diastolic BP in Hong 
Kong Chinese by quantitative trait linkage analysis 
Quantitative „ Ef^ctive Mean IBS ^ . ^ . 
traits e number of sib sharing values P values Intercept Slope  
pairs g 
Systolic BP DRD2 176 0 4 % 0 3 8 7 6 0 M 2 5 4 ^ 
Diastolic BP DRD2 176 0.498 0.462 0.678 405.47 69.19 
BP= blood pressure. “ 
4.4.2 Linkage between each gene locus and obesity in Hong Kong 
hypertensive Chinese families 
In our study, all the subjects we recruited from hypertensive families, so that they 
might have had hypertension or they had the potential to be hypertensive. As obesity 
was a risk factor for developing hypertension, the association between these four 
genes and obesity with a hypertensive family history was explored. 
The linkage between the qualitative trait of obesity defined by WHR/BMI and the 
above four genes was analysed and it was followed by a quantitative traits linkage 
analysis between the four independent genes and WHR/BMI. 
4.4.2.1 Genetic linkage of the uncoupling protein 1 gene locus to 
obesity with hypertensive family history 
Recently, many studies showed that the uncoupling protein 1 gene is associated with 
weight gain, but no linkage between this gene and obesity. In the previous results, we 
found a weak linkage between this gene and systolic blood pressure, and here we 
examine the general obese subjects to find whether there was any evidence of linkage 
between this gene and obesity in our hypertensive families. 
In the ASP analysis, 44 affected-affected sibling pairs were analysed, including 21 
pairs of IBS sharing 2, 21 pairs of IBS sharing 1, 2 pairs of IBS sharing 0. The 
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observed mean IBS sharing was less than expected • No evidence of linkage was 
shown between this gene and central obesity in our hypertensive families (Chi-square 
with 2 df equals 2.5, p = 0.3, observed IBS sharing equals 0.71, expected IBS sharing 
equals 0.78). 
With the APM method, affected-affected sib pairs of 27 families and affected-
unaffected sib pairs of 46 families were detected. Negative T values for affected-
affected sib pairs and positive T values for affected-unaffected sib pairs resulted 
from the three weighting functions (Table 59, page 121). This indicated that there 
was no linkage present between this gene and central obesity in these hypertensive 
families. 
In our data, 128 siblings had general obesity and 81 siblings had general obesity-
related hypertension. That is, more than half of the hypertensive siblings had general 
obesity. The methods of ASP and APM were used to detect whether there was any 
association between this gene and general obesity in our hypertensive families. 
Table 59 Linkage between the UCPl gene locus and central obesity in Hong 
Kong Chinese with hypertensive family history by APM method 
Weighting Affected-Affected sib pairs Affected-Unaffected sib pairs 
functions rva lues P values T values p 
f { p ) = 1 -1-427 27 0.8284 0.674 46 0.8781 
f { p ) = ^ / y f p -1.477 27 0.9777 0.671 46 0.7348 
f { p ) = \ / p -1.524 a9765 0.669 46 0.7074 
100 affected-affected sib pairs were used in ASP analysis, including 57 sib pairs of 
IBS sharing 2 alleles, 40 sib pairs of IBS sharing 1 allele and 3 sib pairs of IBS 
sharing 0 allele. The observed mean IBS sharing was less than expected. It showed 
that there was no significant linkage between this gene and general obesity in these 
hypertensive families (observed IBS sharing equals 0.77, expected IBS sharing 
equals 0.78, chi-square with 2 df equals 0.3, p = 0.87). 
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In the APM analysis, affected-affected sib pairs of 40 hypertensive families and 
affected-unaffected sib pairs of 62 hypertensive families were used. Negative T 
values and positive T values were obtained in affected-affected sib pairs and 
affected-unaffected sib pairs for the weighting functions respectively. These results 
indicated that there was no linkage between the UCPl gene and obesity in the 
hypertensive families. (Table 60, page 122) 
Table 60 Linkage between the UCPl gene locus and general obesity in Hong 
Kong Chinese with hypertensive family history by APM method 
Weighting Affected-Affected sib pairs Affected-Unaffected sib pairs 
f u t o n s l v a l u e s Pval„es l v a l u e s 二 : � f 
/ ( p ) = l 0.772 40 0.2009 -0.765 62 0.4298 
f { p ) = l / ' s l p 0.751 40 0.3138 -0.768 62 0.0761 
f { p ) = l / p 0.730 40 0.3311 -0.770 62 0.1024 
By using the SAGE (SIBPAL) program, we analysed linkage through qualitative trait 
and quantitative trait linkage methods. In the linkage analysis of qualitative traits, no 
linkage evidence was found between the UCPl gene and central obesity/ general 
obesity in the hypertensive families on the basis of 176 effective sib pairs (Table 61, 
page 122). In the quantitative trait linkage analysis, WHR and BMI traits in 183 sib 
pairs were analyzed (Table 62, page 123). Still no evidence of linkage between the 
UCPl gene and WHR/BMI in the hypertensive families was found. 
Table 61 linkage between the UCPl gene and central obesity/ general obesity 
analysed by qualitative/quantitative trait linkage analysis in Hong Kong 
Chinese with hypertensive family history 
Effective ~ , … � ‘ 
. . M e a n IBD ^ . 
number of sharing T values P values Intercepts Slopes  
sib pairs 各 
Qualitative traits “ “ “ 
Central obesity 176 0.511 0.437 0.669 0.350 0 057 
General obesity 176 0.511 -1.205 0.115 0.538 -0.160 
Quantitative traits 
WHR 183 0.512 0.399 0.655 0.008 0 001 
^ 0-512 -0.717 0.237 27.259 -6.121 
WHR= waist-to-hip ratio; BMI= body mass index.  
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4.4.2.2 Genetic linkage of the angiotensin-converting enzyme gene 
locus to obesity with hypertensive family history 
In the affected sib pair linkage analysis, there were totally 44 affected-affected sib 
pairs, including 21 pairs of IBS sharing 2, 21 pairs of IBS sharing 1 and 2 pairs of 
IBS sharing 0. The observed mean IBS sharing was less than the expected. After full-
sib Chi-square test, we found ；^^  with 2 df was equal to 2.5, p greater than 0.05. 
Therefore no linkage was showed. 
By the affected pedigree member linkage analysis, two groups of sib pairs were 
analyzed, including the affected-affected sib pair group and the affected-unaffected 
sib pair group (Table 62, page 123). For each of the sib pair groups, we did not find 
any evidence of significant linkage between this gene locus and central obesity with 
hypertensive family history. 
Table 62 Linkage between the ACE gene and central obesity in Hong Kong 
Chinese with hypertensive family history by APM method 
Weighting Affected-Affected sib pairs Affected-Unaffected sib pairs 
function T values " f P val狀s T va.ues 
f { p ) = 1 -0.563 27 0.7537 1.226 46 0.9011 
f { p ) = l/-y[p -0.636 27 0.7812 0.862 46 0.7267 
f { p ) = VP -0-646 21 0.6751 0.376 46 0.7471 
Linkage between the ACE gene locus and general obesity with hypertensive family 
history was analyzed by affected sib pair linkage analysis. In the 100 affected-
affected sib pairs, including 69 pairs of IBS sharing 2, 30 pairs of IBS sharing 1 and 
1 pair of IBS sharing 0’ the results of full-sib chi-square test, could not reject the null 
hypothesis of no linkage between this gene locus and general obesity defined by BMI 
with hypertensive family history (chi-square with 2df = 3.1, p = 0.2). 
In the affected pedigree member linkage analysis, 40 families of affected-affected sib 
pairs, and 61 families of affected-unaffected sib pairs were analysed (Table 63, page 
123 
124). For each weighting function, there was no linkage found between this gene 
locus and general obesity defined by BMI in Hong Kong Chinese with hypertensive 
family history. 
176 sib pairs were analyzed using qualitative trait linkage analysis. For central 
obesity, it did not show any evidence of linkage between central obesity and the ACE 
gene polymorphism. For the obesity trait, also no significant linkage between obesity 
and the ACE gene polymorphism was found (Table 64, page 124). 
Table 63 Linkage between the ACE gene and general obesity in Hong Kong 
Chinese with hypertensive family history by APM method 
Affected-Affected sib pairs Affected-Unaffected sib pairs 
Weighting function ~ “ “ Number of “ ~ ！ “ ~ ‘ Number of  
T values f細丨丨丨e^ P values T values �^ ^ ^ P values 
/ ( / > ) = ! -0.533 40 0.7578 0.042 61 0.4216 
f { p ) = ^ / 4 p -0.473 40 0.6229 0.090 61 0.4825 
f { p ) = y p -0.422 40 0.5783 0.128 61 0.5565 
Table 64 Linkage between the ACE gene and central obesity/ general obesity in 
Hong Kong Chinese with hypertensive family history by qualitative trait linkage 
analysis 
Qualitative “ 跳 产 ~~~Mean I B S ~ 
traits number of sharing l v a l u e s P values Intercepts Slopes  
sib pairs ^ 
Central obesity AOT 176 0.501 L ^ O ^ 0.201 
Obesity ACE \76 0.344 0.634 0.428 0.057 
4.4.2.3 Genetic linkage of the angiotensin type 1 receptor gene locus 
to obesity with hypertensive family history 
The ATIR gene polymorphism has been identified in Caucasians. Bonnardeaux et al. 
described a positive association between the A1166C polymorphism and 
hypertension (Bonnardeaux, Davies, Jeunemaitre et al. 1994). Because obesity is a 
risk factor for developing hypertension, and in our data, we found that there was a 
large proportion of hypertensive siblings were obese, linkage analysis was used to 
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examine the linkage between the ATIR gene polymorphism and obesity in 
hypertensive families. 
In the affected sib pair linkage analysis, there were totally 44 affected-affected sib 
pairs, including 41 pairs of IBS sharing 2, 3 pairs of IBS sharing 1 and no pairs of 
IBS sharing 0. The observed mean IBS sharing was similar to the expected. After 
using the full-sib chi-square test, showed that there was no significant linkage 
between this gene locus and central obesity. 
In the affected pedigree member linkage analysis, two groups of sib pairs were 
analyzed, which were affected-affected sib pair and affected-unaffected sib pair 
groups. In the affected-affected sib pairs, no evidence of linkage was shown with 
each of weighting functions. However, in the affected-unaffected sib pairs, for the 
weighting functions of /(;?) = 1 and / ( p ) = l/厂，p values are not significant, but for 
the weighting function of the T value was —1.7, p 二 0.03, which 
suggested that this gene might have some linkage to central obesity in the 
hypertensive families (Table 65, page 126). 
The linkage between the ATIR gene locus and general obesity with hypertensive 
family history was analyzed using affected sib pair linkage analysis. In the 100 
affected-affected sib pairs, including 91 pairs of IBS sharing 2, 9 pairs of IBS sharing 
1, the observed mean IBS sharing was less than the expected and there was no 
significant linkage between this gene locus and obesity with hypertensive family 
history (observed IBS sharing equals 0.95, expected IBS sharing 0.95, chi-square 
with2dfeqiials0.2, p = 0.9). 
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Table 65 Linkage between the ATiR gene and central obesity in Hong Kong 
Chinese with hypertensive family history by APM method 
Weighting Affected-Affected sib pairs Affected-Unaffected sib pairs 
functions T v a l u e s p ^ e s l v a l u e s N = = f p values 
f { p ) = l -0.475 27 0.7299 -0.635 46 0.1525 
f ( j ) ) = ]J 石 0.326 27 0.5152 -1.712 46 0.0312 
f { p ) = l / p 0.415 27 0.5752 -0.964 46 0.1027 
Then 40 affected-affected sib pairs and 61 affected-unaffected sib pairs were 
analyzed with affected pedigree member linkage analysis. Significant results were 
obtained in the affected-unaffected sib pairs with the weighting function of 
f { p ) = l/-sJp,T = -\.9,p = 0.02 (Table 66，page 126). 
Table 66 Linkage between the ATiR gene and general obesity in Hong Kong 
Chinese with hypertensive family history by APM method 
Weighting Affected-Affected sib pairs Affected-Unaffected sib pairs 
functions T values Number of sib T values Number of sib ^  
pairs pairs  
f { p ) = l -0.770 40 0.8634 -0.927 ^ 0.1685 
f { p ) = \ l - s [ p -1-316 40 0.8538 -1.928 61 0.0184 
f { p ) = y p -0.564 AO 0.9264 -1.142 61 0.1601 
In the qualitative trait linkage analysis, 176 sib pairs were analyzed with the SAGE 
(SIBPAL) program. For the central obesity trait, the result did not support linkage 
between this gene locus and central obesity with hypertensive family history. Also 
we did not find any evidence of linkage between this gene and the general obesity 
trait with hypertensive family history (Table 67, page 126). 
Table 67 Linkage between the ATiR gene and central obesity/general obesity in 
Hong Kong Chinese with hypertensive family history by qualitative/quatitative 
trait linkage analysis  
Effective � , …^ 
. , . . Mean IBD ^ . 
number of sib sharing T vahies P values Intercepts Slopes 
pairs g 
Qualitative traits  
Central obesity 176 0.494 -0.842 0.201 0.478 -0.201 
General obesity 176 0.4945 -0.783 0.217 0.552 -0.192 
Quantitative traits 
WHR 180 0.496 1.589 0.943 0.004 0 009 
BMI 180 0.496 0.489 0.687 20.451 7.711 
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The linkage between WHR/BMI and this gene locus was examined using the 
quantitative trait linkage analysis. In the 180 sib pairs, we did not find any evidence 
of linkage between them (Table 67, page 126). 
4.4.2.4 Genetic linkage of the dopamine D2 gene locus to obesity 
In the affected sib pair analysis, 43 affected-affected sib pairs were analyzed and 
there was 26 pairs of IBS sharing 2, 16 pairs of IBS sharing 1 and 1 pair of IBS 
sharing 0. We found observed mean IBS sharing 0.79, which was a little bit more 
than expected. Full-sib Chi-square test with 2 df, ； 0 . 1 , p=0.96, so that the null 
hypothesis of no linkage the results could not be rejected. 
In the affected pedigree member linkage analysis from the affected-affected sib pairs 
we did not find any evidence of linkage between this gene and central obesity using 
three weighting functions. However, from the affected-unaffected sib pairs, we found 
the T values all were smaller than -1 for the three weighting functions, and p less 
than 0.05 for the functions 2 and 3. This indicated a significant linkage between this 
gene and central obesity with hypertensive family history (Table 68, page 127). 
Table 68 Linkage between the DRD2 gene and central obesity in Hong Kong 
Chinese with hypertensive family history by APM method 
Weighting Affected-Affected sib pairs Affected-Unaffected sib pairs 
function T values P values l v a l u e s p 
^ ^ 0.2377 46 0.0556 
f { p ) = ^ / 4 p 1.088 26 0.3185 -1.575 46 0.0068 
f{p)=\/p 1-140 ^ 0.3236 -1.503 46 0.0055 
In the affected sib pair analysis, the linkage between the DRD2 gene locus and 
general obesity defined by BMI was examined. There was 99 sib pairs, including 54 
pairs of IBS sharing 2, 42 pairs of IBS sharing 1 and 3 pairs of IBS sharing 0. The 
observed mean IBS sharing was 0.76, and it was less than the expected mean IBS 
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sharing. After testing by the Chi-square test, we found ； 1 . 3 with 2 df, p = 0.53. 
Thus no linkage evidence was found between general obesity and the marker near 
DRD2 gene locus in this analysis. 
In the affected pedigree member linkage analysis, there was no evidence of linkage 
between this gene locus and general obesity with hypertensive family history (Table 
69, page 128). 
Table 69 Linkage between the DRD2 gene and general obesity in Hong Kong 
Chinese with hypertensive family history by APM method 
Weighting Affected-Affected sib pairs Affected-Unaffected sib pairs 
functions l v a l u e s ^ ! - e s 
f{p)=\ -0.212 39 0.5913 -0.603 60 0.3176 
f { p ) = \ / ^ -0.233 39 0.7917 -0.650 60 0.3089 
f{p)=\/p -0.0243 39 0.7817 -0.668 60 0.2733 
In the qualitative traits linkage analysis, 176 sib pairs were analyzed with the SAGE 
(SIBPAL) program. For WHR traits，we found T = -2.02, p < 0.05. This showed a 
significant linkage between this gene locus and central obesity with hypertensive 
family history again (Table 70, page 128). However, there was no linkage between 
the marker near this gene locus and general obesity defined by BMI with 
hypertensive family history. 
Table 70 Linkage between the DRD2 gene and general obesity in Hong Kong 
Chinese with hypertensive family history by qualitative/quatitative trait analysis 
Effective , , 
. . . . Mean IBD ^ . 
number of sib sharirxQ T values P values Intercepts Slopes  
pairs 呂 
Qualitative traits — 
Central obesity 176 0.497 -2.025 0.022 0.503 -0.250 
General obesity 176 0.497 0.956 0.830 0.396 0.122 
Quantitative traits 
WHR 176 0.497 -0.498 0.310 0.009 -0.002 
^ 0.497 -1.036 0.151 28.897 -8.807 
WHR= waist-to-hip ratio; BMI= body mass index.~“ “ 
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In the quantitative trait linkage analysis, the linkage between WHR/BMI and this 
gene locus was detected. In the 176 sib pairs，we did not find any evidence of linkage 
between the marker near this gene locus and WHR or BMI (Table 70, page 128). 
5 Discussion 
5.1 Age-related anomalies 
In our study, the mean age was 5-years higher in the hypertensive siblings than that 
in the normotensive ones and there was a large proportion of hypertensive siblings in 
the age range of 35 - 50 years (more than 70%) (Table 12, page 83), regardless of 
whether they were males or females. The incidence of hypertension among the 
siblings in our data also tends to increase with age, from 50% in the group aged 35 to 
50 years to 70.8% in the group aged older than 50 years. The same situation was 
found in the obese siblings and obesity-related hypertensive siblings. Although our 
results come from a special population of siblings, they correspond with the 
phenomenon seen in general populations (MacMahon et al. 1984; Ueshima et al. 
1987; Dannenberg et al 1988; Cornoni-Huntley et al 1989; Joffres et al. 1992; van 
Leer et al 1994; Whelton et al. 1994). 
5.2 Gender-related anomalies 
In our study, adult males have slightly higher systolic blood pressure and diastolic 
blood pressure than females of the same age ranging from 20 to 50 years, and the rise 
in blood pressure with age was steeper in males than in females, but after the 
menopause, females showed a greater rise and reached levels of blood pressure that 
were higher than those in males, (section 4.1.2, page 81) These findings are similar 
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to the results reported in the Framingham Heart Study and by others (Kannel et al. 
1981; Fiebach et al. 1989; Isles et al. 1992). Possible reason might be the effects of 
estrogen, the reduction of iron stores in the body secondary to menstruation, 
decreased insulin resistance because of different body fat distribution; and a lower 
rate of cigarette smoking. 
In our study, we found that there were 74.6% of hypertensive females with central 
obesity (defined by WHR) which was more than hypertensive males (62.1%). 
However, hypertensive males had a higher proportion of abnormal BMI than 
hypertensive females (77.3% vs. 68.7%). (Table 18, page 86) The gender-related 
difference in body fat distribution found in our sibling data was similar to that found 
in general populations (Vague 1956). 
5.3 Obesity- related hypertension 
In our study, we found that there was a large proportion of siblings with central 
obesity or general obesity, and there were more obese in the hypertensive siblings 
than in the normotensives and more than 80% of hypertensive siblings had abnormal 
percentage body fat, regardless of whether they were males or females. (Table 17, 
page 86) The comparison between normotensive and hypertensive sibling pairs, also 
suggested that obesity might be a major risk factor for developing hypertension since 
the sibling pairs had the same hypertensive family history. However, not only was 
there more obesity in the hypertensive siblings, but also there was a certain 
proportion of normotensive siblings with obesity in our data. (Table 18, page 86) 
Why therefore are some obese individuals not hypertensive, while some lean subjects 
are hypertensive? This led us to further explore the genetic variability of the blood 
pressure responses to weight gain. 
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5.4 Abnormal biochemical parameters in hypertension 
In our sibling families, we found that there were 47.3% siblings with increased total 
cholesterol, 11.5% siblings with elevated serum triglycerides, 31.3% siblings with 
decreased high-density lipoprotein cholesterol levels and 45% siblings with increased 
low-density lipoprotein. Comparison of the lipid profile between hypertensive and 
normotensive siblings after adjusting for age and gender showed that there was no 
evidence of relationship between lipid profile and blood pressure in our sibling data, 
(section 4.1.5.1, page 87) 
However, our data showed that plasma potassium were negatively associated with 
blood pressure. This might support the results from both observational epidemiologic 
studies and randomized controlled trials on general populations which suggest an 
inverse relationship between potassium intake and blood pressure in human 
populations (Puddey et al 1985) and an increased intake of dietary potassium has 
been shown to prevent the development of the salt-induced animal hypertension 
(Suzuki et al 1981; Fujita et al 1983), as well as to lower the blood pressure in 
hypertensive patients (Meneely et al 1976; limura et al 1981; MacGregor et al. 
1982; Fujita et al 1984). Some studies also showed that plasma potassium may 
contribute to the changes of 24 hour blood pressure (Goto et al. 1997; Wilson et al. 
1999). 
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5.5 Genetic parameters involved in the pathogenesis of 
hypertension and obesity 
Hypertension has a well-known familial aggregation and it has been calculated that 
hypertension is (almost equal to) 40% genetically determined (Cusi et al 1998). The 
genetics of some components of the dopaminergic system and the RAS were 
investigated for a possible involvement in blood pressure regulation. The three 
polymorphisms from these systems examined in our study were the dopamine D2 
gene TaqI polymorphism (section 1.4.6.2, page 45), the angiotensin-converting 
enzyme insertion/deletion (section 1.4.4.1, page 29) and the ATIR adenosine to 
cytosine at nucleotide 1166 substitution (section 1.4.5.2, page 36). Because the RAS 
appears to have a role in maintaining blood pressure homeostasis, defects in this 
system may lead to the development of hypertension. 
As obesity may play a role in the development of hypertension and it was positively 
related to blood pressure in our sibling data, the UCPl gene was examined in our 
family study and some evidence of association between the UCPl gene and obesity-
related hypertension was found emerged, (section 1.3.4.3, page 17) These are 
therefore mutations of interest with which to commence the search for a possible 
genetic component to hypertension in our family siblings. 
5.6 The uncoupling protein gene 
5.6.1 Higher frequency in central obese males 
We are not aware of any other studies that have been done in Chinese ethnic subjects 
on the body weight and the UCPl gene polymorphism. In our study, we typed all the 
siblings for this polymorphism, (section 4.3.1.1, page 94) In the whole group of 
siblings, we found 22.8% subjects with genotype GG, 51.6% subjects with AG, and 
132 
the frequency of the G allele was 48.6%. However, in the male subjects, we found 
only 20.2% of GG homozygotes，51.4% of AG heterozygotes and 28.4% of AA 
homozygotes, and the frequency of the G allele was 45.9%. In comparison with 
Japanese men with 49% of G allele, these data are very similar. In Caucasians, such 
as French, Danish and Finns, the frequency of the G allele was 28%, 25%, and 26%, 
respectively (Oppert et al. 1994; Urhammer et al. 1997; Valve et al. 1998). Different 
ethnic groups therefore have different frequencies of the UCPl polymorphism. We 
could assume that different effects on the UCPl activity exist due to other possible 
factors, like genetic, environmental and behavioural factors. 
A previous study showed that body weight and mortality from all causes were 
directly related among middle-aged women (30y to 55y) in America (Manson et al. 
1995). Stevens et al. reported that the relative risk associated with greater body 
weight is higher among middle aged persons (30y to 44y) in America (Stevens et al. 
1998). In our study, we have 70.7% of hypertensive subjects and 72.5% of central 
obese hypertensive subjects in the age range between 35 and 50 years. We compared 
gender-matched groups of central obese and non-central obese in the age range 
between 35 and 50 years, and positive results were obtained in the males with the 
frequency of the variant in the promoter region (A-3826G) of this gene being higher 
in central obese males in contrast to non-central obese males in the hypertensive 
families, (section 4.3.1.1, page 94) However, we did not find any difference in 
females (47% vs 46.3%, respectively). This is the same as the finding in the Japanese 
study, where the BMI was significantly higher in male subjects with the G allele 
versus those without it (Hayakawa et al 1999). The lack of a clear association may 
not be surprising, as the UCPl protein is expressed mainly in brown adipose tissue, 
which is present only in small amounts in man (Garruti et al 1992). 
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5.6.2 Linkage of systolic blood pressure with G allele 
In the multivariate analysis with adjustment for age and gender, between the groups 
with and without the G allele, there was no significant difference in the parameters of 
obesity measurements (weight, waist, hip, WHR, BMI, skinfold thickness, 
percentage body fat). However, there was a trend that all these parameters were 
slightly higher in the group without the G variant. We found that there was a 
significant difference in the weight between the AG and the GG group and there was 
a significant difference in systolic blood pressure between heterozygotes with AG 
and homozygotes with AA. The AG group had higher systolic blood pressure than 
the AA group and systolic blood pressure was higher in the group with the G variant 
in contrast to the group without the G variant (p value = 0.08). However, we did not 
find any significant evidence of this G variant being related to obesity or central 
obesity by using the Conditional Logistic Regression analysis after adjusting for age 
and gender, (section 4.3.1.3, page 99) 
In the quantitative linkage analysis, the results showed that the UCPl gene was 
linked to systolic blood pressure (p<0.05). (section 4.4.1.1, page 114) However, we 
are not aware that there is any other report which mentions that there is a relationship 
between this gene and blood pressure especially in sibling data. Because in our 
family members, they all had a hypertensive family history, and for each family at 
least one of them had hypertension, totally there were 47.3% siblings with 
hypertension when we screened them. 
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5.6.3 Metabolic link 
Complex traits such as obesity are usually not controlled by a single disease gene 
locus but often involve multiple genetic and/or environmental factors, and at least to 
some extent, are subject to specific gene-environment and gene-gene interactions. 
The idea that defective thermogenesis may be important in the development of 
human obesity is not new (James et al. 1976; Miller 1979). We know that brown 
adipose tissue has some potential for heat production, so called "thermogenesis". 
With the development of a specific radioimmunoassay for the mitochondrial 
uncoupling protein, unique to brown adipose tissue, it became possible to 
demonstrate conclusively that brown adipose tissue was present in humans of all 
ages (Lean et al. 1983; Cunningham et al 1985; Lean et al 1986; Lean et al 1986). 
The presence of a 32 kDa uncoupling protein which allows proton re-entry into the 
mitochondrial matrix without the usual obligatory proton coupling to respiration is 
characteristic of the brown fat mitochondria, (section 1.3.4.1, page 15) 
The situation in humans contrasts with that in rodents, where brown fat 
thermogenesis accounts for almost all the extra heat produced in response to 
noradrenaline both in cold adaptation (Foster et al 1978) and in overfeeding 
(Rothwell et al 1981). In several animal models, brown adipose tissue function was 
found to be impaired with decreased levels of uncoupling protein and defective 
energy expenditure, leading to obesity (Trayhum 1986; Stock et al. 1989; Himms-
Hagen 1990). The contribution of reduced energy expenditure to the development of 
obesity has been a point of controversy. Many studies used the measurement of basal 
metabolic rate to measure the energy expenditure. Low basal metabolic rate is one of 
the risk factors for weight gain (Ravussin et al. 1988). There is a study in obese 
Finns which did not find the UCPl gene polymorphism had an independent effect on 
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basal metabolic rate (Valve et al. 1998). A study showed that there might have been 
substantial brown adipose tissue activation in the basal state of temperature changing 
(Dauncey 1981). As mentioned before, in previous epidemiological and clinical 
studies, the UCPl gene A3826G polymorphism was related to body weight. 
A potential role of increased sympathetic neural drive in the pathogenesis of 
hypertension is through increased a-adrenergic receptor mediated vasoconstrictor 
tone of afferent renal arterioles. This reduces the glomerular filtration rate and hence 
natriuresis. Reductions in the excretion of sodium lead to an increase in blood 
volume and blood pressure. Several lines of evidence suggest that obesity may cause 
activation of sympathetic nervous discharge to cardiovascular tissue and that this 
may cause hypertension, (section 1.3.3, page 13) Sowers et al. (Sowers et al. 1982) 
and Tuck et al. (Tuck et al. 1983) observed that borderline hypertensive obese 
subjects had higher norepinephrine levels than did non-obese normotensive control 
subjects, that their blood pressure correlated with norepinephrine levels, and that 
weight loss was accompanied by a fall in blood pressure that correlated with a 
decrease in serum norepinephrine (Sowers et al. 1982). It has been speculated that 
insulin resistance is the common metabolic abnormality connecting obesity, 
hypertension, and increased sympathetic nervous system activity. This hypothesis is 
supported by numerous reports that document a relation between insulin resistance 
and hypertension (O'Hare 1988; Rocchini et al. 1989; Rocchini et al. 1997). 
However, the present study supports the concept, originally proposed by Julius et al, 
that central nervous system-induced sympathetic activation, not insulin resistance or 
hyperinsulinemia, is the metabolic link that connects obesity to hypertension (Julius 
et al 1991). 
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By-analogy，we might explain the results from our data, that UCPl gene is one of the 
risk factors for developing obesity-related hypertension, the link for UCPl, obesity 
and hypertension could be the sympathetic nervous system. 
5.7 The angiotensin-converting enzyme gene 
5.7.1 The ACE D allele and hypertension in previous studies 
It is well known that the renin angiotensin system plays an important role in the 
regulation of blood volume and pressure. The angiotensin-converting enzyme plays a 
key role in this system, (section 1.4.1, page 19) However, it is not clear whether the 
angiotensin-converting enzyme insertion/deletion gene polymorphism has a 
relationship with hypertension per se. Some studies (Cambien, Poirier, Lecerf et al. 
1992; Zee, Lou, Griffiths et al. 1992) found that the I allele was associated with 
elevated blood pressure, but the majority of the studies had found no relationship 
between the polymorphism and blood pressure. However, several recent large studies 
have now suggested the D allele may increase blood pressure (Fomage, Amos, 
Kardia et al. 1998; O'Donnell, Lindpaintner, Larson et al. 1998). Despite these 
results, in our study of hypertension in hypertensive families of Hong Kong Chinese, 
there was no significant difference in the genotype or allele frequencies between the 
hypertensive and normotensive siblings. Furthermore, there was also no significant 
difference in blood pressure between the I and D allele homozygous siblings. 
In our study, we found 38.5% siblings with the II genotype, there were 50.4% 
siblings who were ID heterozygotes, and we found 36.3% siblings with the D allele. 
This is similar to the previous population study in Hong Kong Chinese (x^-0.47 with 
2df, p二0.789 for genotypes, odds ratio=1.04, 95% CI, 0.75-1.38, p二0.799), in which 
they found 38.8% subjects with the II genotype, 48.1% of subjects with the ID 
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genotype, and 37.2% of subjects with the D allele (Thomas et al. 1996; Thomas et al 
1997). In comparison with other Asian populations, there was a significant difference 
between our data and Singaporean (Lee 1994), Taiwanese (Jeng et al. 1997) and 
Korean (Oh et al 1996). They found the frequency of the D allele at 30%, 40%, 
52.9%, respectively. However, there was no difference between our data and 
Japanese studies (Higashimori et al 1993; Morise et al. 1994; Nakai et al. 1994; Doi 
et al 1996; Maguchi et al 1996; Nakauchi et al. 1996; Ohno et al 1996; Kario et al 
1997). There was an obvious difference between different ethnic groups�Compared 
to Caucasians, we found there was a higher frequency of the D allele in Caucasians, 
55.3% in American (Marian et al 1993; Raynolds et al. 1993; Beohar et al 1995; 
Lindpaintner et al, 1995; Ludwig et al. 1995; Bloem et al. 1996; Foy et al 1996). 
54.3% in Finnish (Kupari et al 1994; Kiema et al 1996), 51.7% in Danish 
(Rasmussen et al 1996; Agerholm-Larsen et al. 1997)). It is obvious that there is a 
higher prevalence of the ACE D allele in Caucasians than in Asian populations, 
(section 4.3.2, page 99) 
There is a study in Hong Kong Chinese which was shown that there was lower 
frequency of the D allele in the 98 normoglycemic hypertensive patients with 
albuminuria compared to the 405 normoalbuminuric normoglycemic hypertensives, 
but not in the diabetic groups (Thomas et al. 2001). In the previous population study 
of Hong Kong Chinese, there was no evidence of association between the ACE gene 
I/D polymorphism and hypertension (Thomas et al 1996). Recently, in animal 
studies it has been shown that there was linkage between hypertension and a 
chromosomal region including the ACE locus found in the stroke-prone 
spontaneously hypertensive rats (Hilbert et al. 1991; Jacob et al. 1991). A linkage 
study in America, showed that there was no evidence to support linkage between the 
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ACE gene locus and hypertension, and the authors suggested that mutations at the 
ACE locus do not commonly contribute to the pathogenesis of hypertension in the 
American population (Jeunemaitre et al. 1992). In the Rochester Family Heart Study, 
they suggested that the genetic variation in the region of the ACE gene significantly 
influenced blood pressure variability in males, but not in females (Fornage et al. 
1998). In the Framingham heart study, they also found that there was evidence for 
association and genetic linkage of the ACE locus with hypertension and with 
diastolic blood pressure in men but not in women (O'Donnell et al. 1998). 
5.7.2 Positive role of the ACE DD genotype found in our data 
Microalbuminuria is defined as a 24h UAER of 20-200jLig/min. Macroalbuminuria is 
defined as a 24h UAER over 200iLig/min. It is clear that the level of albuminuria 
varies, and multiple studies suggest that throughout the range from nomoalbuminuria 
to microalbuminuria to macroalbuminuria, the higher the level, the higher the risk of 
further progression and subsequent deterioration in renal function. In our data, most 
urinary parameters were not associated with the ACE gene polymorphism. We 
defined increased albuminuria by 24h UAER > 20|Lig/min. Almost all the siblings 
had 24h UAER under 200|^g/min. In the chi-square test, we found that the frequency 
of DD genotype and D allele were higher in the albuminuric siblings, regardless of 
whether they were hypertension or not. There was a study in the Hong Kong Chinese 
population which showed that the ACE gene polymorphism D allele was less 
frequent in normoglycemic hypertensive patients with albuminuria (Thomas et al. 
2001). In some studies in Caucasians they have found that there was a relationship 
between the D allele and hypertension. In our data, there was a trend for a higher 
frequency of the DD genotype and D allele with increased albuminuria in the 
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combined hypertensive siblings and normotensive siblings. This suggests that the 
ACE gene polymorphism and albuminuria interact with each other, and have an 
effect on blood pressure together, (section 4.3.2.2, page 101) 
In our study, the chi-square test was used to find whether there was any relationship 
between the ACE gene I/D polymorphism and blood pressure in the hypertensive 
families. This showed some trend that the frequency of the DD genotype was higher 
in hypertensive than in normotensive groups. We compared the frequency of each 
genotype in gender-matched hypertensive and normotensive groups. In our study, 
there were almost twice the frequency of the DD genotype in female hypertensive 
and male hypertensive as that in normotensives. In the comparison of the 67 
hypertensive females and 105 normotensive females, we found that there was 16.4% 
of DD genotype in hypertensives, in contrast to 8.6% in normotensives. As the blood 
pressure is influenced by age and gender as elucidated previously, in the age range 
between 35 and 50 years, we compared 46 hypertensive females and 69 
normotensive females, and there were 19.6% of the DD genotype and 8.7% of DD 
the genotype, respectively. Our data have evidence suggestive that the ACE DD 
genotype is associated with hypertension, and also provide evidence suggestive that 
ACE maybe is a sex-specific hypertension candidate gene, (section 4.3.2.1, page 
100) In the analysis of covariance, we found that although there was no significant 
difference in blood pressure between each genotype group, the systolic blood 
pressure was higher in the DD genotype siblings (135±22, 130士20 and 131±22 in 
DD, ID and II genotype, respectively). It showed us a possibility that the DD 
genotype increased systolic blood pressure. The results from Conditional Logistic 
Regression adjusted for age and gender gave us confirmation that the D allele was 
related to blood pressure in our data where DD is a significant risk factor for 
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hypertension, (section 4.3.2.1，page 100) But in the linkage analysis, there is no 
evidence of linkage between this gene and hypertension, (section 4.4.1.2, page 116) 
5.8 Angiotensin II type 1 receptor gene 
Angiotensin II receptors, which mediate the vasoconstrictive and salt-conserving 
actions of the renin-angiotensin system, also represent interesting candidate genes for 
essential hypertension. Two subtypes of cell surface receptors have been identified 
(angiotensin II type 1 and angiotensin II type 2 receptor), using ligand binding 
studies (Chiu et al 1989). Angiotensin II acts mainly via the angiotensin II type 1 
receptor as an acute vasoconstrictor that regulates systemic blood pressure and 
vascular tone. Increased levels of angiotensin II have been suggested to be involved 
in the pathophysiology of cardiovascular disease (Weber 1997). A polymorphism in 
the ATiR (an adenine/cytosine base substitution at position 1166) has been 
associated with essential hypertension (Bonnardeaux et al. 1994), increased artery 
vasoconstriction (Amant et al. 1997; Henrion et al 1998), and cardiac hypertrophy 
(Osterop et al. 1998). The present study is the first to demonstrate that the ATiR 
A1166C polymorphism is associated with an increased response to angiotensin II in 
isolated human arteries (Bonnardeaux et al. 1994).. The A1166C mutation is located 
in a nontranslated region of the gene, and it was shown in one study that the 
frequency of the C allele was increased in patients with hypertension (Bonnardeaux 
et al 1994). (section 1.4.5, page 35) 
5.8.1 No linkage with HT 
The mutation was rarely identified in Chinese population, and in the previous 
Chinese population study, only three individuals with the homozygous C allele 
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genotype were found in 410 unrelated Chinese subjects (Thomas et al. 2000). In our 
sibling study, there was no one with the homozygous C allele genotype. ( section 
4.3.3, page 104) These data might imply that in Chinese, the homozygous CC 
genotype of this gene is very rare. This low frequency makes it impossible for us to 
look reliably for any relationship of the mutation with the biochemical and 
anthropometric markers. Despite this，we tested for a possible relationship between 
the mutation and those markers. In our study, we found that there was still a trend for 
a higher C allele frequency in normotensive siblings than in hypertensive siblings 
(5.1% vs 4.2%). Our study differs with the population study, because all the siblings 
have a family history of hypertension. It is not difficult to explain that there was a 
similar C allele frequency in these two groups, because all the normotensive siblings 
have a trend to develop hypertension, as hypertension is a continuous trait appearing 
relatively late in life. The comparison of biochemical and anthropometric parameters 
between siblings with and without the C allele, only found a trend of lower diastolic 
blood pressure and higher HDL cholesterol in the siblings with the C allele, (section 
4.3.3.2, page 105) This suggested that there is no relationship between this gene 
mutation and developing hypertension. The same results have been found in the 
Chinese population study by Thomas GN et al. (Thomas et al. 2000). However, two 
studies in Caucasian subjects have described differences in genotype frequency 
between normotensive and hypertensive populations (Bonnardeaux et al. 1994; 
Castellano etal. 1996). 
This has also been studied by linkage analysis. No significant evidence of linkage 
was found between this gene and hypertension within the hypertensive families. This 
is similar to studies reported for Caucasians (Bonnardeaux et al. 1994; Davies et al 
1994; Castellano et al. 1996). In the linkage analysis, we found significant linkage 
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between this gene and obesity/central obesity in hypertension-normotension sib pairs 
by the APM method. As obesity is one of the risk factors for developing 
hypertension, there is a close relationship between this and hypertension, so although 
the data did not show direct linkage of this gene locus with hypertension, there still 
maybe a trend that this gene polymorphism might be related to hypertension, (section 
4.4.2.3, page 124) 
5.9 Dopamine D2 gene 
5.9.1 Dopamine and obesity 
Dopamine is an important factor in blood pressure regulation through both the 
central and the peripheral mechanisms. In our sibling data, all the subjects have a 
hypertensive family history, so all these siblings have some chance for developing 
hypertension. Some hypertensive patients have been shown to respond with an 
exaggerated level of natriuresis and diuresis to the administration of dopamine 
(Andrejak et al 1986). 
It is believed that obesity is a primary cause of essential hypertension and type 2 
diabetes mellitus or non-insulin-dependent diabetes mellitus (Hall et al. 1998). It is 
also known that obesity increases tubular sodium reabsorption, which is suggested to 
be closely linked to the enhanced activation of antinatriuretic renin-angiotensin and 
sympathetic systems (Hall et al 1993; Hall et al. 1998). Evidence that the 
dopaminergic system may be implicated in obesity is suggested from studies 
showing the effectiveness of amphetamine-like drugs in weight loss (Scoville 1975). 
Furthermore, neuroleptics, which block the D2 dopamine receptor, have been shown 
to lead to body weight gain in clinical (Doss 1979) and animal studies (Baptista et al 
1987). (section 1.4.6, page 39) In our data, we found that about half the subjects were 
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obese, which is obviously higher than in the general population. Population studies 
have clearly documented the relationship between obesity and hypertension (Najjar 
et al 1987). Even modest weight gain over a period of a few weeks can elevate 
blood pressure in experimental animals and humans, and weight loss reduces blood 
pressure in hypertensive as well as normotensive subjects (Kumanyika 1987). 
5.9.2 Linkage with obese and HT 
In this study a TaqI polymorphism in the DRD2 gene was associated with central 
obese hypertension in our hypertensive families. We selected age-matched subjects 
for the hypertension and normotension groups in males and females, respectively. 
Additionally, we omitted the normotensives that might develop hypertension later in 
life. Allele and genotype frequencies of all the subjects were consistent with Hardy-
Weinberg equilibrium, confirming that the genotypes of our subjects were corrected. 
In our male and female groups, we found that the frequencies of genotypes and 
alleles were associated with central obese hypertension. We found that the DRD2 Al 
allele was associated with increased WHR. (section 4.3.4.2, page 108) With the APM 
method, the results also showed that this gene polymorphism was linked to central 
obesity and hypertension. The association of obesity and the prevalence of the Al 
allele was elucidated as that either the mutation causing the TaqI A polymorphism or 
a mutation in linkage disequilibrium with the TaqI A polymorphism is associated 
with a decrease in the function of the DRD2 gene (Noble et al. 1991). Obesity is a 
metabolic disorder with multiple pathophysiological consequences, including insulin 
resistance, increased renal sodium reabsorption, and development of hypertension 
(Hall et al 1998). It is now well established that a particular obesity phenotype is 
uniquely associated with the propensity to develop hypertension and other 
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cardiovascular risk factors. In the mid-1950s, Jean Vague, a French clinician, noted 
that the cardiovascular and metabolic complications of obesity were most common in 
those individuals with the upper body fat distribution pattern (Vague 1956). Vague's 
observations drew little comment until the 1980s, when epidemiological surveys, 
particularly from Scandinavia, using the WHR as a convenient surrogate for body fat 
distribution, confirmed a relationship between abdominal or upper body obesity and 
cardiovascular risk (Lapidus et al. 1984; Larsson et al 1984). Cardiovascular risk, 
including hypertension, thus tracks with the upper body or abdominal form of 
obesity. Dopamine regulates appetite and behavior through dopaminergic neurons. In 
contrast to the previous studies on Hong Kong populations, we found that the Al 
allele frequency was associated with lower percentage body fat, which was different 
from the results showing the A2 allele was associated with lower skinfold thickness 
in Hong Kong Chinese, (section 4.3.4.3, page 110) However, in the population study, 
they did not find any relationship between the DRD2 gene polymorphism and WHR. 
Because our study was not in a population sample, it included 96 hypertensive 
families, and all of them had hypertensive family history. It is not difficult to explain 
that central obesity in association with this gene polymorphism may promote the risk 
for the development of hypertension in hypertensive families in Hong Kong Chinese. 
We can conclude that the DRD2 TaqI polymorphism gene is associated with central 
obese-related hypertension in hypertensive families of Hong Kong Chinese. The Al 
allele of this gene polymorphism is related to the higher WHR in our hypertensive 
families. 
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5.10 Summary of the study 
Blood pressure levels are determined by complex interactions between 
environmental and genetic factors. The majority of hypertension is currently believed 
to be explained by a polygenic rather than a mono or oligogenic mode of inheritance. 
In our study, we detected four genes, which were ACE gene I/D polymorphism 
(section 1.4.4.1, page 29), ATIR gene A1166C polymorphism (section 1.4.5.2, page 
36), DRD2 gene TaqI polymorphism (section 1.4.6.2, page 45) and the UCPl gene 
A-3826G polymorphism (section 1.3.4.3, page 17). The main findings were found as 
follows: 1. No evidence of association or linkage between the ACE gene I/D 
polymorphism and blood pressure or obesity related hypertension. 2. Significant 
linkage was found between the ATIR gene A1166C polymorphism and 
obesity/central obesity by APM method. 3. Significant association was found 
between the DRD2 gene polymorphism and central obesity-related hypertension. 4. 
There was an evidence of linkage between the UCPl gene and systolic blood 
pressure. 
5.11 Possible further developments in this study 
In a study of such a complex disorder as hypertension it is not possible to answer all 
of the questions posed by a single study such as this one. Time and space limitations 
mean that at some point the study must be truncated. In our study, there were some 
weaknesses of the design and data collection. We recruited all the probands in our 
clinic，but not random selection. The siblings of same family were not completely 
recruited, there may exist some bias by now, some siblings were missed, mostly 
because they were busy or not in Hong Kong, or even had died. It seems that the 
reasons of missing are unlikely related to the question of out study. Such situation 
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could be regarded as random missing, approximately missing data is very popular in 
pedigree data, it is usually assumed such kind of missing is random missing. For the 
limitation of time, the sample size of this sibling data is not big enough. According to 
the manual of software SAGE, ate least double or triple of the current sample size are 
needed. So for the above reason, the next step of our study should recruit at least 
double of the current number of pedigree. 
For the UCPl gene, we haven't aware any other studies mentioned about this gene 
polymorphism genotype/allele frequencies, so it's better to detect this gene in 
Chinese population, to investigate whether there is any association in the population 
data. 
From this study, we got two interesting results, one is we found there was a trend of 
relationship between obesity and ATIR gene polymorphism, the other is there was 
an evidence of linkage between the UCPl gene locus and systolic blood pressure. 
But in the population study of Caucasians, we didn't find any report same as the 
above two results. So whether these two results was true or not, we still need to do 
some further works to confirm it, such as increase the sample size. The strong 
relationship between obesity and blood pressure was clearly seen in this study, so 
maybe we should do some works to investigate the mechanism of the interaction of 
gene polymorphism and obesity related to hypertension. 
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